Amyris (AMRSQ) 10-K/A 4 Oct 19 2018 FY Annual report (amended) Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Sep. 26, 2019	Jun. 28, 2019
Document Information [Line Items]
Entity Registrant Name	AMYRIS, INC.
Entity Central Index Key	0001365916
Trading Symbol	amrs
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		103,400,207
Entity Public Float			$ 226.5
Entity Shell Company	false
Document Type	10-K/A
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	true
Amendment Description	This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K of Amyris, Inc. (the “Company”) for the fiscal year ended December 31, 2018 (the “Form 10-K”), as filed with the Securities and Exchange Commission (the “SEC”) on October 1, 2019 (the “Original Filing Date”). This Amendment is being filed solely (i) for the purpose of furnishing Exhibit 101 (Interactive Data Files) to the Form 10-K, which was not included in the original filing of the Form 10-K with the SEC on the Original Filing Date, (ii) to correct administrative errors in the content of (A) the Report of Independent Registered Public Accounting Firm of BDO USA, LLP (the “BDO Report”), the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2017, contained in Part II, Item 8 of the Form 10-K and (B) the Reports of Independent Registered Public Accounting Firm of Macias Gini & O’Connell LLP (the “MGO Reports”), the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2018, contained in Part II, Item 8 and Part II, Item 9A of the Form 10-K, respectively and (iii) to correct certain other immaterial errors in Part II, Item 8 of the Form 10-K as set forth below. The BDO Report and MGO Reports in the Form 10-K incorrectly contained certain references to September 30, 2019, when the correct date was October 1, 2019. Accordingly, such reports have been updated to refer to the correct date. In addition, (i) certain references to “Contract assets” in the financial statement tables and related disclosure in Part II, Item 8 of the Form 10-K have been amended to refer to “Accounts receivable, unbilled – related party”, (ii) a line item for “Accounts receivable, unbilled, noncurrent - related party” has been added to the “Contract Balances” table in Note 10, “Revenue Recognition” in Part II, Item 8 of this Amendment, (iii) the amount of federal NOL and state NOL carryovers written off by the Company as a result of events occurring during the year ended December 31, 2017, disclosed in Note 14, “Income Taxes” in Part II, Item 8 of the Form 10-K, has been corrected, (iv) certain legend references and explanations in the tables in Note 2, “Restatement of 2017 Consolidated Financial Statements” and the “2017 and 2018 Quarterly Data – Restated Condensed Consolidated Financial Statements” section immediately after Note 16, “Subsequent Events” in Part II, Item 8 of the Form 10-K have been updated by deleting unused explanations, expanding or conforming certain explanations and adding certain explanations that were inadvertently excluded from such tables and (v) certain typographical errors in the financial statement tables and related disclosure in Part II, Item 8 of the Form 10-K have been corrected to conform to the correct disclosure provided elsewhere in Part II, Item 8 of the Form 10-K. No other changes have been made to the Form 10-K. This Amendment speaks as of the Original Filing Date and does not reflect events that may have occurred subsequent to the Original Filing Date, and, except as expressly set forth herein, does not modify or update in any way the disclosures made in the Form 10-K. Pursuant to Rule 12b-15 promulgated under the Securities Exchange Act of 1934, this Amendment sets forth the complete text of Part II, Item 8 and Part II, Item 9A of the Form 10-K as amended hereby. Part IV, Item 15 of this Amendment reflects (i) new consents of BDO USA, LLP and Macias Gini & O’Connell LLP, (ii) Exhibit 101 (Interactive Data Files) and (iii) new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Section 906 of the Sarbanes-Oxley Act of 2002, each of which is filed or furnished herewith, as applicable.
Title of 12(b) Security	Common Stock

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents		$ 45,353	$ 57,059
Restricted cash		741	2,994
Accounts receivable, net of allowance of $642 and $619, respectively		16,003	18,953	[1]
Accounts receivable related party, net of allowance of $0 and $23, respectively		1,349	4,767	[1]
Accounts receivable, unbilled - related party		8,021	9,901
Inventories		9,693	5,408
Deferred cost of products sold, current - related party		489
Prepaid expenses and other current assets		10,566	4,919	[2]
Total current assets		92,215	104,001
Property, plant and equipment, net		19,756	13,892
Accounts receivable, unbilled, noncurrent - related party		1,203	7,940
Deferred cost of products sold, noncurrent - related party		2,828
Restricted cash, noncurrent		960	959
Recoverable taxes from Brazilian government entities		3,005	1,445
Other assets		7,958	12,559	[3]
Total assets		127,925	140,796
Current liabilities:
Accounts payable		26,844	15,515	[4]
Accrued and other current liabilities		28,979	29,202	[5]
Contract liabilities(1)	[6],[7]	8,236	4,308	[8]
Debt, current portion (includes instrument measured at fair value of $57,918 and $0, respectively)		124,010	36,924
Related party debt, current portion		23,667	20,019
Total current liabilities		211,736	105,968
Long-term debt, net of current portion		43,331	60,220	[9]
Related party debt, net of current portion		18,689	46,541
Derivative liabilities		42,796	116,497	[10]
Other noncurrent liabilities		23,192	23,658	[11]
Total liabilities		339,744	352,884
Commitments and contingencies (Note 9)
Mezzanine Equity		5,000	5,000
Stockholders’ deficit:
Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of December 31, 2018 and 2017, and 14,656 and 22,171 shares issued and outstanding as of December 31, 2018 and 2017, respectively
Common stock - $0.0001 par value, 250,000,000 shares authorized as of December 31, 2018 and 2017, respectively; 76,564,829 and 45,637,433 shares issued and outstanding as of December 31, 2018 and 2017, respectively		8	5
Additional paid-in capital		1,346,996	1,114,546	[12]
Accumulated other comprehensive loss		(43,343)	(42,156)
Accumulated deficit		(1,521,417)	(1,290,420)	[13]
Total Amyris, Inc. stockholders’ deficit		(217,756)	(218,025)
Noncontrolling interest		937	937
Total stockholders' deficit		(216,819)	(217,088)
Total liabilities, mezzanine equity and stockholders' deficit		$ 127,925	$ 140,796
[1]	Reclassification of related party accounts receivable to a separate line on the balance sheet.
[2]	Write-off of unrecoverable receivable in connection with facilities subleased to a related party.
[3]	Correction of error in recording amounts payable under Ginkgo Partnership Agreement as prepaid royalties instead of reduction in revenue.
[4]	Adjustment to uninvoiced receipts liability.
[5]	Adjustment to accrued liability.
[6]	The balance in contract liabilities at December 31, 2017 represents deferred revenue, current prior to the Company's adoption of ASC 606, "Revenue".
[7]	The balance in contract liabilities, current at December 31, 2017 represents deferred revenue, current prior to the Company's adoption of ASC 606, "Revenue".
[8]	Revision to accounting for equity received in satisfaction of a customer receivable.
[9]	Adjustment to issuance-date fair value of a debt instrument.
[10]	Make-whole derivative liabilities adjustment.
[11]	Accrual of the Ginkgo Partnership Payments obligation, net of reduction to deferred revenue liability.
[12]	Correction to the accounting for a make-whole equity instrument in connection with May 2017 equity offering.
[13]	Sum of adjustments to net loss for the year ended December 31, 2017 as result of corrections.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accounts receivable, allowance	$ 642	$ 619
Accounts receivable, related party, allowance	0	23
Debt, current portion, fair value	$ 57,918	$ 0
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	14,656	22,171
Preferred stock, shares outstanding (in shares)	14,656	22,171
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	76,564,829	45,637,433
Common stock, shares outstanding (in shares)	76,564,829	45,637,433

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue
Revenues	$ 63,604	$ 127,671
Cost and operating expenses
Cost of products sold	36,698	62,307	[1]
Research and development	68,722	57,562	[2]
Sales, general and administrative	90,902	63,853	[3]
Impairment of other assets	3,865
Total cost and operating expenses	200,187	183,722	[3]
Loss from operations	(136,583)	(56,051)
Other income (expense)
(Loss) gain on divestiture	(1,778)	5,732
Interest expense	(42,703)	(37,081)	[4]
Loss from change in fair value of derivative instruments	(30,880)	(48,852)	[5]
Gain from change in fair value of debt	2,082
Loss upon extinguishment of debt	(17,424)	(11,897)	[6]
Other income (expense), net	(2,949)	(956)
Total other expense, net	(93,652)	(93,054)
Loss before income taxes	(230,235)	(149,105)
Provision for income taxes		(6,877)	[7]
Net loss attributable to Amyris, Inc.	(230,235)	(155,982)
Less deemed dividend related to beneficial conversion feature on Series A preferred stock		(562)
Less deemed dividend related to beneficial conversion feature on Series B preferred stock		(634)
Less deemed dividend related to beneficial conversion feature on Series D preferred stock		(5,757)
Less deemed dividend upon settlement of make-whole provision on Series A preferred stock		(10,505)	[8]
Less deemed dividend upon settlement of make-whole provision on Series B preferred stock		(22,632)	[8]
Less deemed dividend related to the recognition of discounts on Series A preferred stock upon conversion		(21,578)	[8]
Less deemed dividend related to the recognition of discounts on Series B preferred stock upon conversion		(24,366)	[8]
Less deemed dividend related to proceeds discount upon conversion of Series D preferred stock	(6,852)
Add: losses allocated to participating securities	13,991	40,159	[9]
Net loss attributable to Amyris, Inc. common stockholders	$ (223,096)	$ (201,857)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (in shares)	60,405,910	32,253,570
Basic and diluted loss per share (in dollars per share)	$ (3.69)	$ (6.26)
Product [Member]
Revenue
Revenues	$ 33,598	$ 42,370
Licenses and Royalties [Member]
Revenue
Revenues	7,658	48,703	[10]
Grants and Collaborations [Member]
Revenue
Revenues	$ 22,348	$ 36,598
[1]	Correction in connection with a sales return, and adjustment to uninvoiced receipts liability.
[2]	Write-off of unrecoverable receivable in connection with facilities subleased to a related party, and reclassification of operating expense by classification to conform to the Company's current presentation.
[3]	Expense incurred in connection with May 2017 equity offering.
[4]	Correction to amortization of debt discounts, and interest expense in connection with partnership payments obligation.
[5]	Correction to accounting for make-whole liability in connection with May 2017 Offering.
[6]	Loss on extinguishment of related and unrelated party debt.
[7]	Tax provision to accrue liability for unrecognized tax benefit.
[8]	Correction to record deemed dividend in connection with discounts and freestanding instruments related to preferred stock offerings.
[9]	Correction in the computation of loss per share to reflect participating securities.
[10]	Ginkgo partnership obligation and promissory note issuance recorded as reduction to revenue and correction of errors in recording revenue from non-cash consideration.

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues, related party	$ 1,053	$ 60,942
Product [Member]
Revenues, related party	360	1,291
Licenses and Royalties [Member]
Revenues, related party	5,958	57,972
Grants and Collaborations [Member]
Revenues, related party	$ 4,735	$ 1,679

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Comprehensive loss:
Net loss	$ (230,235)	$ (155,982)
Foreign currency translation adjustment	(1,187)	(1,252)
Comprehensive loss attributable to Amyris, Inc.	$ (231,422)	$ (157,234)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit and Mezzanine Equity - USD ($) $ in Thousands	Series A Preferred Stock [Member]Preferred Stock [Member]	Series A Preferred Stock [Member]Common Stock [Member]	Series A Preferred Stock [Member]Additional Paid-in Capital [Member]	Series A Preferred Stock [Member]AOCI Attributable to Parent [Member]	Series A Preferred Stock [Member]Retained Earnings [Member]	Series A Preferred Stock [Member]Noncontrolling Interest [Member]	Series A Preferred Stock [Member]Mezzanine Equity, Common Stock [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]Preferred Stock [Member]	Series B Preferred Stock [Member]Common Stock [Member]	Series B Preferred Stock [Member]Additional Paid-in Capital [Member]	Series B Preferred Stock [Member]AOCI Attributable to Parent [Member]	Series B Preferred Stock [Member]Retained Earnings [Member]	Series B Preferred Stock [Member]Noncontrolling Interest [Member]	Series B Preferred Stock [Member]Mezzanine Equity, Common Stock [Member]	Series B Preferred Stock [Member]	Series D Preferred Stock [Member]Preferred Stock [Member]	Series D Preferred Stock [Member]Common Stock [Member]	Series D Preferred Stock [Member]Additional Paid-in Capital [Member]	Series D Preferred Stock [Member]AOCI Attributable to Parent [Member]	Series D Preferred Stock [Member]Retained Earnings [Member]	Series D Preferred Stock [Member]Noncontrolling Interest [Member]	Series D Preferred Stock [Member]Mezzanine Equity, Common Stock [Member]	Series D Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Mezzanine Equity, Common Stock [Member]	Total
Balance (in shares) at Dec. 31, 2016																										18,273,921
Balance at Dec. 31, 2016																										$ 2	$ 990,895	$ (40,904)	$ (1,134,438)	$ 937	$ 5,000	$ (183,508)
Issuance of Series A preferred stock for cash (in shares)	22,140								55,700								12,958
Issuance of Series A preferred stock for cash			$ 562					$ 562			$ 16,675					$ 16,675			$ 6,197					$ 6,197
Issuance of Series B preferred stock upon conversion of debt, net of issuance costs of $0 (in shares)									40,204
Issuance of Series B preferred stock upon conversion of debt, net of issuance costs of $0											11,530					11,530
Issuance of common stock due to rounding from reverse stock split (in shares)																										6,473
Issuance of common stock due to rounding from reverse stock split
Issuance of common stock for cash (in shares)																										2,826,711
Issuance of common stock for cash																											5,527					5,527
Issuance of common stock upon conversion of preferred stock (in shares)																									(108,831)	17,274,017
Issuance of common stock upon conversion of preferred stock																										$ 3						3
Issuance of common stock upon conversion of debt (in shares)																										2,257,786
Issuance of common stock upon conversion of debt																											12,687					12,687
Issuance of common stock for settlement of debt principal payments (in shares)																										1,246,165
Issuance of common stock for settlement of debt principal payments																											10,707					10,707
Issuance of common stock for settlement of debt interest payments (in shares)																										400,967
Issuance of common stock for settlement of debt interest payments																											3,436					3,436
Issuance of common stock upon exercise of warrants (in shares)																										3,148,097
Issuance of common stock upon exercise of warrants																											50,449					50,449
Issuance of common stock upon restricted stock settlement (in shares)																										156,104
Issuance of common stock upon restricted stock settlement																											(385)					(385)
Issuance of common stock upon ESPP purchase (in shares)																										47,058
Issuance of common stock upon ESPP purchase
Issuance of common stock upon exercise of stock options (in shares)																										134
Issuance of common stock upon exercise of stock options																											1					1
Beneficial conversion feature of preferred stock			562					562			634					634			5,757					5,757
Deemed dividend			(562)					(562)			(634)					(634)			(5,757)					(5,757)
Deemed dividend on preferred stock discounts upon conversion of preferred stock			21,578					21,578			24,366					24,366
Deemed dividend on preferred stock discounts upon conversion of preferred stock			(21,578)					(21,578)			(24,366)					(24,366)
Settlement of make-whole provision on preferred stock			10,505					10,505			22,632					22,632
Deemed dividend upon settlement of make-whole provision on preferred stock			$ (10,505)					(10,505)			$ (22,632)					(22,632)
Stock-based compensation																											6,265					6,265
Foreign currency translation adjustment																												(1,252)				(1,252)
Net loss																													(155,982)			(155,982)
Balance (in shares) at Dec. 31, 2017																									22,171	45,637,433
Balance at Dec. 31, 2017																										$ 5	1,114,546	(42,156)	(1,290,420)	937	5,000	(217,088)
Issuance of Series A preferred stock for cash																											1,415					1,415
Issuance of common stock for cash (in shares)																										205,168
Issuance of common stock upon conversion of preferred stock (in shares)																									(7,515)	1,548,480
Issuance of common stock upon conversion of preferred stock
Issuance of common stock upon conversion of debt (in shares)																										5,674,926
Issuance of common stock upon conversion of debt																										$ 1	42,368					42,369
Issuance of common stock for settlement of debt interest payments (in shares)																										238,898
Issuance of common stock for settlement of debt interest payments																											1,800					$ 1,800
Issuance of common stock upon exercise of warrants (in shares)																										20,891,038						20,928,439
Issuance of common stock upon exercise of warrants																										$ 2	62,152					$ 62,154
Issuance of common stock upon restricted stock settlement (in shares)																										407,858
Issuance of common stock upon restricted stock settlement																											(260)					(260)
Issuance of common stock upon ESPP purchase (in shares)																										246,230
Issuance of common stock upon ESPP purchase																											777					$ 777
Issuance of common stock upon exercise of stock options (in shares)																										70,807						70,807
Issuance of common stock upon exercise of stock options																											288					$ 288
Deemed dividend on preferred stock discounts upon conversion of preferred stock																			6,852					6,852
Deemed dividend on preferred stock discounts upon conversion of preferred stock																			$ (6,852)					$ (6,852)
Deemed dividend upon settlement of make-whole provision on preferred stock
Stock-based compensation																											9,190					9,190
Foreign currency translation adjustment																												(1,187)				(1,187)
Net loss																													(230,235)			(230,235)
Cumulative effect of change in accounting principle (Accounting Standards Update 2014-09 [Member]) at Dec. 31, 2017																													(762)			(762)
Settlement of derivatives liability upon exercise of warrants																											108,670					108,670
Issuance of common stock in private placement - related party, net of issuance costs of $0 (in shares)																										1,643,991
Issuance of common stock in private placement - related party, net of issuance costs of $0																											6,050					$ 6,050
Balance (in shares) at Dec. 31, 2018																									14,656	76,564,829						76,564,829
Balance at Dec. 31, 2018																										$ 8	$ 1,346,996	$ (43,343)	$ (1,521,417)	$ 937	$ 5,000	$ (216,819)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Series B Preferred Stock [Member]
Issuance costs		$ 0
Issuance costs		860
Series D Preferred Stock [Member]
Issuance costs		$ 176
Additional Paid-in Capital [Member]
Issuance costs	$ 0
Issuance costs	$ 0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating activities
Net loss	$ (230,235)	$ (155,982)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss from change in fair value of derivative liabilities	30,880	48,852
Loss upon conversion or extinguishment of debt	17,424	11,897
Amortization of debt discount	16,602	15,239
Stock-based compensation	9,190	6,265
Modification of warrants recorded as legal expense	6,764
Depreciation and amortization	4,921	11,358
Issuance costs on warrant exercises for cash	4,389
Impairment of other assets	3,865
Debt issuance costs expensed due to fair value option	3,810
Loss (gain) on divestiture	1,778	(5,732)
Loss on disposal of property, plant and equipment	941	142
Gain on foreign currency exchange rates	(2,223)	(1,230)
Gain from change in fair value of debt	(2,082)
Noncash revenue reduction related to issuance of debt obligations under Ginkgo Partnership Agreement		13,413
Receipt of noncash consideration in connection with license revenue		(8,046)
Changes in assets and liabilities:
Accounts receivable	7,448	(19,647)
Accounts receivable, unbilled – related party	8,056	(7,940)
Inventories	(4,416)	(3,126)
Deferred cost of products sold	(3,317)
Prepaid expenses and other assets	(6,383)	(18,730)
Accounts payable	11,603	5,452
Accrued and other liabilities	8,461	13,877
Contract liabilities	3,158	(7,241)
Net cash used in operating activities	(109,366)	(101,179)
Investing activities
Purchases of property, plant and equipment	(12,472)	(4,412)
Proceeds from divestiture, net of cash transferred		54,827
Maturities of short-term investments		12,403
Sale of short-term investments		676
Purchase of short-term investments		(11,786)
Net cash (used in) provided by investing activities	(12,472)	51,708
Financing activities
Proceeds from issuance of debt, net of issuance costs	94,371	18,925
Proceeds from exercise of warrants, net of issuance costs	57,767
Proceeds from issuance of common stock in private placements, net of issuance costs	1,415
Proceeds from ESPP purchases	777
Proceeds from exercises of common stock options	288
Principal payments on debt	(41,668)	(37,500)
Debt issuance costs incurred in connection with debt instrument accounted at fair value	(3,752)
Principal payments on capital leases	(981)
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units	(260)	(385)
Proceeds from issuance of convertible preferred stock		98,246
Proceeds from issuance of common stock in August 2017 offering		5,759
Issuance costs incurred		(2,159)
Payment of swap termination		(3,113)
Payment on early redemption of debt		(1,909)
Net cash provided by financing activities	107,957	77,864
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(77)	186
Net (decrease) increase in cash, cash equivalents and restricted cash	(13,958)	28,579
Cash, cash equivalents and restricted cash at beginning of year	61,012	32,433
Cash, cash equivalents and restricted cash at end of year	47,054	61,012
Cash and cash equivalents	45,353	57,059
Restricted cash, current	741	2,994
Restricted cash, noncurrent	960	959
Supplemental disclosures of cash flow information:
Cash paid for interest	18,524	11,539
Supplemental disclosures of non-cash investing and financing activities:
Derecognition of derivative liabilities upon exercise of warrants	108,670
Issuance of common stock upon conversion of convertible notes	24,970	28,702
Issuance of common stock - related party	6,050
Accrued interest added to debt principal	3,664	2,816
Issuance of common stock for settlement of debt principal and interest payments	1,800	3,436
Cumulative effect adjustment of ASC 606	762
Financing of insurance premium under note payable	495	467
Financing of equipment under financing leases	271
Issuance of preferred stock attributed to derivative liabilities		72,725
Issuance of convertible preferred stock upon conversion of debt		40,204
Settlement of debt principal by a related party		25,000
Issuance of note payable in exchange for debt extinguishment with third party		16,954
Issuance of common stock for settlement of debt		$ 10,708

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Business Description Amyris, Inc. (Amyris or the Company) is a leading industrial biotechnology company that applies its technology platform to engineer, manufacture and sell high performance, natural, sustainably-sourced products into the Health & Wellness, Clean Beauty, and Flavor & Fragrance markets. The Company's proven technology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. The Company's biotechnology platform and industrial fermentation process replace existing complex and expensive manufacturing processes. The Company has successfully used its technology to develop and produce several distinct molecules at commercial volumes. Going Concern The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 December 31, 2018, $119.5 $1.5 As of December 31, 2018, $17.1 $2.1 $209.7 $147.7 December 31, 2018, 5, April 2019, ( December 31, 2018 April 8, 2019, June 30, 2020 16, Cash and cash equivalents of $45.4 December 31, 2018 not September 30, 2020. one not 12 2019, 2019 December 31, 2018, may may not July 2019, may not On September 16, 2019, $63.6 The Company does not not no no not not Basis of Consolidation The accompanying consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States (U.S. GAAP). The consolidated financial statements include the accounts of Amyris, Inc. and its wholly-owned and partially-owned subsidiaries in which the Company has a controlling interest after elimination of all significant intercompany accounts and transactions. Investments and joint venture arrangements are assessed to determine whether the terms provide economic or other control over the entity requiring consolidation of the entity. Entities controlled by means other than a majority voting interest are referred to as variable-interest entities (VIEs) and are consolidated when Amyris has both the power to direct the activities of the VIE that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant to the entity. For any investment or joint venture in which (i) the Company does not not 2016 01 January 1, 2018 not not 3 Sale of Subsidiary and Entry into Commercial Agreements On December 28, 2017, $5.7 2017, $1.8 2018 not not 10, 11, 13, 16, Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may Significant Accounting Policies Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original or remaining maturity of three Inventories Inventories, which consist of farnesene-derived products, flavors and fragrances ingredients and clean beauty products, are stated at the lower of actual cost or net realizable value and are categorized as finished goods, work in process or raw material inventories. The Company evaluates the recoverability of its inventories based on assumptions about expected demand and net realizable value. If the Company determines that the cost of inventories exceeds their estimated net realizable value, the Company records a write-down equal to the difference between the cost of inventories and the estimated net realizable value. If actual net realizable values are less favorable than those projected by management, additional inventory write-downs may may Property, Plant and Equipment, Net Property, plant and equipment are recorded at cost. Depreciation and amortization are computed straight-line based on the estimated useful lives of the related assets, ranging from 3 15 15 The Company expenses costs for maintenance and repairs and capitalizes major replacements, renewals and betterments. For assets retired or otherwise disposed, both cost and accumulated depreciation are eliminated from the asset and accumulated depreciation accounts, and gains or losses related to the disposal are recorded in the statement of operations for the period. Impairment Long-lived assets that are held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not Recoverable Taxes from Brazilian Government Entities Recoverable taxes from Brazilian government entities represent value-added taxes paid on purchases in Brazil, which are reclaimable from the Brazilian tax authorities, net of reserves for amounts estimated not Fair Value Measurements The carrying amounts of certain financial instruments, such as cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The Company measures the following financial assets and liabilities at fair value: • Freestanding and bifurcated derivatives in connection with certain debt and equity financings; and • 6% 2021 4, 5, 16, Fair value is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Where available, fair value is based on or derived from observable market prices or other observable inputs. Where observable prices or inputs are not Changes to the inputs used in these valuation models have a significant impact on the estimated fair value of the 6% 2021 The changes during 2018 2017 For debt instruments for which the Company has not not 6% 2021, 4, 6% 2021 For all debt instruments, including any for which the Company has elected fair value accounting, the Company classifies interest that has been accrued during each period as Interest expense on the consolidated statements of operations. Derivatives Embedded derivatives that are required to be bifurcated from the underlying debt instrument (i.e., host) are accounted for and valued as separate financial instruments. The Company has evaluated the terms and features of its convertible notes payable and convertible preferred stock and identified compound embedded derivatives requiring bifurcation and accounting at fair value, using the valuation techniques mentioned in the Fair Value Measurements Cash warrants and anti-dilution warrants issued in conjunction with the convertible debt and equity financings are freestanding financial instruments which are also classified as derivative liabilities. Noncontrolling Interest Noncontrolling interests represent the portion of net income (loss), net assets and comprehensive income (loss) that is not Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and accounts receivable. The Company places its cash equivalents and investments (primarily certificates of deposits) with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one may not The Company performs ongoing credit evaluation of its customers, does not Customers representing 10% As of December 31, 2018 2017 Customer B 24 % 10 % Customer C 19 % 15 % Customer G 11 % ** Customer A (related party) ** 38 % ______________ ** Less than 10% Customers representing 10% Years Ended December 31, 2018 2017 (As Restated, Note 2) Customer A (related party) 17 % 46 % Customer B 18 % 13 % Customer C 13 % ** Customer D 13 % ** Customer E ** 11 % Customer F ** ** ______________ ** Less than 10% Revenue Recognition Year ended December 31, 2017 For the year ended December 31, 2017, Renewable Product Sales The Company’s renewable product sales do not not two not Licenses and Royalties License fees for intellectual property transferred to other parties, representing non-refundable payments received at the time of signature of license agreements, are recognized as revenue upon signature of the license agreements when the Company has no Royalties from intellectual property licenses that allow Amyris's customers to use the Company’s intellectual property to produce and sell their products in which the Company shares in the profits are recognized in the period the royalty report is received. Grants and Collaborative Research and Development Services Revenues from collaborative research and development services are recognized as the services are performed consistent with the performance requirements of the contract. In cases where the planned levels of research and development services fluctuate over the research term, the Company recognizes revenues using the proportional performance method based upon actual efforts to date relative to the amount of expected effort to be incurred by us. When up-front payments are received and the planned levels of research and development services do not Grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. Revenues from grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the grants were provided have been met and only perfunctory obligations are outstanding. Year ended December 31, 2018 In accordance with a new revenue recognition standard that the Company adopted January 1, 2018, not The Company accounts for a contract when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance and collectability of the consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators, among others, when determining if it is acting as a principal in the transaction and recording revenue on a gross basis: (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer and (iii) the Company has discretion in establishing the price for the specified good or service. If a transaction does not The Company’s significant contracts and contractual terms with its customers are presented in Note 10, The Company recognizes revenue when control has passed to the customer. The following indicators are evaluated in determining when control has passed to the customer: (i) the Company has a right to receive payment for the product or service, (ii) the customer has legal title to the product, (iii) the Company has transferred physical possession of the product to the customer, (iv) the customer has the significant risk and rewards of ownership of the product and (v) the customer has accepted the product. For most of the Company's renewable products customers, supply agreements between the Company and each customer indicate when transfer of title occurs. In some cases, the Company may Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may The following is a description of the principal goods and services from which the Company generates revenue. Renewable Product Sales Revenues from renewable product sales are recognized as a distinct performance obligation on a gross basis as the Company is acting as a principal in these transactions, with the selling price to the customer recorded net of discounts and allowances. Revenues are recognized at a point in time when control has passed to the customer, which typically is upon the renewable products leaving the Company’s facilities with the first may not not not two not Licenses and Royalties Licensing of Intellectual Property: Royalties from Licensing of Intellectual Property: When the Company’s intellectual property license is the only performance obligation, or it is the predominant performance obligation in arrangements with multiple performance obligations, the Company applies the sales-based royalty exception which requires the Company to estimate the revenue that is recognized at a point in time when the licensee’s product sales occur. Estimates of sales-based royalty revenues are made using the most likely outcome method, which is the single amount in a range of possible amounts, using the best evidence available at the time, derived from the licensee’s historical sales volumes and sales prices of its products and recent commodity market pricing data and trends. Estimates are adjusted to actual or as new information becomes available. When the Company’s intellectual property license is not not Grants and Collaborative Research and Development Services Collaborative Research and Development Services: one Collaboration agreements are evaluated at inception to determine whether the intellectual property licenses represent distinct performance obligations separate from the research and development services. If the licenses are determined to be distinct, the non-refundable upfront license fee is recognized as revenue at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license while the research and development service fees are recognized over time as the performance obligations are satisfied. The research and development service fees represent variable consideration. Estimates of the amount of variable consideration to include in the transaction price are made using the expected value method, which is the sum of probability-weighted amounts in a range of possible amounts. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not Collaboration agreements that include milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement, and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not The Company generally invoices its collaboration partners on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Deferred revenue arises from amounts received in advance of performing the research and development activities and is recognized as revenue in future periods as the performance obligations are satisfied. Grants: The milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not Cost of Products Sold Cost of products sold includes the production costs of renewable products, which include the cost of raw materials, in-house manufacturing labor and overhead, amounts paid to contract manufacturers, including amortization of tolling fees, and period costs including inventory write-downs resulting from applying lower of cost or net realizable value inventory adjustments. Cost of products sold also includes certain costs related to the scale-up of production. Shipping and handling costs charged to customers are recorded as revenues. Outbound shipping costs incurred are included in cost of products sold. Such charges were not The Company recognizes deferred cost of products sold as an asset on the balance sheet when a cost is incurred in connection with a revenue performance obligation that will not Research and Development Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements and government grants, including internal research. Research and development costs consist of direct and indirect internal costs related to specific projects, as well as fees paid to others that conduct certain research activities on the Company’s behalf. Debt Extinguishment The Company accounts for the income or loss from extinguishment of debt in accordance with ASC 470, Debt, Stock-based Compensation The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of U.S. GAAP. Those provisions require all stock-based payments to employees, including grants of stock options and restricted stock units (RSUs), to be measured using the grant-date fair value of each award. The Company recognizes stock-based compensation expense net of expected forfeitures over each award's requisite service period, which is generally the vesting term. Expected forfeiture rates are estimated based on the Company's historical experience. Stock-based compensation plans are described more fully in Note 12, Income Taxes The Company is subject to income taxes in the United States and foreign jurisdictions and uses estimates to determine its provisions for income taxes. The Company uses the asset and liability method of accounting for income taxes, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect for the year in which the differences are expected to affect taxable income. Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. not The Company applies the provisions of Financial Accounting Standards Board (FASB) guidance on accounting for uncertainty in income taxes. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability, and the tax benefit to be recognized is measured at the largest amount of benefit that is greater than 50 may Foreign Currency Translation The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at each balance sheet date, and revenue and expense amounts are translated at average rates during each period, with resulting foreign currency translation adjustments recorded in other comprehensive loss, net of tax, in the consolidated statements of stockholders’ deficit. As of December 31, 2018 2017, $43.3 $42.2 Where the U.S. dollar is the functional currency, remeasurement adjustments are recorded in other income (expense), net in the accompanying consolidated statements of operations. Net losses resulting from foreign exchange transactions were $1.6 $0.4 December 31, 2018 2017, New Accounting Standards or Updates Recently Adopted During the year ended December 31, 2018 Revenue Recognition 606, Revenue from Contracts with Customers January 1, 2018. 606 606 not January 1, 2018. not 605, The Company applied ASC 606 January 1, 2018, The cumulative effect of initially applying ASC 606 January 1, 2018 $0.8 not The following table presents the amounts by which revenue is affected in the current reporting period by the application of ASC 606 Year Ended December 31, 2018 (In thousands) As Reported Adjustments Amounts Without the Adoption of ASC 606 Renewable products $ 33,598 $ — $ 33,598 Licenses and royalties 7,658 5,094 12,752 Grants and collaborations 22,348 (5,786 ) 16,562 Total revenue from all customers $ 63,604 $ (692 ) $ 62,912 Financial Instruments January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01 January 1, 2018. not Classification of Cash Flow Elements August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15 2016 15 January 1, 2018 not Income Taxes Related to Intra-entity Asset Transfers October 2016, 2016 16, Intra-Entity Transfers of Assets Other Than Inventory 2016 16 January 1, 2018, Restricted Cash in Statement of Cash Flows November 2016, 2016 18, Statement of Cash Flows (Topic 230 January 1, 2018 2016 18 Derecognition of Nonfinancial Assets February 2017, 2017 05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610 20 606 not 1 not not not 2 not January 1, 2018 not Income Taxes March 2018, 2018 05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 not December 31, 2018, December 31, 2017 not 2018 05. may Non-employee Stock-based Compensation June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting, no January 1, 2018 not Recent Accounting Standards or Updates Not Leases February 2016, 2016 02, Leases (Topic 842 The Company is adopting the new standard effective January 1, 2019 not not The adoption of this standard on January 1, 2019 $25.7 not $33.6 $29.7 Financial Instruments with "Down Round" Features July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019 $41.0 $41.0 January 1, 2019. Fair Value Measurement August 2018, 2018 13, Fair Value Measurement (Topic 820 820, Fair Value Measurement 2018 13 first 2020, Collaborative Revenue Arrangements November 2018, 2018 18, Clarifying the Interaction between Topic 808 606 606, two first 2020 not Credit Losses June 2016, 2016 13, Financial Instruments—Credit Losses (Topic 326 2016 13 2016 13 2016 13 first 2020. not

Note 2 - Restatement of Consoli

Note 2 - Restatement of Consolidated Financial Statements	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Accounting Changes and Error Corrections [Text Block]	2. Restatement Background Subsequent to the issuance of the Company's unaudited condensed consolidated financial statements as of September 30, 2018 April 5, 2019 May 14, 2019, March 31, 2018, June 30, 2018 September 30, 2018 ( 2018 December 31, 2017 ( 2017 Restated 2017 During the course of the re-audit of the Restated 2017 2017, The error corrections for the year to date audited 2017 Consolidated Balance Sheet The following table presents the Company's consolidated balance sheet at December 31, 2017 December 31, 2017 (In thousands) As Previously Reported Corrections Ref. As Restated Assets Current assets: Cash and cash equivalents $ 57,059 $ — $ 57,059 Restricted cash 2,994 — 2,994 Accounts receivable, net 24,281 (5,328 ) a 18,953 Accounts receivable - related party, net 9,340 (4,573 ) a 4,767 Accounts receivable, unbilled - related party — 9,901 9,901 Inventories 5,408 — 5,408 Prepaid expenses and other current assets 5,525 (606 ) b 4,919 Total current assets 104,607 (606 ) 104,001 Property, plant and equipment, net 13,892 — 13,892 Accounts receivable, unbilled, noncurrent – related party 7,940 — 7,940 Restricted cash, noncurrent 959 — 959 Recoverable taxes from Brazilian government entities 1,445 — 1,445 Other assets 22,640 (10,081 ) c 12,559 Total assets $ 151,483 $ (10,687 ) $ 140,796 Liabilities, Mezzanine Equity and Stockholders' Deficit Current liabilities: Accounts payable $ 15,921 $ (406 ) d $ 15,515 Accrued and other current liabilities 29,402 (200 ) e 29,202 Contract liabilities 4,880 (572 ) f 4,308 Debt, current portion 36,924 — 36,924 Related party debt, current portion 20,019 — 20,019 Total current liabilities 107,146 (1,178 ) 105,968 Long-term debt, net of current portion 61,893 (1,673 ) g 60,220 Related party debt, net of current portion 46,541 — 46,541 Derivative liabilities 119,978 (3,481 ) h 116,497 Other noncurrent liabilities 10,632 13,026 i 23,658 Total liabilities 346,190 6,694 352,884 Commitments and contingencies Mezzanine equity: Contingently redeemable common stock 5,000 — 5,000 Stockholders’ deficit: Preferred stock — — — Common stock - $0.0001 par value 5 — 5 Additional paid-in capital 1,048,274 66,272 j 1,114,546 Accumulated other comprehensive loss (42,156 ) — (42,156 ) Accumulated deficit (1,206,767 ) (83,653 ) k (1,290,420 ) Total Amyris, Inc. stockholders’ deficit (200,644 ) (17,381 ) (218,025 ) Noncontrolling interest 937 — 937 Total stockholders' deficit (199,707 ) (17,381 ) (217,088 ) Total liabilities, mezzanine equity and stockholders' deficit $ 151,483 $ (10,687 ) $ 140,796 Restatement adjustments: a. Reclassification of related party accounts receivable to a separate line on the balance sheet. b. Write-off of unrecoverable receivable in connection with facilities subleased to a related party. c. Correction of error in recording amounts payable under Ginkgo Partnership Agreement as prepaid royalties instead of reduction in revenue. d. Adjustment to uninvoiced receipts liability. e. Adjustment to accrued liability. f. Revision to accounting for equity received in satisfaction of a customer receivable. g. Adjustment to issuance-date fair value of a debt instrument. h. Make-whole derivative liabilities adjustment. i. Accrual of the Ginkgo Partnership Payments obligation, net of reduction to deferred revenue liability. j. Correction to the accounting for a make-whole equity instrument in connection with May 2017 k. Sum of adjustments to net loss for the year ended December 31, 2017 Consolidated Statement of Operations The following table presents the Company's consolidated statements of operations for the year ended December 31, 2017 Year Ended (In thousands, except shares and per share amounts) As Previously Reported Reclassifications (1) Corrections Ref As Restated Renewable products $ 45,781 $ (3,411 ) $ – $ 42,370 Licenses and royalties 57,703 6,774 (15,774 ) ab 48,703 Grants and collaborations 39,960 (3,363 ) 1 36,598 Total revenue 143,444 – (15,773 ) 127,671 Cost and operating expenses – Cost of products sold 62,713 – (406 ) ad 62,307 Research and development 57,027 (72 ) 607 ae 57,562 Sales, general and administrative 63,219 72 562 af 63,853 Total cost and operating expenses 182,959 – 763 183,722 Loss from operations (39,515 ) – (16,536 ) (56,051 ) Other income (expense) (Loss) gain on divestiture 5,732 – – 5,732 Interest expense (34,033 ) – (3,048 ) ah (37,081 ) (Loss) gain from change in fair value of derivative instruments (1,742 ) – (47,110 ) ai (48,852 ) Loss upon extinguishment of debt (1,521 ) – (10,376 ) ak (11,897 ) Other income (expense), net (955 ) – (1 ) (956 ) Total other expense, net (32,519 ) – (60,535 ) (93,054 ) Loss before income taxes (72,034 ) – (77,071 ) (149,105 ) Provision for income taxes (295 ) – (6,582 ) am (6,877 ) Net loss attributable to Amyris, Inc. (72,329 ) – (83,653 ) (155,982 ) Less deemed dividend on capital distribution to related parties (8,648 ) – 8,648 an – Less deemed dividend related to beneficial conversion feature on Series A preferred stock (562 ) – – (562 ) Less deemed dividend related to beneficial conversion feature on Series B preferred stock (634 ) – – (634 ) Less deemed dividend related to beneficial conversion feature on Series D preferred stock (5,757 ) – – (5,757 ) Less deemed dividend upon settlement of make-whole provision on Series A preferred stock – – (10,505 ) ap (10,505 ) Less deemed dividend upon settlement of make-whole provision on Series B preferred stock – – (22,632 ) aq (22,632 ) Less deemed dividend related to proceeds discount and issuance costs upon conversion of Series A preferred stock – – (21,578 ) ar (21,578 ) Less deemed dividend related to proceeds discount and issuance costs upon conversion of Series B preferred stock – – (24,366 ) as (24,366 ) Less cumulative dividends on Series A and Series B preferred stock (5,439 ) – 5,439 aw – Add: losses allocated to participating securities – – 40,159 au 40,159 Net loss attributable to Amyris, Inc. common stockholders $ (93,369 ) – $ (108,488 ) $ (201,857 ) Net loss per share attributable to common stockholders Basic and diluted $ (2.89 ) $ (6.26 ) Weighted-average shares of common stock outstanding used in computing loss per share of common stock: Basic and diluted 32,253,570 32,253,570 ( 1 Restatement adjustments: ab. Ginkgo partnership obligation and promissory note issuance recorded as reduction to revenue and correction of errors in recording revenue from non-cash consideration. ad. Correction in connection with a sales return, and adjustment to uninvoiced receipts liability. ae. Write-off of unrecoverable receivable in connection with facilities subleased to a related party, and reclassification of operating expense by classification to conform to the Company's current presentation. af. Expense incurred in connection with May 2017 ah. Correction to amortization of debt discounts, and interest expense in connection with partnership payments obligation. ai. Correction to accounting for make-whole liability in connection with May 2017 ak. Loss on extinguishment of related and unrelated party debt. am. Tax provision to accrue liability for unrecognized tax benefit. an. Loss on extinguishment of related and unrelated party debt. ap. Correction to record deemed dividend in connection with discounts and freestanding instruments related to preferred stock offerings. aq. Correction to record deemed dividend in connection with discounts and freestanding instruments related to preferred stock offerings. ar. Correction to record deemed dividend in connection with discounts and freestanding instruments related to preferred stock offerings. as. Correction to record deemed dividend in connection with discounts and freestanding instruments related to preferred stock offerings. au. Correction in the computation of loss per share to reflect participating securities. aw. Correction in the computation of net loss per share related to make-whole deemed dividends. Consolidated Statement of Cash Flows The following table presents the Company's consolidated statements of cash flows for the year ended December 31, 2017 December 31, 2017 December 31, 2017, 2016 18, Year Ended December 31, 2017 (In thousands) As Previously Reported Corrections (1) As Restated Operating activities Net loss $ (72,329 ) (83,653 ) $ (155,982 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 11,358 – 11,358 (Gain) loss on disposal of property, plant and equipment 142 – 142 Stock-based compensation 6,265 – 6,265 Amortization of debt discount 12,490 2,749 15,239 (Gain) loss upon extinguishment of debt 1,521 10,376 11,897 Receipt of equity in connection with collaboration arrangements revenue (2,661 ) 2,661 – (Gain) loss from change in fair value of derivative liabilities 1,742 47,110 48,852 (Gain) loss on foreign currency exchange rates (1,230 ) – (1,230 ) Noncash revenue reduction related to issuance of debt obligations – 13,413 13,413 Non-cash gain on divestiture (5,732 ) – (5,732 ) Receipt of noncash consideration in connection with license revenue (8,046 ) – (8,046 ) Changes in assets and liabilities: Accounts receivable (19,647 ) – (19,647 ) Accounts receivable, unbilled – related party (7,940 ) – (7,940 ) Inventories (3,126 ) – (3,126 ) Prepaid expenses and other assets (19,336 ) 606 (18,730 ) Accounts payable 5,858 (406 ) 5,452 Accrued and other liabilities 7,295 6,582 13,877 Contract liabilities (7,241 ) – (7,241 ) Net cash used in operating activities (100,617 ) (562 ) (101,179 ) Investing activities Proceeds from divestiture 54,827 – 54,827 Change in short-term investments 712 581 1,293 Change in restricted cash 865 (865 ) – Purchases of property, plant and equipment (4,412 ) – (4,412 ) Net cash (used in) provided by investing activities 51,992 (284 ) 51,708 Financing activities Proceeds from issuance of convertible preferred stock 101,124 (2,878 ) 98,246 Proceeds from exercises of common stock options 160 (160 ) – Payment of minimum employee taxes withheld upon net share settlement of restricted stock units (385 ) – (385 ) Proceeds from issuance of common stock in August 2017 offering – 5,759 5,759 Issuance costs incurred – (2,159 ) (2,159 ) Change in restricted cash related to contingently redeemable common stock 1,046 (1,046 ) – Proceeds from issuance of debt, net of issuance costs 18,925 – 18,925 Principal payments on debt (37,500 ) – (37,500 ) Payment of swap termination (3,113 ) – (3,113 ) Payment on early redemption of debt (1,909 ) – (1,909 ) Net cash provided by financing activities 78,348 (484 ) 77,864 Effect of exchange rate changes on cash, cash equivalents and restricted cash 186 – 186 Net (decrease) increase in cash, cash equivalents and restricted cash 29,909 (1,330 ) 28,579 Cash, cash equivalents and restricted cash at beginning of year 27,150 5,283 32,433 Cash, cash equivalents and restricted cash at end of year $ 57,059 3,953 61,012 Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets Cash and cash equivalents $ 57,059 Restricted cash, current 2,994 Restricted cash, noncurrent 959 Total cash, cash equivalents and restricted cash $ 61,012 Supplemental disclosures of cash flow information: Cash paid for interest $ 11,539 $ – $ 11,539 Supplemental disclosures of non-cash investing and financing activities: Issuance of common stock upon conversion of debt $ 28,702 $ – $ 28,702 Accrued interest added to debt principal $ 2,816 $ – $ 2,816 Issuance of common stock for settlement of debt principal and interest payments $ 3,436 $ – $ 3,436 Financing of insurance premium under note payable $ 467 $ – $ 467 Issuance of convertible preferred stock upon conversion of debt $ 40,204 $ – $ 40,204 Settlement of debt principal by a related party $ 25,000 $ – $ 25,000 Issuance of note payable in exchange for debt extinguishment with third party $ 16,954 $ – $ 16,954 Issuance of common stock for settlement of debt $ 10,708 $ – $ 10,708 Issuance of preferred stock attributed to derivative liabilities $ – $ 72,725 $ 72,725 ( 1

Note 3 - Balance Sheet Details

Note 3 - Balance Sheet Details	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	3. Allowance for Doubtful Accounts Allowance for doubtful accounts activity and balances were as follows: (In thousands) Balance at Provisions Recoveries Balance at Allowance for doubtful accounts: Year Ended December 31, 2018 $ 642 $ – $ – $ 642 Year Ended December 31, 2017 (as restated, Note 2) $ 501 $ 141 $ – $ 642 Inventories December 31, 2018 2017 (As Restated, Note 2) Raw materials $ 3,901 $ 819 Work in process 539 364 Finished goods 5,253 4,225 Total inventories $ 9,693 $ 5,408 Prepaid expenses and other current assets December 31, 2018 2017 (As Restated, Note 2) Prepayments, advances and deposits $ 5,644 $ 3,599 Recoverable taxes from Brazilian government entities 631 87 Other 4,291 1,233 Total prepaid expenses and other current assets $ 10,566 $ 4,919 Property, plant and equipment, net December 31, 2018 2017 (As Restated, Note 2) Machinery and equipment $ 43,713 $ 46,317 Leasehold improvements 39,922 40,036 Computers and software 9,987 9,555 Furniture and office equipment, vehicles and land 3,016 3,415 Construction in progress 1,749 2,838 Total property, plant and equipment, gross 98,387 102,161 Less: accumulated depreciation and amortization (78,631 ) (88,269 ) Total property, plant and equipment, net $ 19,756 $ 13,892 Property, plant and equipment, net includes $5.0 $4.2 December 31, 2018 2017, $2.3 $1.6 December 31, 2018 2017, Depreciation and amortization expense, including amortization of assets under capital leases, was $4.9 $11.4 December 31, 2018 2017, Losses on disposal of property, plant and equipment were $0.9 $0.1 December 31, 2018 2017, In December 2017, 13, 11, Other assets December 31, 2018 2017 (As Restated, Note 2) Contingent consideration $ 4,286 $ 8,150 Deposits 2,465 2,462 Other 1,207 1,947 Total other assets $ 7,958 $ 12,559 Accrued and other current liabilities December 31, 2018 2017 (As Restated, Note 2) Payroll and related expenses $ 9,220 $ 7,238 Contract termination fees 4,092 — Accrued interest 3,853 8,213 Asset retirement obligation (1) 3,063 3,587 Ginkgo partnership payments obligation 2,155 — Tax-related liabilities 2,139 5,837 Professional services 1,173 1,694 Other 3,284 2,633 Total accrued and other current liabilities $ 28,979 $ 29,202 ______________ ( 1 The asset retirement obligation represents liabilities incurred but not 2013 Other noncurrent liabilities December 31, 2018 2017 (As Restated, Note 2) Liability for unrecognized tax benefit $ 6,582 $ 6,582 Deferred rent, net of current portion 6,440 7,818 Ginkgo partnership payments obligation, net of current portion 6,185 6,444 Contract liabilities, net of current portion 1,587 383 Contract termination fees, net of current portion (1) 1,530 — Capital leases, net of current portion 195 217 Other 673 2,214 Total other noncurrent liabilities $ 23,192 $ 23,658 ______________ ( 1 Contract liabilities, net of current portion at December 31, 2018 2017 $1,204 $383 In November 2017, one $0.8 December 31, 2018 September 2022. December 31, 2018, $12.7 $6.1 $6.6 five $12.0 $8.0 10, In September 2019, December 2017 not $3.9 not December 31, 2018.

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurement	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	4. Assets and liabilities are measured and reported at fair value per related accounting standards that define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset's or liability's level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one three • 1: • 2: • 3: not Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis As of December 31, 2018 2017, December 31, 2018 2017 (As Restated, Note 2) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Money market funds $ — — $ — $ — $ 53,199 $ — $ — $ 53,199 Certificates of deposit — — — — — 4,153 — 4,153 Total assets measured and recorded at fair value $ — — $ — $ — $ 53,199 $ 4,153 $ — $ 57,352 Liabilities 6% Convertible Notes Due 2021 $ — — $ 57,918 $ 57,918 $ — $ — $ — $ — Embedded derivatives in connection with the issuance of debt and equity instruments — — — — — — 723 723 Freestanding derivative instruments in connection with the issuance of equity instruments — — 42,796 42,796 — — 115,774 115,774 Total liabilities measured and recorded at fair value $ — $ — $ 100,714 $ 100,714 $ — $ — $ 116,497 $ 116,497 There were no 2018 2017. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgements and consider factors specific to the asset or liability. The fair values of money market funds and certificates of deposit are based on fair values of identical assets. The method of determining the fair value of compound embedded derivative liabilities is described subsequently in this note. Market risk associated with compound embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates. At December 31, 2018 December 31, 2017, Changes in fair value of derivative liabilities are presented as gains or losses in the consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of derivative instruments". Changes in the fair value of debt that is accounted for at fair value are presented as gains or losses in the consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of debt". 6% 2021 The Company issued $60.0 6% 2021 December 10, 2018 ( 5, December 31, 2018, $60.0 $57.9 25.2% 45% 50% 50% 5% 5, 8, December 31, 2018, $2.1 6% 2021, In thousands Fair value at issuance on December 10, 2018 $ 60,000 Change in fair value (2,082 ) Fair value at December 31, 2018 $ 57,918 Derivative Instruments Derivative instruments measured at fair value on a recurring basis as of December 31, 2018 2017 December 31, (In thousands) 2018 2017 (As Restated, Note 2) Equity-related derivative liabilities $ 41,272 $ 108,887 Debt-related derivative liabilities 1,524 7,610 Total derivative liabilities $ 42,796 $ 116,497 The following table provides a reconciliation of the beginning and ending liability balances associated with derivative liabilities – either freestanding or compound embedded – measured at fair value using significant unobservable inputs (Level 3 (in thousands) 2018 2017 (As Restated, Note 2) Balance at January 1 $ 116,497 $ 4,135 Additions 4,089 133,517 Loss from change in fair value of derivative liabilities 30,880 48,852 Derecognition to additional paid-in capital upon conversion or extinguishment (108,670 ) (70,007 ) Balance at December 31 $ 42,796 $ 116,497 The liabilities associated with freestanding and compound embedded derivatives represent the fair value of the equity conversion options, make-whole provisions, down round conversion price or conversion rate adjustment provisions and antidilution provisions in some of the Company's debt, preferred stock, cash warrants and antidilution warrants; see Note 5, 7, no A binomial lattice model was used to determine if a convertible note or share of convertible preferred stock would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the convertible note or share of convertible preferred stock will be converted early if the conversion value is greater than the holding value and (ii) the convertible note or share of convertible preferred stock will be called if the holding value is greater than both (a) redemption price and (b) the conversion value at the time. If the convertible note or share of convertible preferred stock is called, the holder will maximize their value by finding the optimal decision between ( 1 2 not The Company used a Monte Carlo simulation valuation model to determine the fair value of the May 2017 August 2017 The market-based assumptions and estimates used in valuing the compound embedded and freestanding derivative liabilities include amounts in the following ranges/amounts: December 31, 2018 2017 Risk-free interest rate 2.5% - 3.0% 1.7% - 2.4% Risk-adjusted discount yield 17.2% - 27.3% 18.4% - 28.5% Stock price volatility 45.0% - 85.0% 45.0% - 80.0% Probability of change in control 0.0% 5.0% Stock price $3.34 $3.75 Credit spread 14.6% - 24.9% 16.6% - 26.7% Estimated conversion dates 2019 - 2025 2018 - 2025 Changes in valuation assumptions can have a significant impact on the valuation of the embedded and freestanding derivative liabilities and debt that the Company elects to account for at fair value. For example, all other things being equal, a decrease/increase in the Company’s stock price, probability of change of control, credit spread, term to maturity/conversion or stock price volatility decreases/increases the valuation of the liabilities, whereas a decrease/increase in risk adjusted yields or risk-free interest rates increases/decreases the valuation of the liabilities. Certain of the convertible notes, shares of convertible preferred stock and warrants also include conversion or exercise price adjustment features and, for example, certain issuances of common stock by the Company at prices lower than the current conversion or exercise price result in a reduction of the conversion price of such notes or convertible preferred stock, or a reduction in the exercise price of, or an increase in the number of shares subject to, such warrants, which increases the value of the embedded and freestanding derivative liabilities and debt measured at fair value; see Note 5, The Series A Preferred Stock issued in May 2017 May 2017 ( 7, July 2017 May 2017 August 2017 August 2017 May 2017 August 2017 August 2017 $113.1 In June 2012, R$22.0 $6.6 December 31, 2017 4, 3.94%. December 31, 2017, Assets and Liabilities Recorded at Carrying Value Financial Assets and Liabilities The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable, credit facilities and convertible notes are recorded at carrying value (except for the 6% 2021, 2 3 December 31, 2018, 6% December 31, 2017, $151.7 $165.4 December 31, 2018 December 31, 2017 $149.3 $156.9 third Assets and Liabilities Measured and Recorded at Fair Value on a Non-Recurring Basis On November 19, 2018, 10, $22.7 1,643,991 $6.1 $7.3 March 29, 2019. $2.9 $1.8 2017 11, 16, November 2018 $33.3 Element Fair Value Allocation Manufacturing capacity reservation fee $ 24,395 Legal settlement and consent waiver 6,764 Working capital adjustment 2,145 Total fair value of consideration transferred $ 33,304 The fair value of these elements is based on Level 3 22.5% 0% August 2018 August 2018

Note 5 - Debt

Note 5 - Debt	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	5. December 31, (In thousands) 2018 2017 Principal Unamortized Change in Net Principal Unamortized Net Convertible notes payable (As Restated, Note 2) 6% convertible notes due 2021 $ 60,000 $ – $ (2,082 ) $ 57,918 $ – $ – $ – 2015 Rule 144A convertible notes 37,887 (2,413 ) – 35,474 37,887 (9,458 ) 28,429 2014 Rule 144A convertible notes 24,004 (867 ) – 23,137 24,004 (3,170 ) 20,834 August 2013 financing convertible notes 4,415 (70 ) – 4,345 4,009 (2,126 ) 1,883 December 2017 convertible notes – – – – 5,000 (25 ) 4,975 126,306 (3,350 ) (2,082 ) 120,874 70,900 (14,779 ) 56,121 Related party convertible notes payable 2014 Rule 144A convertible notes 24,705 (1,038 ) – 23,667 24,705 (3,784 ) 20,921 August 2013 financing convertible notes – – – – 21,711 897 22,608 R&D note – – – – 3,700 (18 ) 3,682 24,705 (1,038 ) – 23,667 50,116 (2,905 ) 47,211 Loans payable and credit facilities GACP term loan facility 36,000 (1,349 ) – 34,651 – – – Ginkgo note 12,000 (4,047 ) – 7,953 12,000 (4,862 ) 7,138 Other loans payable 4,910 (1,047 ) – 3,863 6,463 (1,277 ) 5,186 Senior secured loan facility – – – – 28,566 (253 ) 28,313 Other credit facilities – – – – 381 – 381 52,910 (6,443 ) – 46,467 47,410 (6,392 ) 41,018 Related party loans payable DSM note 25,000 (6,311 ) – 18,689 25,000 (8,039 ) 16,961 February 2016 private placement – – – – 2,000 – 2,000 Other DSM loan – – – – 393 – 393 25,000 (6,311 ) – 18,689 27,393 (8,039 ) 19,354 Total debt $ 228,921 $ (17,142 ) $ (2,082 ) 209,697 $ 195,819 $ (32,115 ) 163,704 Less: current portion (147,677 ) (56,943 ) Long-term debt, net of current portion $ 62,020 $ 106,761 Future minimum payments under the debt agreements as of December 31, 2018 Years ending December 31 Convertible Notes Loans Related Party Convertible Notes Related Party Loans Payable and Credit Facilities Total 2019 $ 134,368 $ 10,219 $ 25,508 $ 2,500 $ 172,595 2020 — 9,981 — 2,500 12,481 2021 — 34,740 — 27,521 62,261 2022 — 13,417 — — 13,417 2023 — 367 — — 367 Thereafter — 2,200 — — 2,200 Total future minimum payments 134,368 70,924 25,508 32,521 263,321 Less: amount representing interest (1) (7,368 ) (18,014 ) (803 ) (7,521 ) (33,706 ) Less: future conversion of accrued interest to principal (694 ) — — — (694 ) Present value of minimum debt payments 126,306 52,910 24,705 25,000 228,921 Less: current portion of debt principal (126,306 ) (3,829 ) (24,705 ) — (154,840 ) Noncurrent portion of debt principal $ — $ 49,081 $ — $ 25,000 $ 74,081 ______________ ( 1 Excluding net debt discount of $17.1 Convertible Notes Payable 6% 2021 On December 6, 2018, $60.0 6% 2021 December 6, 2018 90 December 10, 2018 30 6% 2021 The closing of the issuance and sale of the 6% 2021 December 10, 2018, $56.2 The 6% 2021 6% 2021 third 6% 2021 $6.32 6% 2021 The 6% 2021 April 1, 2019 ( 108% 6% 2021 6% 2021 three The 6% 2021 6% first 6% 2021 may January 1, 2019 The 6% 2021 may 6% 2021 125% may 6% 2021 In the event of a Fundamental Transaction (as defined in the 6% 2021 6% 2021 may 6% 2021 125% Notwithstanding the foregoing, the holders will not 6% 2021, not 4.99% not 9.99%, not 61 6% 2021 15,271,047 6% 2021 6% 2021 6% 2021 6% 2021 In connection with the offering of the 6% 2021, December 10, 2018, 6% 2021, 6% 2021 1933, 30 December 10, 2018, 60 December 10, 2018. not not not 2% 30 no January 8, 2019, February 7, 2019. The Company has elected to account for the 6% 2021 6% 2021, 6% 2021. December 31, 2018, $2.1 4. 4, 6% 2021. In May, June July 2019, 6% 2021 16, 2015 144A In October 2015, $57.6 9.50% 2019 2015 144A $54.4 $18.3 $22.9 2014 144A 2015 144A 9.50% April 15 October 15 2015 144A 92.5% April 15, 2016 2017 October 15, 2018 October 15, 2016 2017 April 15, 2018 2015 144A April 15, 2019. 16, The 2015 144A 61.7246 $1,000 2015 144A $16.20 December 31, 2018. 2015 144A April 15, 2019, 0.75%. may 92.5% December 31, 2018, In January 2017, $19.1 2015 144A 2015 144A $15.3 2015 144A 2015 144A 3,652,935 $0.1 December 31, 2017. In May 2017, $3.7 2015 144A 17.38% 7, $2.0 December 31, 2017. On April 16, 2019, 2015 144A 16, 2014 144A In May 2014, $75.0 6.50% 2019 2014 144A $72.0 $9.7 2014 144A $24.7 2014 144A 2014 144A 6.5%, May 15 November 15 2014 144A May 15, 2019, The 2014 144A 17.8073 $1,000 2014 144A $56.16 December 31, 2018. In May 2017, $3.4 2014 144A 17.38% 7, $1.8 December 31, 2017. In May 2019, 2014 144A $38.2 2014 144A 16, 2014 144A August 2013 In August 2013, August 2013 $73.0 August 2013 August 2013 August 2013 two sixty October 16, 2018). 5% six $15.2 October 16, 2018 August 2013 $10.9 2018. The Tranche II Notes are due sixty January 15, 2019). 10% December 31, 2018, November 8, 2018, $9.8 August 2013 $6.5 In August 2018, August 2017 7, $5.2977 $4.40 December 31, 2018, $4.40 August 2013 $200 50% $125 30% August 2013 one $20.0 may On January 14, 2019, July 15, 2019 July 15, 2019, $0.6 July 2, 2019, 1,767,632 1,080,000 16, Maturity Treatment Agreement In July 2015, 2015 $71.0 $70.0 $34.50 2015 2015 July 29, 2015, 2014 144A not 2015 not May 2017, 2014 144A $9.7 December 31, 2017 $10.0 December 31, 2017 no December 31, 2017, not $21.8 October November 2018 August 2013 2015 $200 50% $125 30% December 2017 In December 2017, April 2017 $5.0 June 1, 2018, $5.0 $0, May 2018. Related Party Convertible Notes Payable August 2013 Certain of the August 2013 11, On October 16, 2018, $15.2 3,448,821 $10.9 On November 8, 2018, $9.8 January 15, 2019, 2,226,105 $6.5 2014 144A Certain of the 2014 144A 11, R&D Note In March 2016, $3.7 $105.0 2012. March May 2018, May 31, 2018 July 2, 2018, March 31, 2018, May 31, 2018 July 2, 2018. July 2, 2018, Loans Payable and Credit Facilities GACP Term Loan Facility On June 29, 2018, $36.0 $35.0 July 2, 2018 Loans under the GACP Term Loan Facilities have a maturity date of July 1, 2021; not January 7, 2019 2015 144A 2014 144A July 1, 2021 January 12, 2019, January 12, 2019. 16, July 1, 2019 2.5% 4.0%, 6.25%, first The Company paid origination fees at closing equal to 4%, $1.4 $0.2 $25,000 $1.6 3 In November 2018, two December 31, 2018 4.0% 6.25% 4.0% 8.25%. December 2018, 10, 4.0% 8.25% 4.75% 9.00%. In April 2019, ( December 31, 2018 April 8, 2019, June 30, 2020 16, Senior Secured Loan Facility In March 2014, $25.0 June 2014, March 2015 November 2015 $31.0 $16.0 In June 2016, In March May 2018, $5.5 May 31, 2018 July 2, 2018, April 1, 2018 $5.5 5.0%. On June 29, 2018, Ginkgo Note In November 2017, $12.0 November 2017 10, November 2017 10.5% October 19, 2022. November 2017 may November 2017 may $7.0 November 2017 $5.0 no November 2017 November 2017 $7.0 December 31, 2017. 10, Other Loans Payable Nikko Note: December 2016, $3.9 December 2016, $3.5 5% 13 January 1, 2017 first 10% $400,000 $100,000 January 1, 2017, February 1, 2017, March 1, 2017 April 1, 2017 fourth may may Aprinnova Working Capital Loans: February 2017, December 2016, $1.5 $375,000 May 1, 2017, August 1, 2017, November 1, 2017 February 1, 2018. January 2018. August 2017, second $1.5 August 1, 2019, 2.75% July 31, 2019, August 1, 2020. 16, Related Party Loans Payable DSM Note In December 2017, $25.0 December 28, 2017, $25.0 $25 December 2016 ( $8.0 The DSM Note (i) is an unsecured obligation of the Company, (ii) matures on December 31, 2021 December 28, 2017 10% may 10, may February 2016 In February 2016, $20.0 February 2016 190,477 $0.15 December 31, 2018 February 2016 $20.0 five $16.0 February 2016 152,381 $2.0 February 2016 19,048 $2.0 February 2016 19,048 The February 2016 13.50% May 15, 2017. May 2017, February 2016 17.38% 7, In May 2017, February 2016 November 15, 2017, November 13, 2017, December 31, 2017. January 2, 2018. The February 2016 five February 2016 December 31, 2017, $0.1 December 31, 2018, none 171,429 February 2016 For information regarding related party loans payable subsequent to December 31, 2018, 16, Letters of Credit In June 2012, $1.0 $1.0 December 31, 2018 2017.

Note 6 - Mezzanine Equity

Note 6 - Mezzanine Equity	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Mezzanine Equity Disclosure [Text Block]	6. Mezzanine equity at December 31, 2018 2017 May 10, 2016 April 8, 2016, 292,398 $17.10, twenty April 7, 2016, $5.0 In connection with the entry into the Securities Purchase Agreement, on April 8, 2016, not 2017. third $17.10 10%. December 31, 2018, $0.7

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7. Warrants The Company issues warrants in certain debt and equity transactions in order to facilitate raising equity capital or reduce borrowing costs. In connection with various debt and equity transactions (see Note 5, May 2017 August 2017 July 2015 December 31, 2018: Transaction Number Outstanding as of Additional Exercises Number Outstanding as of August 2018 warrant exercise agreements – 12,097,164 – 12,097,164 May 2017 cash and dilution warrants 18,042,568 – (11,749,770 ) 6,292,798 August 2017 cash and dilution warrants 9,543,234 1,713,565 (7,288,683 ) 3,968,116 April 2018 warrant exercise agreements – 3,616,174 – 3,616,174 July 2015 related party debt exchange 2,082,010 471,204 (1,889,986 ) 663,228 February 2016 related party private placement 171,429 – – 171,429 July 2015 private placement 81,197 – – 81,197 Other 1,406 – – 1,406 29,921,844 17,898,107 (20,928,439 ) 26,891,512 For information regarding warrants issued subsequent to December 31, 2018, 16, Shares Issuable under Convertible Notes In connection with various debt transactions (see Note 5, December 31, 2018, Debt Instrument Number of Shares into Which 6% convertible notes due 2021 9,493,672 2015 Rule 144A convertible notes 2,338,560 August 2013 financing convertible notes 1,003,554 2014 Rule 144A convertible notes 867,376 13,703,162 2018 April 2018 On April 12, 2018, May 2017 “May 2017 May 2017 3,616,174 $14.5 May 2017 May 2017 May 2017 May 2017 May 2017 May 2017 3,616,174 $7.00 July 12, 2019. not six not September 26, 2018, October 11, 2018. August 2018 In August 2018 May 2017 August 2017 “August 2017 12.6 $43.0 August 2017 $6.39 $4.40 August 2017 May 2017 August 2017 12.1 $7.52 six 15 May 2020. not twelve not Temasek Funding Warrant – Related Party Following amendments to certain common stock purchase warrants in August 2018 ( “May 2017 “August 2017 August 2013 $5.2977 $4.40 5, 471,204 October 19, 2018, 1,889,986 1,852,585 December 31, 2018, 471,204 $14.0 November 2018 On November 20, 2018, 1,643,991 $3.68 November 19, 2018, 10, $4.41 March 28, 2019, 1,643,991. $1.2 $4.41 November 20, 2018. December 31, 2018 $1.8 $0.6 December 31, 2018. March 28, 2019, $2.10, $3.8 181 not 144 11, November 2018 April 2019, 10, $4.41 March 28, 2019. 16, At Market Issuance Sales Agreement On March 8, 2016, $50.0 3 No. 333 203216 April 15, 2015. 415 1933, 3.0% no During the year ended December 31, 2018, 205,168 $6.90 $1.4 During December 31, 2017, not April 15, 2018, zero December 31, 2018. May 2017 In May 2017, 22,140 17.38% 70,904 17.38% 7,384,190 $7.80 7,384,190 $9.30 May 2017 May 2017 The May 2017 $50.7 May 2017 $22.1 May 2017 $30.7 $40.2 $33.1 Series A and B Preferred Stock Series A Prefer red Stock Each share of Series A Preferred Stock has a stated value of $1,000 $17.25 not October 9, 2017, 90th July 2017 May 2017 Dividends, at a rate per year equal to 17.38% tenth October 15 April 15, October 15, 2017, tenth $1,738 per $1,000 not first Unless and until converted into common stock in accordance with its terms, the Series A Preferred Stock has no Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Preferred Stock shall be entitled to receive out of the assets of the Company the same amount that a holder of Common Stock would receive if the Series A Preferred Stock were fully converted to common stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series A Preferred Stock is convertible at such time), which amount shall be paid pari passu The conversion of the Series A Preferred Stock is subject to a beneficial ownership limitation of 4.99% not 9.99%, not 61 May 2017 July 2017 not 3,792,778 May 2017 The Series A Preferred Stock is classified as permanent equity, as the Company controls all actions or events required to settle the optional and mandatory conversion feature in shares. The Make-Whole Payment was determined to be an embedded derivative requiring bifurcation and separate recognition as a derivative liability recognized at its fair value as of the issuance date with subsequent changes in fair value recorded in earnings until the earlier of (i) July 7, 2017 $11.0 July 7, 2017 July 7, 2017, May 2017 $10.6 $0.6 $0.6 As of December 31, 2017, 22,140 zero May 2017 $21.6 $10.5 Series B Preferred Stock The Series B Preferred Stock has substantially identical terms to the Series A Preferred Stock, except that (i) the conversion of the Series B Preferred Stock was subject to the July 2017 May 2017 not “July 2017 July 2017 May 2017 The investors that purchased shares of the Series B Preferred Stock included related parties affiliated with members of the Board: Foris exchanged an aggregate principal amount of $27.0 30,729 May 2017 4,877,386 $2.0 2,333 May 2017 370,404 $8.6 The investors that purchased shares of the Series B Preferred Stock also included non-related party holders of the Company's 2014 144A 2015 144A $3.4 2014 144A $3.7 2015 144A May 2017 May 2017 $1.9 Issuance costs of $1.2 $0.2 May 2017 Upon the closing of the May 2017 A derivative liability was recognized at fair value on the date of issuance for the May 2017 $12.4 May 2017 $11.9 May 2017 May 2017 $24.4 May 2017 $22.6 May 2017 three September 30, 2017 July 2017 $0.6 As of December 31, 2018, 89,528 August 2017 6,376 December 31, 2017, 9,213 May 2017 Warrants The Company issued to each investor in the May 2017 100% 14,768,380 May 2017 May 2017 three May 2017 May 2017 December 31, 2017, May 2017 $4.40 no May 2017 December 31, 2018, May 2017 $4.40 8,523,560 May 2017 “April 2018 “August 2018 In addition, the Company issued to each investor a warrant, with an exercise price of $0.0015 December 31, 2018 May 2017 May 2017 $6.30, December 31, 2018, May 2017 6,377,466 $4.40 6,329,488 $64.1 “April 2018 “August 2018 May 2017 The May 2017 five July 2017 May 2017 May 2017 May 2017 August 2018 “August 2018 May 2017 May 2017 May 2017 May 2017 $39.5 December 31, 2018, May 2017 $24.1 third For the years ended December 31, 2018 2017, $13.5 $40.4 May 2017 May 2017 July 2022. July 2017 Stockholder Approval In connection with the May 2017 May 2017 May 2017 July 2017 July 10, 2017, July 2017 May 2017 July 7, 2017. August 2017 – Related Party On August 7, 2017, in a private placement ( August 2017 • 25,000 August 2017 $1,000 • a warrant to purchase 3,968,116 $6.30 five August 2017 • the August 2017 Net proceeds to the Company were $25.9 The exercise price of the August 2017 three August 7, 2017 ( August 2017 December 31, 2018, August 2017 $4.40 The August 2017 $6.30, $0.10 August 2017 five In connection with the August 2017 not October 31, 2017, ( May 11, 2018 November 19, 2018, August 2017 $6.30 $4.40 “August 2018 7 $6.8 December 31, 2018 4, November 2018 11, August 2017 1,713,565 $0.0001 November 2018. In connection with the August 2017 May 11, 2017 ( one 4.5%, not May 2017 May 2018 three no not, 33% one 1933, May 2017 second 10%, August 2017 In addition, pursuant to the Amended and Restated DSM Stockholder Agreement, the Company and DSM agreed to negotiate in good faith regarding an agreement concerning the development of certain products in the Health & Wellness field and, in the event that the parties did not 90 August 2017 August 2017 first August 2017 $5.0 not $25.0 September 2017, August 2017 In connection with the August 2017 $25.9 $9.0 October 28, 2017, 2018. $7.1 $34.0 August 2017 August 2017 August 2017 3 August 2017 $15.6 $0.2 August 2017 not August 2017 August 2017 $10.6 August 2017 August 2017 December 31, 2018 2017 $7.5 $4.0 As of December 31, 2018, August 2017 The DSM Credit Letter was initially recorded as deferred revenue at its $7.1 18 4 50% 90% 8.6% $34.0 $7.8 $3.3 December 31, 2017. December 2017, $4.5 10, August 2017 – Related Party On August 3, 2017, August 2017 $24.8 • 2,826,711 $4.26 • 12,958 $1,000 • warrants to purchase an aggregate of 5,575,118 $6.39 five August 2017 • the August 2017 Each share of Series D Preferred Stock has a stated value of $1,000 August 2017 $4.26 Prior first $0.0001 no December 31, 2018 2017. Unless no The Series D Preferred Stock is classified as permanent equity, as the Company controls all actions or events required to settle the optional conversion feature in shares. The August 2017 August 2017 $13.0 third 3 December 31, 2018 $7.7 $3.0 December 31, 2018 2017, $12.0 $25.0 $5.6 $0.2 August 2017 $6.2 $5.8 $12.0 $6.2 $5.8 third 2017. At December 31, 2018 2017, 8,280 12,958 third 2018 4,678 August 2017 $6.8 In the event of a Fundamental Transaction, the holders of the Series D Preferred Stock will have the right to receive the consider pari passu one 50% 50% Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series D Preferred Stock shall be entitled to receive out of the assets of the Company the same amount that a holder of common stock would receive if the Series D Preferred Stock were fully converted to common stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series D Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of common stock. The conversion of the Series D Preferred Stock is subject to a beneficial ownership limitation of 9.99% August 2017 may 61 The exercise price of the August 2017 three August 3, 2017 ( August 2017 August 2018 “August 2018 August 2017 $6.39 $4.40 August 2017 The August 2017 $4.26, August 2017 five As of December 31, 2017, none August 2017 December 31, 2018, 5,575,118 August 2017 August 2017 not August 2018 “August 2018 August 2017 August 2017 In connection with the August 2017 not In connection with the August 2017 4.5%, one . Furthermore, Vivo will have the right to purchase additional shares of capital stock of the Company in connection with a sale of equity or equity-linked securities by the Company in a capital raising transaction for cash, subject to certain exceptions, to maintain its proportionate ownership percentage in the Company. Vivo agreed not August 2017 August 2018 . three August 2017 three no not, 33% one August 2017 August 2017 May 2017 Exchange of Common Stock for Series C Convertible Preferred Stock - Related Party In May 2017, May 2017 1,394,706 20,921 $0.0001 Each share of Series C Preferred Stock had a stated value of $1,000 $15.00 The shares of Series C Preferred Stock automatically converted to common stock on June 6, 2017 May 2017 no July 2015 In July 2015, 1,068,379 $23.40 $25.0 $0.15 10% December 31, 2018 2017, 25,643 81,197 For information regarding issuances of equity securities subsequent to December 31, 2018, 8, Right of First Investment to Certain Investors In connection with investments in the Company has granted certain investors, including Vivo and DSM, a right of first may

Note 8 - Net Loss Per Share Att

Note 8 - Net Loss Per Share Attributable to Common Stockholders	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	8. The Company computes net loss per share in accordance with ASC 260, December 31, 2018 2017, The Company follows the two two two The following table presents the calculation of basic and diluted net loss per share of common stock attributable to Amyris, Inc. common stockholders: Years Ended December 31, (In thousands, except shares and per share amounts) 2018 2017 (As Restated, Note 2) Net loss attributable to Amyris, Inc. (230,235 ) (155,982 ) Less deemed dividend related to beneficial conversion feature on Series A preferred stock — (562 ) Less deemed dividend related to beneficial conversion feature on Series B preferred stock — (634 ) Less deemed dividend related to beneficial conversion feature on Series D preferred stock — (5,757 ) Less deemed dividend upon settlement of make-whole provision on Series A preferred stock — (10,505 ) Less deemed dividend upon settlement of make-whole provision on Series B preferred stock — (22,632 ) Less deemed dividend related to the recognition of discounts on Series A preferred stock upon conversion — (21,578 ) Less deemed dividend related to the recognition of discounts on Series B preferred stock upon conversion — (24,366 ) Less deemed dividend related to proceeds discount upon conversion of Series D preferred stock (6,852 ) — Add: losses allocated to participating securities 13,991 40,159 Net loss attributable to Amyris, Inc. common stockholders $ (223,096 ) $ (201,857 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted 60,405,910 32,253,570 Basic and diluted loss per share $ (3.69 ) $ (6.26 ) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive: Years Ended December 31, 2018 2017 (As Restated, Note 2) Period-end common stock warrants 25,986,370 29,921,844 Convertible promissory notes (1) 13,703,162 8,203,821 Period-end stock options to purchase common stock 5,392,269 1,338,367 Period-end restricted stock units 5,294,848 685,007 Period-end preferred shares on an as-converted basis 2,955,732 4,504,212 Total potentially dilutive securities excluded from computation of diluted net loss per share 53,332,381 44,653,251 ______________ ( 1 The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect at the respective year-end. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Contingencies Disclosure [Text Block]	9. Lease Obligations The Company leases certain facilities and finances certain equipment under operating and capital leases, respectively. Operating leases include leased facilities, and capital leases include leased equipment (see Note 3, May 2023. $5.8 $5.1 December 31, 2018 2017, Future minimum payments under the Company's lease obligations as of December 31, 2018, Years Ending December 31 (In thousands) Capital Operating Total Lease 2019 $ 513 $ 10,416 $ 10,929 2020 198 7,932 8,130 2021 1 7,226 7,227 2022 – 7,399 7,399 2023 – 3,034 3,034 Thereafter – – – Total future minimum payments 712 $ 36,007 $ 36,719 Less: amount representing interest (33 ) Present value of minimum lease payments 679 Less: current portion (484 ) Long-term portion $ 195 Guarantor Arrangements The Company has agreements whereby it indemnifies its executive officers and directors for certain events or occurrences while the executive officer or director is serving in his or her official capacity. The indemnification period remains enforceable for the executive officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no December 31, 2018 2017. The GACP Term Loan Facility (see Note 5, 16, first The Nikko Note is collateralized by a first 10% 5, Other Matters Certain conditions may may one may If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not not On April 3, 2019, March 15, 2018 March 19, 2019. June 21, 2019, No. 4:19 03621 not The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not not may not one

Note 10 - Revenue Recognition

Note 10 - Revenue Recognition	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	10. Disaggregation of Revenue The following tables present revenue by primary geographical market, based on the location of the customer, as well as by major product and service: Years Ended December 31, 2018 2017 (As Restated, Note 2) Europe $ 29,405 $ 23,823 United States 26,241 78,286 Asia 6,331 23,290 Brazil 942 2,159 Other 685 113 $ 63,604 $ 127,671 Significant Revenue Agreements For the years ended December 31, 2018 and 2017, Years Ended December 31, (In thousands) 2018 2017 (As Restated, Note 2) Renewable Products Licenses and Royalties Grants and Collaborations TOTAL Renewable Products Licenses and Royalties Grants and Collaborations TOTAL Revenue from significant revenue agreements with: DSM (related party) $ 18 $ 5,958 $ 4,735 $ 10,711 $ – $ 57,972 $ 1,679 $ 59,651 Firmenich 3,727 1,700 5,717 11,144 9,621 1,199 5,803 16,623 DARPA – – 8,436 8,436 – – 12,333 12,333 Givaudan 4,078 – 4,358 8,436 1,950 – 6,000 7,950 Nenter – – – – 12,057 2,633 – 14,690 Ginkgo – – – – – (13,113 ) – (13,113 ) Subtotal revenue from significant revenue agreements 7,823 7,658 23,246 38,727 23,628 48,691 25,815 98,134 Revenue from all other customers 25,775 – (898 ) 24,877 18,742 12 10,783 29,537 Total revenue from all customers $ 33,598 $ 7,658 $ 22,348 $ 63,604 $ 42,370 $ 48,703 $ 36,598 $ 127,671 Renewable Products Firmenich Agreements In 2013, 2014, Firmenich Supply Agreement (F In July 2017, the 70/30 70% two 70/30 70% $15.0 50/50 not In August 2018, second September 2014 Pursuant to the Firmenich Collaboration Agreement, the Company agreed to pay a one $2.5 not December 31, 2018. one 10 3 December 31, 2018 $0.5 one that has been recorded as a reduction to the associated collaboration revenue. Nenter Agreements In April 2016, December 31, 2020 five December 2017, 13, 11, Licenses and Royalties DSM Agreements DSM July September 2017 In July September 2017, three three In $9.0 one As discussed in Note 7, $34.0 August 2017 first $10.6 August 2017 $15.6 August 2017 $7.8 In connection with the entry into the DSM Agreements, the Company and DSM entered into the DSM Credit Letter, pursuant to which the Company granted a credit to DSM in an aggregate amount of $12.0 not $6.0 2018. $7.8 $3.3 $4.5 three December 31, 2017, $12.0 $4.5 December 2017 1 11, 13, DSM Value Sharing Agreement In December 2017, 13, 11, first three December 2017 first three 2018, not 5, December 2027, 2018, 2018 2018 2019 December 31, 2018 June 30, 2018 $750,000. December 31, 2018, $7.9 In April 2019, 16, DSM Performance Agreement In December 2017, 13, not $1.8 December 2020, In April 2019, 16, DSM November 2017 In November 2017, 13, November 2017 December 2017, $27.5 $54.6 December 31. 2017. DSM December 2017 November 2018 On November 19, 2018, December 28, 2017 ( no December 31, 2021 December 28, 2037, December 31, 2022, 2022, two $15.5 2018 2019, 1,643,991 $7.3 March 29, 2019, $4.41 1,643,991. The Company also entered into other transactions with DSM in November 2018 2018 11, In April 2019, 16, DSM November 2018 On November 19, 2018, November 2018 not December 15, 2018, $5.0 December 14, 2018, November 2018 Ginkgo Agreements Ginkgo Initial Strategic Partnership Agreement and Collaboration Agreement In June 2016, $20.0 two 10% first $15.0 July 2016, 2016. not second $5.0 not In September 2016, third not Under the Ginkgo Collaboration Agreement, subject to certain exceptions, including excluded or refused products and cost savings initiatives, the profit on the sale of products subject to the Ginkgo Collaboration Agreement as well as cost-sharing, milestone and “value-creation” payments associated with the development and production of such products would be shared equally between the parties. The parties also agreed to provide each other with a license and other rights to certain intellectual property necessary to support the development and manufacture of the products under the Ginkgo Collaboration, and also to provide each other with access to certain other intellectual property useful in connection with the activities to be undertaken under the Ginkgo Collaboration Agreement, subject to certain carve-outs. Ginkgo Partnership Agreement In November 2017, • to continue to collaborate on limited research and development; • to provide each other licenses (with royalties) to specified intellectual property for limited purposes; • for the Company to pay Ginkgo quarterly fees of $0.8 $12.7 December 31, 2018 September 30, 2022; • to share profit margins from sales of a certain product to be developed under the Ginkgo Partnership Agreement on a 50/50 November 2017 5, • for the Company to issue the $12 $12 • for the Company to pay Ginkgo $0.5 The Ginkgo Partnership Agreement provides for an initial term of two one not The Company recorded the $6.1 $12.7 3, $6.6 five $6.1 December 31, 2017. $12.0 5, $7.0 December 31, 2017 $13.1 $13.1 December 31, 2017 Collaborations DARPA Technology Investment Agreement In September 2015, $35.0 four $15.5 four Contract Assets and Liabilities When a contract results in revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional. Contract assets are presented as Accounts receivable, unbilled – related party on the consolidated balance sheets. Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not Trade receivables related to revenue from contracts with customers are included in accounts receivable on the consolidated balance sheets, net of the allowance for doubtful accounts. Trade receivables are recorded at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company for sale of goods or the performance of services, and for which the Company has the unconditional right to receive payment. Contract Balances The following table provides information about accounts receivable and contract liabilities from contracts with customers: December 31, (In thousands) 2018 2017 Accounts receivable, net $ 16,003 $ 18,953 Accounts receivable - related party, net $ 1,349 $ 4,767 Accounts receivable, unbilled - related party $ 8,021 $ 9,901 Accounts receivable, unbilled, noncurrent - related party $ 1,203 $ 7,940 Contract liabilities (1) $ 8,236 $ 4,308 Contract liabilities, noncurrent (2) $ 1,587 $ – ( 1 December 31, 2017 606, ( 2 Unbilled receivables relate to the Company’s right to consideration from DSM for (i) minimum future royalties and (ii) a material right arising from a customer option for a future transfer of technology. The Company’s right to cash receipt for these minimum royalty amounts occurs on or before December 31, 2019, December 31, 2020. Contract liabilities, current increased by $3.9 December 31, 2018 $0.8 606 January 1, 2018 $3.3 December 31, 2018 Remaining Performance Obligations The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of December 31, 2018. (In thousands) As of December 31, 2018 2019 $ 14,131 2020 7,925 2021 — 2022 and thereafter — Total from all customers $ 22,056 In accordance with the disclosure provisions of ASC 606, one $21.4

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	11. Related Party Divestiture See Note 13, December 2017. Related Party Equity See Note 7, • November 2018 • August 2018 • August 2017 • May 2017 • May 2017 • July 2015 • Related Party Debt See Note 5, • 13, • February 2016 • 2014 144A • August 2013 • Related party debt was as follows: December 31, (in thousands) 2018 2017 Principal Unamortized Net Principal Unamortized Net Total 2014 Rule 144A convertible notes $ 9,705 $ (422 ) $ 9,283 $ 9,705 $ (1,538 ) $ 8,167 August 2013 financing convertible notes – – – 21,711 897 22,608 R&D note – – – 3,700 (18 ) 3,682 9,705 (422 ) 9,283 35,116 (659 ) 34,457 DSM DSM note 25,000 (6,311 ) 18,689 25,000 (8,039 ) 16,961 Other DSM loan – – – 393 – 393 25,000 (6,311 ) 18,689 25,393 (8,039 ) 17,354 Biolding February 2016 private placement – – – 2,000 – 2,000 Foris 2014 Rule 144A convertible notes 5,000 (181 ) 4,819 5,000 (660 ) 4,340 Temasek 2014 Rule 144A convertible notes 10,000 (435 ) 9,565 10,000 (1,591 ) 8,409 $ 49,705 $ (7,349 ) $ 42,356 $ 77,509 $ (10,949 ) $ 66,560 The fair value of the derivative liabilities related to the related party R&D Note, related party August 2013 2014 144A December 31, 2018 2017 $0 $0.2 $8.5 $0.6 December 31, 2018 2017, 4, At December 31, 2018, no 2014 144A Related Party Revenue The Company recognized revenue from related parties and from all other customers as follows: Years Ended December 31, (In thousands) 2018 2017 (As restated, Note 2) Renewable Products Licenses and Royalties Grants and Collaborations TOTAL Renewable Products Licenses and Royalties Grants and Collaborations TOTAL Revenue from related parties: DSM $ 18 $ 5,958 $ 4,735 $ 10,711 $ — $ 57,972 $ 1,679 $ 59,651 Total 342 — — 342 (200 ) — — (200 ) Novvi — — — — 1,491 — — 1,491 Subtotal revenue from related parties 360 5,958 4,735 11,053 1,291 57,972 1,679 60,942 Revenue from all other customers (1) 33,238 1,700 17,613 52,551 41,079 (9,269 ) 34,919 66,729 Total revenue from all customers $ 33,598 $ 7,658 $ 22,348 $ 63,604 $ 42,370 $ 48,703 $ 36,598 $ 127,671 ( 1 Licenses and royalties revenue is negative for 2017 $13.1 2017 10. See Note 10, Related Party Accounts Receivable Related party accounts receivable was as follows: December 31, (In thousands) 2018 2017 DSM $ 1,071 $ 12,823 Novvi 188 1,607 Total 90 238 Related party accounts receivable, net $ 1,349 $ 14,668 In addition to the amounts shown above, there were the following amounts on the consolidated balance sheet at December 31, 2018: • $8.0 • $4.3 Related Party Accounts Payable Amounts due to DSM that were included in Accounts payable and Accrued and other current liabilities at December 31, 2018 $2.1 $0.6 Related Party DSM Transactions The Company is party to the following significant agreements (and related amendments) with related party DSM: Related to Agreement For Additional Information, See the Note Indicated Debt DSM Credit Agreement 5. 10. Debt DSM Note 5. Debt November 2018 5. Divestiture November 2017 13. Divestiture December 2017 13. Equity May 2017 7. Equity August 2017 7. Equity November 2018 7. Revenue July September 2017 10. Revenue December 2017 10. Revenue December 2017 10. Revenue December 2017 10. Revenue November 2017 10. Revenue November 2018 10. Concurrent with the sale of Amyris Brasil in December 2017, six six $27.5 $15.0 December 2017 $25 5, In June 2018, $9.3 $0.7 $8.1 2019. $17.8 In November 2018, 1 2022. 10, November 2018 November 2018 November 2018 November 2018 2018 November 2018 November 2018 1 December 2017 August 2017 August 2017 August 2017 The contractual consideration transferred to DSM under the combined arrangement was $34.7 $24.4 $6.8 $2.1 $24.4 $3.3 December 31, 2018 $21.0 five $6.8 December 31, 2018. $2.1 December 31, 2018. $1.4 three December 31, 2018. Related Party Joint Venture In December 2016, not third 50% $10.0 three 2017 2019, $10.0 The Aprinnova JV operates in accordance with the Aprinnova Operating Agreement under which the Aprinnova JV is managed by a Board of Directors consisting of four two two 810, 810. Under the Aprinnova Operating Agreement, profits from the operations of the Aprinnova JV, if any, are distributed as follows: (i) first, to the Company and Nikko (the Members) in proportion to their respective unreturned capital contribution balances, until each Member’s unreturned capital contribution balance equals zero 50%/50% Pursuant to the Aprinnova JV Agreement, the Company and Nikko agreed to make working capital loans to the Aprinnova JV in the amounts of $0.5 $1.5 5, In connection with the contribution of the Leland Facility by the Company to the Aprinnova JV, at the closing of the formation of the Aprinnova JV, Nikko made a loan to the Company in the principal amount of $3.9 5, The following presents the carrying amounts of the Aprinnova JV’s assets and liabilities included in the accompanying consolidated balance sheets. Assets presented below are restricted for settlement of the Aprinnova JV's obligations and all liabilities presented below can only be settled using the Aprinnova JV resources. December 31, (In thousands) 2018 2017 Assets $ 12,904 $ 7,635 Liabilities $ 2,364 $ 3,187 The Aprinnova JV's assets and liabilities are primarily comprised of inventory, property, plant and equipment, accounts payable and debt, which are classified in the same categories in the Company's consolidated balance sheets. There was no December 31, 2018 2017, 100% 2017 2020. Office Sublease The Company subleases certain office space to Novvi, for which the Company charged Novvi $0.6 $0.5 December 31, 2018 2017, See Note 16, December 31, 2018.

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Stock-based Compensation Expense Related to All Plans Stock-based compensation expense related to all employee stock compensation plans, including options, restricted stock units and ESPP, was as follows: Years Ended December 31, (In thousands) 2018 2017 Research and development $ 1,797 $ 2,204 Sales, general and administrative 7,393 4,061 Total stock-based compensation expense $ 9,190 $ 6,265 Plans 2010 The Company's 2010 2010 September 27, 2010 2020. 2010 2010 may may may no 2,000,000 2010 2010 may ten ten may not 100% 10% may not 110% three five As of December 31, 2018 2017, 5,339,214 1,255,045 2010 $33.40 $26.29, December 31, 2018 2017, 5,294,803 683,554 2010 December 31, 2018 2017, 2,359,750 252,107 may 2010 The number of shares reserved for issuance under the 2010 January 1 January 1, 2011, 5% December 31. In May 2018, 2010 9.0 4.0 9,280,000, not 2005 In 2005, 2005 2005 2005 2005 All options issued under the 2005 ten 2005 not 100% 10% not 110% 5 As of December 31, 2018 2017, 52,389 79,322 2005 2010 zero 2005 2005 December 31, 2018 2017 $185.93 $144.58, 2010 The 2010 2010 September 27, 2010. 2010 2010 May 16 November 16, one two six 2010 85% first 2010 January 1 January 1, 2011, 1% December 31. May 2018, 2010 may 1 No 1,666,666 may 2010 no may 2018 In May 2018, 3,250,000 may December 31, 2021, December 31, 2022. four may zero 3,250,000 $5.08 Stock-based compensation expense for this award is recognized using a graded-vesting approach over the service period beginning at the grant date through December 31, 2022, four December 31, 2018, $5.1 December 31, 2018, $0.7 Stock Option Award with Performance and Market Vesting Conditions: Fair value of the Company’s common stock on grant date $ 5.08 Expected volatility 70 % Risk-free interest rate 2.75 % Dividend yield 0.0 % Stock Option Activity Stock option activity is summarized as follows: Year ended December 31, 2018 2017 Options granted 4,337,119 661,094 Weighted-average grant-date fair value per share $ 5.18 $ 3.26 Compensation expense related to stock options (in millions) $ 2.6 $ 3.3 Unrecognized compensation costs as of December 31 (in millions) $ 8.5 $ 2.7 The Company expects to recognize the December 31, 2018 3.8 Stock-based compensation expense for stock options and employee stock purchase plan rights is estimated at the grant date and offering date, respectively, based on the fair-value using the Black-Scholes option pricing model. The fair value of employee stock options is amortized on a ratable basis over the requisite service period of the awards. The fair value of employee stock options and employee stock purchase plan rights was estimated using the following weighted-average assumptions: Years Ended December 31, 2018 2017 Expected dividend yield —% —% Risk-free interest rate 2.8 % 2.1 % Expected term (in years) 6.90 6.12 Expected volatility 80 % 84 % The expected life of options is based primarily on historical share option exercise experience of the employees for options granted by the Company. All options are treated as a single group in the determination of expected life, as the Company does not no Stock-based compensation expense associated with options is based on awards ultimately expected to vest. At the time of an option grant, the Company estimates the expected future rate of forfeitures based on historical experience. These estimates are revised, if necessary, in subsequent periods if actual forfeiture rates differ from those estimates. If the actual forfeiture rate is lower than estimated the Company will record additional expense and if the actual forfeiture is higher than estimated the Company will record a recovery of prior expense. The Company’s stock option activity and related information for the year ended December 31, 2018 Number of Weighted- Weighted-average Aggregate Outstanding - December 31, 2017 1,338,367 $ 33.40 7.7 $ 97 Options granted 4,337,119 $ 5.18 Options exercised (70,807 ) $ 3.68 Options forfeited or expired (214,409 ) $ 19.61 Outstanding - December 31, 2018 5,390,270 $ 11.55 8.5 $ 29 Vested or expected to vest after December 31, 2018 4,833,615 $ 12.28 8.4 $ 28 Exercisable at December 31, 2018 972,229 $ 39.73 5.8 $ 12 The aggregate intrinsic value of options exercised under all option plans was $0.2 $0 December 31, 2018 2017, Restricted Stock Units Activity and Expense During the years ended December 31, 2018 2017, 5,452,664 523,167 $5.36 $5.51, $6.4 $2.8 December 31, 2018 2017. December 31, 2018 2017, $23.8 $5.0 Stock-based compensation expense for RSUs is measured based on the closing fair market value of the Company's common stock on the date of grant. The Company’s RSU and restricted stock activity and related information for the year ended December 31, 2018 Number of Weighted- Weighted- Outstanding - December 31, 2017 683,554 $ 8.66 1.4 Awarded 5,452,664 $ 5.36 Vested (445,828 ) $ 8.43 Forfeited (395,587 ) $ 5.64 Outstanding - December 31, 2018 5,294,803 $ 5.50 1.7 Vested or expected to vest after December 31, 2018 4,953,264 $ 5.50 1.6 ESPP Activity and Expense During the years ended December 31, 2018 2017, 246,230 47,058 2010 December 31, 2018 2017, 382,824 80,594 2010 During the years ended December 31, 2018 2017, $0.2 $0.1

Note 13 - Divestiture

Note 13 - Divestiture	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	13. On December 28, 2017, $33.0 $12.6 $56.9 $5.7 November 2018, $1.8 $1.8 2018 Concurrent with the sale of Amyris Brasil, the Company and DSM entered into a series of commercial agreements including (i) a license agreement to DSM of its farnesene product for DSM to use in the Vitamin E and lubricant markets; (ii) a royalty agreement, pursuant to which DSM agreed to pay the Company specified royalties representing a portion of the profit on the sale of Vitamin E produced from farnesene sold under the Nenter Supply Agreement assigned to DSM; (iii) a performance agreement for the Company to perform research and development to optimize farnesene for production and sale of farnesene products; and (iv) a transition services agreement for the Company to provide finance, legal, logistics, and human resource services to support the Brotas facility under DSM ownership for a six six 10, 16, $27.5 $15.0 2018 2019. $17.8 10, 11, $25.0 5, The Company accounted for the sale of Amyris Brasil as a sale of a business for proceeds of $54.8 $54.7 $2.1 December 31, 2017. Results from the operations of Amyris Brasil are included in the Company's Consolidated Statements of Operations for 2017, not not not

Note 14 - Income Taxes

Note 14 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14. The components of loss before income taxes are as follows: Years Ended December 31, (In thousands) 2018 2017 (As Restated, Note 2) United States $ (218,109 ) $ (156,020 ) Foreign (12,125 ) 6,915 Loss before income taxes $ (230,234 ) $ (149,105 ) The components of the provision for income taxes are as follows: Years Ended December 31, (In thousands) 2018 2017 (As Restated, Note 2) Current: Federal $ — $ 6,564 State — 18 Foreign — 964 Total current provision — 7,546 Deferred: Federal — (669 ) State — — Foreign — — Total deferred benefit — (669 ) Total provision for income taxes$ $ — $ 6,877 A reconciliation between the statutory federal income tax and the Company’s effective tax rates as a percentage of loss before income taxes is as follows: Years Ended December 31, 2018 2017 (As Restated, Note 2) Statutory tax rate (21.0 )% (34.0 )% State taxes, net of federal tax benefit — % — % Stock-based compensation — % — % Federal R&D credit (0.6 )% (0.2 )% Derivative liability 4.3 % 13.9 % Nondeductible interest 1.0 % 3.0 % Other (0.1 )% (0.2 )% Foreign losses 0.9 % 8.5 % Change in U.S. federal tax rate — % 25.1 % IRC Section 382 limitation — % 7.2 % Change in valuation allowance 15.5 % (18.6 )% Effective income tax rate — % 4.7 % Temporary differences and carryforwards that gave rise to significant portions of deferred taxes are as follows: December 31, (In thousands) 2018 2017 (As Restated, Note 2) Net operating loss carryforwards $ 57,921 $ 20,066 Property, plant and equipment 9,269 9,653 Research and development credits 12,046 9,480 Foreign tax credit – – Accruals and reserves 8,526 7,286 Stock-based compensation 6,496 5,471 Disallowed interest carryforward 2,359 – Capitalized start-up costs – – Capitalized research and development costs 27,888 32,085 Intangible and others 3,114 3,584 Equity investments 156 – Total deferred tax assets 127,775 87,625 Debt discount and derivatives (3,750 ) (6,539 ) Total deferred tax liabilities (3,750 ) (6,539 ) Net deferred tax assets prior to valuation allowance 124,025 81,086 Less: valuation allowance (124,025 ) (81,086 ) Net deferred tax assets $ – $ – Activity in the deferred tax assets valuation allowance is summarized as follows: (In thousands) Balance at Beginning Additions Reductions / Balance at Deferred tax assets valuation allowance: Year Ended December 31, 2018 $ 81,086 $ 42,939 $ – $ 124,025 Year Ended December 31, 2017 (As Restated, Note 2) $ 386,867 $ – $ (305,781 ) $ 81,086 Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. not not December 31, 2018 2017. $305.8 December 31, 2017 $42.9 December 31, 2018. $305.8 December 31, 2017 382 35% 21%. On December 22, 2017, not 1 35 21 2 one 3 4 5 6 7 8 December 31, 2017. On December 22, 2017, No. 118 118 not 118, $37.7 December 31, 2017. December 22, 2018, no 118. As of December 31, 2018, $290.7 $154.3 1986, may 382 382 may may one not 50% three December 31, 2017, 50%. $456.2 $115.5 $14.7 December 31, 2018, $7.3 As of December 31, 2018, $1.6 $13.5 If not 2025, 2028. 2038 not A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In thousands) Balance at December 31, 2016 $ 9,101 Increases in tax positions for prior period 50 Increases in tax positions during current period 19,682 Balance at December 31, 2017 28,833 Increases in tax positions for prior period 55 Increases in tax positions during current period 1,239 Balance at December 31, 2018 $ 30,127 The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the provision for taxes. The Company determined that accrual for interest and penalties was not December 31, 2018 2017. None not 12 The Company’s primary tax jurisdiction is the United States. For United States federal and state tax purposes, returns for tax years 2005 2010 As of December 31, 2018, 2008 no 2008, may

Note 15 - Geographical Informat

Note 15 - Geographical Information	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	15. The chief operating decision maker is the Company's Chief Executive Officer, who makes resource allocation decisions and assesses performance based on financial information presented on a consolidated basis. There are no Revenue Revenue by geography, based on each customer's location, is shown in Note 10, Property, Plant and Equipment December 31, 2018 2017 (As Restated, Note 2) United States $ 13,111 $ 10,357 Brazil 6,447 3,357 Europe 198 178 $ 19,756 $ 13,892

Note 16 - Subsequent Events

Note 16 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	16. Extension and Exchange of Tranche II Note On January 14, 2019, 5, July 15, 2019 July 15, 2019, $0.6 July 15, 2019, October 13, 2019 1.75% July 16, 2019 Evergreen Shares for 2010 2010 In February 2019, 2010 2010 3,828,241 5.0% 76,564,829 December 31, 2018. January 1, 2019. 382,824 0.5% 76,564,829 December 31, 2018. January 1, 2019. Cannabinoid Agreement On March 18, 2019, $300 $300 20 third 2014 144A 2015 144A 5, May 2, 2019, 5, LSA Amendments, Assignment and Waivers On April 4, 2019, 5, December 31, 2018, July 1, 2021, ( $15 On April 4, 2019, December 31, 2018 April 8, 2019, $0.8 On April 15, 2019, five $2.5 April 16, 2019. On August 14, 2019, No 5 July 1, 2021 July 1, 2022, ( x 4.75% 9% 12% December 16, 2019, ( December 16, 2019, ( April 8, 2019, June 11, 2019, July 10, 2019 July 26, 2019 ( $32.5 $71.0 August 14, 2019 1,438,829 $2.87 two may not 19.99% 2019 Foris Credit Agreements On April 8, 2019, $8.0 April 8, 2019 $8.0 April April October 14, 2019. April April no $1.0 April April April $0.5 April July 15, 2019. April 5, 16, On June 11, 2019, $8.5 June 11, 2019 $8.5 June June 12.5% June 11, 2019, June August 28, 2019; May 2017 August 2017 7, June On July 10, 2019, $16.0 July $8.0 July 10, 2019 $8.0 July 26, 2019 $8.0 July July 12.5% July December 31, 2019. July August 17, 2018 ( 7, $7.52 $2.87 The Company may April April June July 100% June July On August 14, 2019, April June July On August 28, 2019, $19.0 August August 28, 2019 $19.0 August August 12% August 28, 2019, March 31, June 30, September 30 December 31, December 31, 2019, January 1, 2023. may August 100% In connection with the entry into the August August 28, 2019 4,871,795 $3.90 two 4 2 1933, not six not may not 19.99% 2019 Private Placements On April 16, 2019, 6,732,369 $2.87 5,424,804 $2.87 two 4 2 $20.0 2015 144A 5, On April 26, 2019, 2,832,440 $5.12 3,983,230 $5.12 two 2,043,781 $4.02 1,635,025 $5.02 two 4 2 $23.2 August 28, 2019, August April 26, 2019 $5.12 $3.90 On April 29, 2019, 913,529 $4.76 1,212,787 $4.76 two 323,382 $4.02 258,704 $5.02 two 4 2 $5.8 On May 3, 2019, 1,243,781 $4.02 995,024 $5.02 two 4 2 $5 The exercise price of the warrants issued in the foregoing private placements is subject to standard adjustments but does not six not not not 19.99% 2019 DSM Agreements On April 16, 2019, 10, $57.0 $29.1 $27.9 10, 2015 144A 5, In addition, on April 16, 2019 10, December 2017 13, 11, 2021, no On September 17, 2019, “2019 $8.0 $3.0 $3.0 $2.0 September 17, 2019, first $3.0 2019 $3.0 September 19, 2019, second $3.0 2019 $3.0 September 23, 2019, $2.0 2019 $1.5 $2.0 2019 August 7, 2022, ( 12.5% January 1, April 1, July 1 October 1, January 1, 2020, first may 2019 100% 2019 May 11, 2017 August 7, 2017 ( 7, $50.0 one June 30, 2020. Raizen Joint Venture Agreement On May 10, 2019, not December 31, 2019, may not Upon the closing of the joint venture, each party will make an initial capital contribution to the joint venture of 2,500,000 R$2,500,000 50% 50% 60 U.S.$9,000,000 U.S.$3,000,000. six 10 After the formation of the joint venture, the parties will not not third seventh 2014 144A On May 10, 2019, $13.5 2014 144A 5, May 15, 2019, 3,479,008 1,391,603 $5.02 two 3 9 On May 14, 2019, $5.0 2014 144A May 15, 2019, 1,122,460 352,638 $4.56 two 3 9 August 28, 2019, August May 14, 2019 $4.56 $3.90 On May 15, 2019, $10.0 2014 144A 2,500,000 3 9 On May 15, 2019, $9.7 2014 144A June 14, 2019, 3 9 June 14, 2019, June 14, 2019 July 18, 2019. July 18, 2019, July 18, 2019 August 28, 2019 10.5% July 18, 2019. August 28, 2019, August 28, 2019 October 28, 2019 12% August 28, 2019. The exercise price of the warrants issued in the foregoing exchanges is subject to standard adjustments but does not six not 2019 may not 4.99% 6% 2021 On May 15, 2019 June 24, 2019, $53.3 $4.7 6% 2021 5, 6% 2021, 2,000,000 181,818 $5.12 two 3 9 6% 2021 July 22, 2019, July 22, 2019 July 29, 2019, 125% not six not may not may not 4.99% On July 26, 2019, one 6% 2021, $4.7 125% July 30, 2019 August 30, 2019. August 30, 2019. On July 24, 2019, $53.3 6% 2021 2,000,000 May 15, 2019, $68.3 2,000,000 $2.87 two May 15, 2019 ( 3 9 May 15, 2019, $68.3 25% July 1, 2019 $6.4 not 18% July 22, 2019 September 16, 2019, ( first October 1, 2019, ( $3.2 August 2, 2019 August 22, 2019, September 16, 2019, 8 September 16, 2019, $2.87 On September 16, 2019, $63.6 The Company does not not no no not The consolidated financial statements do not Exchange of August 2013 On July 8, 2019, August 2013 4, 1,767,632 1,080,000 3 9 not six not may not 4.99% Nikko Loan Agreement On July 29, 2019, $5.0 $3.0 $2.0 11, July 30, 2019, first $3.0 $2.8 $0.2 August 8, 2019, $2.0 $1.9 $0.1 December 18, 2020, ( 5% first 12.8% Aprinnova Working Capital Loan Effective July 31, 2019, 5, August 1, 2019 August 1, 2020. Naxyris Loan and Security Agreement On August 14, 2019, $10,435,000 August 14, 2019. Loans under the Naxyris Loan Facility have a maturity date of July 1, 2022 12% 25 August 14, 2019 December 1, 2019 December 15, 2019. The obligations of the Company under the Naxyris Loan Facility are (i) guaranteed by the Subsidiary Guarantors and (ii) secured by a perfected security interest in substantially all of the assets of the Company and the Subsidiary Guarantors (the Collateral), junior in payment priority to Foris Ventures subject to certain limitations and exceptions, as well as the terms of the Intercreditor Agreement (as defined above). Mandatory prepayments of the outstanding amounts under the Naxyris Loan Facility will be required upon the occurrence of certain events, including asset sales, a change in control, and the incurrence of additional indebtedness, subject to certain exceptions and reinvestment rights. Outstanding amounts under the Naxyris Loan Facility must also be prepaid to the extent that the borrowing base exceeds the outstanding principal amount of the loans under the Naxyris Loan Facility. In addition, the Company may one 6% three not The affirmative and negative covenants in the Naxyris Loan Agreement relate to, among other items: (i) payment of taxes; (ii) financial reporting; (iii) maintenance of insurance; and (iv) limitations on indebtedness, liens, mergers, consolidations and acquisitions, transfers of assets, dividends and other distributions in respect of capital stock, investments, loans and advances, and corporate changes. The Naxyris Loan Agreement also contains financial covenants, including covenants related to minimum revenue, liquidity, and asset coverage. September 2019 On September 10, 2019, $12.5 September 10, 2019 $12.5 12% September 10, 2019, March 31, June 30, September 30 December 31, December 31, 2019, January 1, 2023. may 100% In connection with the entry into the Investor Credit Agreements, on September 10, 2019, 3,205,128 $3.90 two 4 2 not six not no may 9.99% 60 120 no 144 not 10%, 5% 90 $3.31 $3.90 In connection with the entry into the Investor Credit Agreements and the issuance of the warrants, on September 10, 2019, no 6.99% third

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Liquidity [Policy Text Block]	Going Concern The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 December 31, 2018, $119.5 $1.5 As of December 31, 2018, $17.1 $2.1 $209.7 $147.7 December 31, 2018, 5, April 2019, ( December 31, 2018 April 8, 2019, June 30, 2020 16, Cash and cash equivalents of $45.4 December 31, 2018 not September 30, 2020. one not 12 2019, 2019 December 31, 2018, may may not July 2019, may not On September 16, 2019, $63.6 The Company does not not no no not not
Basis of Accounting, Policy [Policy Text Block]	Basis of Consolidation The accompanying consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States (U.S. GAAP). The consolidated financial statements include the accounts of Amyris, Inc. and its wholly-owned and partially-owned subsidiaries in which the Company has a controlling interest after elimination of all significant intercompany accounts and transactions. Investments and joint venture arrangements are assessed to determine whether the terms provide economic or other control over the entity requiring consolidation of the entity. Entities controlled by means other than a majority voting interest are referred to as variable-interest entities (VIEs) and are consolidated when Amyris has both the power to direct the activities of the VIE that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant to the entity. For any investment or joint venture in which (i) the Company does not not 2016 01 January 1, 2018 not not 3
Sale of Subsidiary and Entry Into Commercial Agreements, Policy [Policy Text Block]	Sale of Subsidiary and Entry into Commercial Agreements On December 28, 2017, $5.7 2017, $1.8 2018 not not 10, 11, 13, 16,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original or remaining maturity of three
Inventory, Policy [Policy Text Block]	Inventories Inventories, which consist of farnesene-derived products, flavors and fragrances ingredients and clean beauty products, are stated at the lower of actual cost or net realizable value and are categorized as finished goods, work in process or raw material inventories. The Company evaluates the recoverability of its inventories based on assumptions about expected demand and net realizable value. If the Company determines that the cost of inventories exceeds their estimated net realizable value, the Company records a write-down equal to the difference between the cost of inventories and the estimated net realizable value. If actual net realizable values are less favorable than those projected by management, additional inventory write-downs may may
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment, Net Property, plant and equipment are recorded at cost. Depreciation and amortization are computed straight-line based on the estimated useful lives of the related assets, ranging from 3 15 15 The Company expenses costs for maintenance and repairs and capitalizes major replacements, renewals and betterments. For assets retired or otherwise disposed, both cost and accumulated depreciation are eliminated from the asset and accumulated depreciation accounts, and gains or losses related to the disposal are recorded in the statement of operations for the period.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment Long-lived assets that are held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not
Recoverable Taxes from Brazilian Government Entities [Policy Text Block]	Recoverable Taxes from Brazilian Government Entities Recoverable taxes from Brazilian government entities represent value-added taxes paid on purchases in Brazil, which are reclaimable from the Brazilian tax authorities, net of reserves for amounts estimated not
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The carrying amounts of certain financial instruments, such as cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The Company measures the following financial assets and liabilities at fair value: • Freestanding and bifurcated derivatives in connection with certain debt and equity financings; and • 6% 2021 4, 5, 16, Fair value is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Where available, fair value is based on or derived from observable market prices or other observable inputs. Where observable prices or inputs are not Changes to the inputs used in these valuation models have a significant impact on the estimated fair value of the 6% 2021 The changes during 2018 2017 For debt instruments for which the Company has not not 6% 2021, 4, 6% 2021 For all debt instruments, including any for which the Company has elected fair value accounting, the Company classifies interest that has been accrued during each period as Interest expense on the consolidated statements of operations.
Derivatives, Policy [Policy Text Block]	Derivatives Embedded derivatives that are required to be bifurcated from the underlying debt instrument (i.e., host) are accounted for and valued as separate financial instruments. The Company has evaluated the terms and features of its convertible notes payable and convertible preferred stock and identified compound embedded derivatives requiring bifurcation and accounting at fair value, using the valuation techniques mentioned in the Fair Value Measurements Cash warrants and anti-dilution warrants issued in conjunction with the convertible debt and equity financings are freestanding financial instruments which are also classified as derivative liabilities.
Noncontrolling Interest [Policy Text Block]	Noncontrolling Interest Noncontrolling interests represent the portion of net income (loss), net assets and comprehensive income (loss) that is not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and accounts receivable. The Company places its cash equivalents and investments (primarily certificates of deposits) with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one may not The Company performs ongoing credit evaluation of its customers, does not Customers representing 10% As of December 31, 2018 2017 Customer B 24 % 10 % Customer C 19 % 15 % Customer G 11 % ** Customer A (related party) ** 38 % ______________ ** Less than 10% Customers representing 10% Years Ended December 31, 2018 2017 (As Restated, Note 2) Customer A (related party) 17 % 46 % Customer B 18 % 13 % Customer C 13 % ** Customer D 13 % ** Customer E ** 11 % Customer F ** ** ______________ ** Less than 10%
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Year ended December 31, 2017 For the year ended December 31, 2017, Renewable Product Sales The Company’s renewable product sales do not not two not Licenses and Royalties License fees for intellectual property transferred to other parties, representing non-refundable payments received at the time of signature of license agreements, are recognized as revenue upon signature of the license agreements when the Company has no Royalties from intellectual property licenses that allow Amyris's customers to use the Company’s intellectual property to produce and sell their products in which the Company shares in the profits are recognized in the period the royalty report is received. Grants and Collaborative Research and Development Services Revenues from collaborative research and development services are recognized as the services are performed consistent with the performance requirements of the contract. In cases where the planned levels of research and development services fluctuate over the research term, the Company recognizes revenues using the proportional performance method based upon actual efforts to date relative to the amount of expected effort to be incurred by us. When up-front payments are received and the planned levels of research and development services do not Grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. Revenues from grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the grants were provided have been met and only perfunctory obligations are outstanding. Year ended December 31, 2018 In accordance with a new revenue recognition standard that the Company adopted January 1, 2018, not The Company accounts for a contract when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance and collectability of the consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators, among others, when determining if it is acting as a principal in the transaction and recording revenue on a gross basis: (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer and (iii) the Company has discretion in establishing the price for the specified good or service. If a transaction does not The Company’s significant contracts and contractual terms with its customers are presented in Note 10, The Company recognizes revenue when control has passed to the customer. The following indicators are evaluated in determining when control has passed to the customer: (i) the Company has a right to receive payment for the product or service, (ii) the customer has legal title to the product, (iii) the Company has transferred physical possession of the product to the customer, (iv) the customer has the significant risk and rewards of ownership of the product and (v) the customer has accepted the product. For most of the Company's renewable products customers, supply agreements between the Company and each customer indicate when transfer of title occurs. In some cases, the Company may Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may The following is a description of the principal goods and services from which the Company generates revenue. Renewable Product Sales Revenues from renewable product sales are recognized as a distinct performance obligation on a gross basis as the Company is acting as a principal in these transactions, with the selling price to the customer recorded net of discounts and allowances. Revenues are recognized at a point in time when control has passed to the customer, which typically is upon the renewable products leaving the Company’s facilities with the first may not not not two not Licenses and Royalties Licensing of Intellectual Property: Royalties from Licensing of Intellectual Property: When the Company’s intellectual property license is the only performance obligation, or it is the predominant performance obligation in arrangements with multiple performance obligations, the Company applies the sales-based royalty exception which requires the Company to estimate the revenue that is recognized at a point in time when the licensee’s product sales occur. Estimates of sales-based royalty revenues are made using the most likely outcome method, which is the single amount in a range of possible amounts, using the best evidence available at the time, derived from the licensee’s historical sales volumes and sales prices of its products and recent commodity market pricing data and trends. Estimates are adjusted to actual or as new information becomes available. When the Company’s intellectual property license is not not Grants and Collaborative Research and Development Services Collaborative Research and Development Services: one Collaboration agreements are evaluated at inception to determine whether the intellectual property licenses represent distinct performance obligations separate from the research and development services. If the licenses are determined to be distinct, the non-refundable upfront license fee is recognized as revenue at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license while the research and development service fees are recognized over time as the performance obligations are satisfied. The research and development service fees represent variable consideration. Estimates of the amount of variable consideration to include in the transaction price are made using the expected value method, which is the sum of probability-weighted amounts in a range of possible amounts. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not Collaboration agreements that include milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement, and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not The Company generally invoices its collaboration partners on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Deferred revenue arises from amounts received in advance of performing the research and development activities and is recognized as revenue in future periods as the performance obligations are satisfied. Grants: The milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not
Cost of Goods and Service [Policy Text Block]	Cost of Products Sold Cost of products sold includes the production costs of renewable products, which include the cost of raw materials, in-house manufacturing labor and overhead, amounts paid to contract manufacturers, including amortization of tolling fees, and period costs including inventory write-downs resulting from applying lower of cost or net realizable value inventory adjustments. Cost of products sold also includes certain costs related to the scale-up of production. Shipping and handling costs charged to customers are recorded as revenues. Outbound shipping costs incurred are included in cost of products sold. Such charges were not The Company recognizes deferred cost of products sold as an asset on the balance sheet when a cost is incurred in connection with a revenue performance obligation that will not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements and government grants, including internal research. Research and development costs consist of direct and indirect internal costs related to specific projects, as well as fees paid to others that conduct certain research activities on the Company’s behalf.
Debt, Policy [Policy Text Block]	Debt Extinguishment The Company accounts for the income or loss from extinguishment of debt in accordance with ASC 470, Debt,
Compensation Related Costs, Policy [Policy Text Block]	Stock-based Compensation The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of U.S. GAAP. Those provisions require all stock-based payments to employees, including grants of stock options and restricted stock units (RSUs), to be measured using the grant-date fair value of each award. The Company recognizes stock-based compensation expense net of expected forfeitures over each award's requisite service period, which is generally the vesting term. Expected forfeiture rates are estimated based on the Company's historical experience. Stock-based compensation plans are described more fully in Note 12,
Income Tax, Policy [Policy Text Block]	Income Taxes The Company is subject to income taxes in the United States and foreign jurisdictions and uses estimates to determine its provisions for income taxes. The Company uses the asset and liability method of accounting for income taxes, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect for the year in which the differences are expected to affect taxable income. Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. not The Company applies the provisions of Financial Accounting Standards Board (FASB) guidance on accounting for uncertainty in income taxes. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability, and the tax benefit to be recognized is measured at the largest amount of benefit that is greater than 50 may
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at each balance sheet date, and revenue and expense amounts are translated at average rates during each period, with resulting foreign currency translation adjustments recorded in other comprehensive loss, net of tax, in the consolidated statements of stockholders’ deficit. As of December 31, 2018 2017, $43.3 $42.2 Where the U.S. dollar is the functional currency, remeasurement adjustments are recorded in other income (expense), net in the accompanying consolidated statements of operations. Net losses resulting from foreign exchange transactions were $1.6 $0.4 December 31, 2018 2017,
New Accounting Pronouncements, Policy [Policy Text Block]	New Accounting Standards or Updates Recently Adopted During the year ended December 31, 2018 Revenue Recognition 606, Revenue from Contracts with Customers January 1, 2018. 606 606 not January 1, 2018. not 605, The Company applied ASC 606 January 1, 2018, The cumulative effect of initially applying ASC 606 January 1, 2018 $0.8 not The following table presents the amounts by which revenue is affected in the current reporting period by the application of ASC 606 Year Ended December 31, 2018 (In thousands) As Reported Adjustments Amounts Without the Adoption of ASC 606 Renewable products $ 33,598 $ — $ 33,598 Licenses and royalties 7,658 5,094 12,752 Grants and collaborations 22,348 (5,786 ) 16,562 Total revenue from all customers $ 63,604 $ (692 ) $ 62,912 Financial Instruments January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01 January 1, 2018. not Classification of Cash Flow Elements August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15 2016 15 January 1, 2018 not Income Taxes Related to Intra-entity Asset Transfers October 2016, 2016 16, Intra-Entity Transfers of Assets Other Than Inventory 2016 16 January 1, 2018, Restricted Cash in Statement of Cash Flows November 2016, 2016 18, Statement of Cash Flows (Topic 230 January 1, 2018 2016 18 Derecognition of Nonfinancial Assets February 2017, 2017 05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610 20 606 not 1 not not not 2 not January 1, 2018 not Income Taxes March 2018, 2018 05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 not December 31, 2018, December 31, 2017 not 2018 05. may Non-employee Stock-based Compensation June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting, no January 1, 2018 not Recent Accounting Standards or Updates Not Leases February 2016, 2016 02, Leases (Topic 842 The Company is adopting the new standard effective January 1, 2019 not not The adoption of this standard on January 1, 2019 $25.7 not $33.6 $29.7 Financial Instruments with "Down Round" Features July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019 $41.0 $41.0 January 1, 2019. Fair Value Measurement August 2018, 2018 13, Fair Value Measurement (Topic 820 820, Fair Value Measurement 2018 13 first 2020, Collaborative Revenue Arrangements November 2018, 2018 18, Clarifying the Interaction between Topic 808 606 606, two first 2020 not Credit Losses June 2016, 2016 13, Financial Instruments—Credit Losses (Topic 326 2016 13 2016 13 2016 13 first 2020. not

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	As of December 31, 2018 2017 Customer B 24 % 10 % Customer C 19 % 15 % Customer G 11 % ** Customer A (related party) ** 38 % Years Ended December 31, 2018 2017 (As Restated, Note 2) Customer A (related party) 17 % 46 % Customer B 18 % 13 % Customer C 13 % ** Customer D 13 % ** Customer E ** 11 % Customer F ** **
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Year Ended December 31, 2018 (In thousands) As Reported Adjustments Amounts Without the Adoption of ASC 606 Renewable products $ 33,598 $ — $ 33,598 Licenses and royalties 7,658 5,094 12,752 Grants and collaborations 22,348 (5,786 ) 16,562 Total revenue from all customers $ 63,604 $ (692 ) $ 62,912

Note 2 - Restatement of Conso_2

Note 2 - Restatement of Consolidated Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	December 31, 2017 (In thousands) As Previously Reported Corrections Ref. As Restated Assets Current assets: Cash and cash equivalents $ 57,059 $ — $ 57,059 Restricted cash 2,994 — 2,994 Accounts receivable, net 24,281 (5,328 ) a 18,953 Accounts receivable - related party, net 9,340 (4,573 ) a 4,767 Accounts receivable, unbilled - related party — 9,901 9,901 Inventories 5,408 — 5,408 Prepaid expenses and other current assets 5,525 (606 ) b 4,919 Total current assets 104,607 (606 ) 104,001 Property, plant and equipment, net 13,892 — 13,892 Accounts receivable, unbilled, noncurrent – related party 7,940 — 7,940 Restricted cash, noncurrent 959 — 959 Recoverable taxes from Brazilian government entities 1,445 — 1,445 Other assets 22,640 (10,081 ) c 12,559 Total assets $ 151,483 $ (10,687 ) $ 140,796 Liabilities, Mezzanine Equity and Stockholders' Deficit Current liabilities: Accounts payable $ 15,921 $ (406 ) d $ 15,515 Accrued and other current liabilities 29,402 (200 ) e 29,202 Contract liabilities 4,880 (572 ) f 4,308 Debt, current portion 36,924 — 36,924 Related party debt, current portion 20,019 — 20,019 Total current liabilities 107,146 (1,178 ) 105,968 Long-term debt, net of current portion 61,893 (1,673 ) g 60,220 Related party debt, net of current portion 46,541 — 46,541 Derivative liabilities 119,978 (3,481 ) h 116,497 Other noncurrent liabilities 10,632 13,026 i 23,658 Total liabilities 346,190 6,694 352,884 Commitments and contingencies Mezzanine equity: Contingently redeemable common stock 5,000 — 5,000 Stockholders’ deficit: Preferred stock — — — Common stock - $0.0001 par value 5 — 5 Additional paid-in capital 1,048,274 66,272 j 1,114,546 Accumulated other comprehensive loss (42,156 ) — (42,156 ) Accumulated deficit (1,206,767 ) (83,653 ) k (1,290,420 ) Total Amyris, Inc. stockholders’ deficit (200,644 ) (17,381 ) (218,025 ) Noncontrolling interest 937 — 937 Total stockholders' deficit (199,707 ) (17,381 ) (217,088 ) Total liabilities, mezzanine equity and stockholders' deficit $ 151,483 $ (10,687 ) $ 140,796 Year Ended (In thousands, except shares and per share amounts) As Previously Reported Reclassifications (1) Corrections Ref As Restated Renewable products $ 45,781 $ (3,411 ) $ – $ 42,370 Licenses and royalties 57,703 6,774 (15,774 ) ab 48,703 Grants and collaborations 39,960 (3,363 ) 1 36,598 Total revenue 143,444 – (15,773 ) 127,671 Cost and operating expenses – Cost of products sold 62,713 – (406 ) ad 62,307 Research and development 57,027 (72 ) 607 ae 57,562 Sales, general and administrative 63,219 72 562 af 63,853 Total cost and operating expenses 182,959 – 763 183,722 Loss from operations (39,515 ) – (16,536 ) (56,051 ) Other income (expense) (Loss) gain on divestiture 5,732 – – 5,732 Interest expense (34,033 ) – (3,048 ) ah (37,081 ) (Loss) gain from change in fair value of derivative instruments (1,742 ) – (47,110 ) ai (48,852 ) Loss upon extinguishment of debt (1,521 ) – (10,376 ) ak (11,897 ) Other income (expense), net (955 ) – (1 ) (956 ) Total other expense, net (32,519 ) – (60,535 ) (93,054 ) Loss before income taxes (72,034 ) – (77,071 ) (149,105 ) Provision for income taxes (295 ) – (6,582 ) am (6,877 ) Net loss attributable to Amyris, Inc. (72,329 ) – (83,653 ) (155,982 ) Less deemed dividend on capital distribution to related parties (8,648 ) – 8,648 an – Less deemed dividend related to beneficial conversion feature on Series A preferred stock (562 ) – – (562 ) Less deemed dividend related to beneficial conversion feature on Series B preferred stock (634 ) – – (634 ) Less deemed dividend related to beneficial conversion feature on Series D preferred stock (5,757 ) – – (5,757 ) Less deemed dividend upon settlement of make-whole provision on Series A preferred stock – – (10,505 ) ap (10,505 ) Less deemed dividend upon settlement of make-whole provision on Series B preferred stock – – (22,632 ) aq (22,632 ) Less deemed dividend related to proceeds discount and issuance costs upon conversion of Series A preferred stock – – (21,578 ) ar (21,578 ) Less deemed dividend related to proceeds discount and issuance costs upon conversion of Series B preferred stock – – (24,366 ) as (24,366 ) Less cumulative dividends on Series A and Series B preferred stock (5,439 ) – 5,439 aw – Add: losses allocated to participating securities – – 40,159 au 40,159 Net loss attributable to Amyris, Inc. common stockholders $ (93,369 ) – $ (108,488 ) $ (201,857 ) Net loss per share attributable to common stockholders Basic and diluted $ (2.89 ) $ (6.26 ) Weighted-average shares of common stock outstanding used in computing loss per share of common stock: Basic and diluted 32,253,570 32,253,570 Year Ended December 31, 2017 (In thousands) As Previously Reported Corrections (1) As Restated Operating activities Net loss $ (72,329 ) (83,653 ) $ (155,982 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 11,358 – 11,358 (Gain) loss on disposal of property, plant and equipment 142 – 142 Stock-based compensation 6,265 – 6,265 Amortization of debt discount 12,490 2,749 15,239 (Gain) loss upon extinguishment of debt 1,521 10,376 11,897 Receipt of equity in connection with collaboration arrangements revenue (2,661 ) 2,661 – (Gain) loss from change in fair value of derivative liabilities 1,742 47,110 48,852 (Gain) loss on foreign currency exchange rates (1,230 ) – (1,230 ) Noncash revenue reduction related to issuance of debt obligations – 13,413 13,413 Non-cash gain on divestiture (5,732 ) – (5,732 ) Receipt of noncash consideration in connection with license revenue (8,046 ) – (8,046 ) Changes in assets and liabilities: Accounts receivable (19,647 ) – (19,647 ) Accounts receivable, unbilled – related party (7,940 ) – (7,940 ) Inventories (3,126 ) – (3,126 ) Prepaid expenses and other assets (19,336 ) 606 (18,730 ) Accounts payable 5,858 (406 ) 5,452 Accrued and other liabilities 7,295 6,582 13,877 Contract liabilities (7,241 ) – (7,241 ) Net cash used in operating activities (100,617 ) (562 ) (101,179 ) Investing activities Proceeds from divestiture 54,827 – 54,827 Change in short-term investments 712 581 1,293 Change in restricted cash 865 (865 ) – Purchases of property, plant and equipment (4,412 ) – (4,412 ) Net cash (used in) provided by investing activities 51,992 (284 ) 51,708 Financing activities Proceeds from issuance of convertible preferred stock 101,124 (2,878 ) 98,246 Proceeds from exercises of common stock options 160 (160 ) – Payment of minimum employee taxes withheld upon net share settlement of restricted stock units (385 ) – (385 ) Proceeds from issuance of common stock in August 2017 offering – 5,759 5,759 Issuance costs incurred – (2,159 ) (2,159 ) Change in restricted cash related to contingently redeemable common stock 1,046 (1,046 ) – Proceeds from issuance of debt, net of issuance costs 18,925 – 18,925 Principal payments on debt (37,500 ) – (37,500 ) Payment of swap termination (3,113 ) – (3,113 ) Payment on early redemption of debt (1,909 ) – (1,909 ) Net cash provided by financing activities 78,348 (484 ) 77,864 Effect of exchange rate changes on cash, cash equivalents and restricted cash 186 – 186 Net (decrease) increase in cash, cash equivalents and restricted cash 29,909 (1,330 ) 28,579 Cash, cash equivalents and restricted cash at beginning of year 27,150 5,283 32,433 Cash, cash equivalents and restricted cash at end of year $ 57,059 3,953 61,012 Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets Cash and cash equivalents $ 57,059 Restricted cash, current 2,994 Restricted cash, noncurrent 959 Total cash, cash equivalents and restricted cash $ 61,012 Supplemental disclosures of cash flow information: Cash paid for interest $ 11,539 $ – $ 11,539 Supplemental disclosures of non-cash investing and financing activities: Issuance of common stock upon conversion of debt $ 28,702 $ – $ 28,702 Accrued interest added to debt principal $ 2,816 $ – $ 2,816 Issuance of common stock for settlement of debt principal and interest payments $ 3,436 $ – $ 3,436 Financing of insurance premium under note payable $ 467 $ – $ 467 Issuance of convertible preferred stock upon conversion of debt $ 40,204 $ – $ 40,204 Settlement of debt principal by a related party $ 25,000 $ – $ 25,000 Issuance of note payable in exchange for debt extinguishment with third party $ 16,954 $ – $ 16,954 Issuance of common stock for settlement of debt $ 10,708 $ – $ 10,708 Issuance of preferred stock attributed to derivative liabilities $ – $ 72,725 $ 72,725

Note 3 - Balance Sheet Details

Note 3 - Balance Sheet Details (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Allowance for Doubtful Accounts Activity and Balances [Table Text Block]	<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-decoration: underline"><div style="display: inline; text-decoration: underline;">(In thousands)</div></td> <td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Balance at <br /> Beginning of Year</td> <td style="font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Provisions</td> <td style="font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Recoveries <br /> (Write-offs), Net</td> <td style="font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Balance at <br /> End of Year</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Allowance for doubtful accounts:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%">Year Ended December 31, 2018</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">642</div></td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">–</div></td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">–</td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">642</div></td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year Ended December 31, 2017 (as restated, Note 2)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">501</div></td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">141</div></td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">–</td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">642</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> </table></div>" id="sjs-B4">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt">&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> &lt;tr style="vertical-align: bottom"> &lt;td style="white-space: nowrap; font-weight: bold; text-decoration: underline">&lt;div style="display: inline; text-decoration: underline;">(In thousands)&lt;/div>&lt;/td> &lt;td style="font-weight: bold">&nbsp;&lt;/td> &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Balance at &lt;br /> Beginning of Year&lt;/td> &lt;td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;&lt;/td> &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Provisions&lt;/td> &lt;td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;&lt;/td> &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Recoveries &lt;br /> (Write-offs), Net&lt;/td> &lt;td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;&lt;/td> &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Balance at &lt;br /> End of Year&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> &lt;td style="text-align: left">Allowance for doubtful accounts:&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td style="text-align: left">&nbsp;&lt;/td> &lt;td style="text-align: right">&nbsp;&lt;/td> &lt;td style="white-space: nowrap; text-align: left">&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td style="text-align: left">&nbsp;&lt;/td> &lt;td style="text-align: right">&nbsp;&lt;/td> &lt;td style="white-space: nowrap; text-align: left">&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td style="text-align: left">&nbsp;&lt;/td> &lt;td style="text-align: right">&nbsp;&lt;/td> &lt;td style="white-space: nowrap; text-align: left">&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td style="text-align: left">&nbsp;&lt;/td> &lt;td style="text-align: right">&nbsp;&lt;/td> &lt;td style="white-space: nowrap; text-align: left">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: White"> &lt;td style="width: 48%">Year Ended December 31, 2018&lt;/td> &lt;td style="width: 1%">&nbsp;&lt;/td> &lt;td style="width: 1%; text-align: left">$&lt;/td> &lt;td style="width: 10%; text-align: right">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">642&lt;/div>&lt;/td> &lt;td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;&lt;/td> &lt;td style="width: 1%">&nbsp;&lt;/td> &lt;td style="width: 1%; text-align: left">$&lt;/td> &lt;td style="width: 10%; text-align: right">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;&lt;/div>&lt;/td> &lt;td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;&lt;/td> &lt;td style="width: 1%">&nbsp;&lt;/td> &lt;td style="width: 1%; text-align: left">$&lt;/td> &lt;td style="width: 10%; text-align: right">&#x2013;&lt;/td> &lt;td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;&lt;/td> &lt;td style="width: 1%">&nbsp;&lt;/td> &lt;td style="width: 1%; text-align: left">$&lt;/td> &lt;td style="width: 10%; text-align: right">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">642&lt;/div>&lt;/td> &lt;td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> &lt;td>Year Ended December 31, 2017 (as restated, Note 2)&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td style="text-align: left">$&lt;/td> &lt;td style="text-align: right">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">501&lt;/div>&lt;/td> &lt;td style="white-space: nowrap; text-align: left">&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td style="text-align: left">$&lt;/td> &lt;td style="text-align: right">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">141&lt;/div>&lt;/td> &lt;td style="white-space: nowrap; text-align: left">&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td style="text-align: left">$&lt;/td> &lt;td style="text-align: right">&#x2013;&lt;/td> &lt;td style="white-space: nowrap; text-align: left">&nbsp;&lt;/td> &lt;td>&nbsp;&lt;/td> &lt;td style="text-align: left">$&lt;/td> &lt;td style="text-align: right">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">642&lt;/div>&lt;/td> &lt;td style="white-space: nowrap; text-align: left">&nbsp;&lt;/td> &lt;/tr> &lt;/table>&lt;/div>
Schedule of Inventory, Current [Table Text Block]	December 31, 2018 2017 (As Restated, Note 2) Raw materials $ 3,901 $ 819 Work in process 539 364 Finished goods 5,253 4,225 Total inventories $ 9,693 $ 5,408
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	December 31, 2018 2017 (As Restated, Note 2) Prepayments, advances and deposits $ 5,644 $ 3,599 Recoverable taxes from Brazilian government entities 631 87 Other 4,291 1,233 Total prepaid expenses and other current assets $ 10,566 $ 4,919
Property, Plant and Equipment [Table Text Block]	December 31, 2018 2017 (As Restated, Note 2) Machinery and equipment $ 43,713 $ 46,317 Leasehold improvements 39,922 40,036 Computers and software 9,987 9,555 Furniture and office equipment, vehicles and land 3,016 3,415 Construction in progress 1,749 2,838 Total property, plant and equipment, gross 98,387 102,161 Less: accumulated depreciation and amortization (78,631 ) (88,269 ) Total property, plant and equipment, net $ 19,756 $ 13,892
Schedule of Other Assets, Noncurrent [Table Text Block]	December 31, 2018 2017 (As Restated, Note 2) Contingent consideration $ 4,286 $ 8,150 Deposits 2,465 2,462 Other 1,207 1,947 Total other assets $ 7,958 $ 12,559
Schedule of Accrued and Other Current Liabilities [Table Text Block]	December 31, 2018 2017 (As Restated, Note 2) Payroll and related expenses $ 9,220 $ 7,238 Contract termination fees 4,092 — Accrued interest 3,853 8,213 Asset retirement obligation (1) 3,063 3,587 Ginkgo partnership payments obligation 2,155 — Tax-related liabilities 2,139 5,837 Professional services 1,173 1,694 Other 3,284 2,633 Total accrued and other current liabilities $ 28,979 $ 29,202
Other Noncurrent Liabilities [Table Text Block]	December 31, 2018 2017 (As Restated, Note 2) Liability for unrecognized tax benefit $ 6,582 $ 6,582 Deferred rent, net of current portion 6,440 7,818 Ginkgo partnership payments obligation, net of current portion 6,185 6,444 Contract liabilities, net of current portion 1,587 383 Contract termination fees, net of current portion (1) 1,530 — Capital leases, net of current portion 195 217 Other 673 2,214 Total other noncurrent liabilities $ 23,192 $ 23,658

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	December 31, 2018 2017 (As Restated, Note 2) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Money market funds $ — — $ — $ — $ 53,199 $ — $ — $ 53,199 Certificates of deposit — — — — — 4,153 — 4,153 Total assets measured and recorded at fair value $ — — $ — $ — $ 53,199 $ 4,153 $ — $ 57,352 Liabilities 6% Convertible Notes Due 2021 $ — — $ 57,918 $ 57,918 $ — $ — $ — $ — Embedded derivatives in connection with the issuance of debt and equity instruments — — — — — — 723 723 Freestanding derivative instruments in connection with the issuance of equity instruments — — 42,796 42,796 — — 115,774 115,774 Total liabilities measured and recorded at fair value $ — $ — $ 100,714 $ 100,714 $ — $ — $ 116,497 $ 116,497
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	In thousands Fair value at issuance on December 10, 2018 $ 60,000 Change in fair value (2,082 ) Fair value at December 31, 2018 $ 57,918
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	December 31, (In thousands) 2018 2017 (As Restated, Note 2) Equity-related derivative liabilities $ 41,272 $ 108,887 Debt-related derivative liabilities 1,524 7,610 Total derivative liabilities $ 42,796 $ 116,497
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	(in thousands) 2018 2017 (As Restated, Note 2) Balance at January 1 $ 116,497 $ 4,135 Additions 4,089 133,517 Loss from change in fair value of derivative liabilities 30,880 48,852 Derecognition to additional paid-in capital upon conversion or extinguishment (108,670 ) (70,007 ) Balance at December 31 $ 42,796 $ 116,497
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	December 31, 2018 2017 Risk-free interest rate 2.5% - 3.0% 1.7% - 2.4% Risk-adjusted discount yield 17.2% - 27.3% 18.4% - 28.5% Stock price volatility 45.0% - 85.0% 45.0% - 80.0% Probability of change in control 0.0% 5.0% Stock price $3.34 $3.75 Credit spread 14.6% - 24.9% 16.6% - 26.7% Estimated conversion dates 2019 - 2025 2018 - 2025
Fair Value of Consideration [Table Text Block]	Element Fair Value Allocation Manufacturing capacity reservation fee $ 24,395 Legal settlement and consent waiver 6,764 Working capital adjustment 2,145 Total fair value of consideration transferred $ 33,304

Note 5 - Debt (Tables)

Note 5 - Debt (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Debt [Table Text Block]	December 31, (In thousands) 2018 2017 Principal Unamortized Change in Net Principal Unamortized Net Convertible notes payable (As Restated, Note 2) 6% convertible notes due 2021 $ 60,000 $ – $ (2,082 ) $ 57,918 $ – $ – $ – 2015 Rule 144A convertible notes 37,887 (2,413 ) – 35,474 37,887 (9,458 ) 28,429 2014 Rule 144A convertible notes 24,004 (867 ) – 23,137 24,004 (3,170 ) 20,834 August 2013 financing convertible notes 4,415 (70 ) – 4,345 4,009 (2,126 ) 1,883 December 2017 convertible notes – – – – 5,000 (25 ) 4,975 126,306 (3,350 ) (2,082 ) 120,874 70,900 (14,779 ) 56,121 Related party convertible notes payable 2014 Rule 144A convertible notes 24,705 (1,038 ) – 23,667 24,705 (3,784 ) 20,921 August 2013 financing convertible notes – – – – 21,711 897 22,608 R&D note – – – – 3,700 (18 ) 3,682 24,705 (1,038 ) – 23,667 50,116 (2,905 ) 47,211 Loans payable and credit facilities GACP term loan facility 36,000 (1,349 ) – 34,651 – – – Ginkgo note 12,000 (4,047 ) – 7,953 12,000 (4,862 ) 7,138 Other loans payable 4,910 (1,047 ) – 3,863 6,463 (1,277 ) 5,186 Senior secured loan facility – – – – 28,566 (253 ) 28,313 Other credit facilities – – – – 381 – 381 52,910 (6,443 ) – 46,467 47,410 (6,392 ) 41,018 Related party loans payable DSM note 25,000 (6,311 ) – 18,689 25,000 (8,039 ) 16,961 February 2016 private placement – – – – 2,000 – 2,000 Other DSM loan – – – – 393 – 393 25,000 (6,311 ) – 18,689 27,393 (8,039 ) 19,354 Total debt $ 228,921 $ (17,142 ) $ (2,082 ) 209,697 $ 195,819 $ (32,115 ) 163,704 Less: current portion (147,677 ) (56,943 ) Long-term debt, net of current portion $ 62,020 $ 106,761
Schedule of Long-term Debt Instruments [Table Text Block]	Years ending December 31 Convertible Notes Loans Related Party Convertible Notes Related Party Loans Payable and Credit Facilities Total 2019 $ 134,368 $ 10,219 $ 25,508 $ 2,500 $ 172,595 2020 — 9,981 — 2,500 12,481 2021 — 34,740 — 27,521 62,261 2022 — 13,417 — — 13,417 2023 — 367 — — 367 Thereafter — 2,200 — — 2,200 Total future minimum payments 134,368 70,924 25,508 32,521 263,321 Less: amount representing interest (1) (7,368 ) (18,014 ) (803 ) (7,521 ) (33,706 ) Less: future conversion of accrued interest to principal (694 ) — — — (694 ) Present value of minimum debt payments 126,306 52,910 24,705 25,000 228,921 Less: current portion of debt principal (126,306 ) (3,829 ) (24,705 ) — (154,840 ) Noncurrent portion of debt principal $ — $ 49,081 $ — $ 25,000 $ 74,081

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Transaction Number Outstanding as of Additional Exercises Number Outstanding as of August 2018 warrant exercise agreements – 12,097,164 – 12,097,164 May 2017 cash and dilution warrants 18,042,568 – (11,749,770 ) 6,292,798 August 2017 cash and dilution warrants 9,543,234 1,713,565 (7,288,683 ) 3,968,116 April 2018 warrant exercise agreements – 3,616,174 – 3,616,174 July 2015 related party debt exchange 2,082,010 471,204 (1,889,986 ) 663,228 February 2016 related party private placement 171,429 – – 171,429 July 2015 private placement 81,197 – – 81,197 Other 1,406 – – 1,406 29,921,844 17,898,107 (20,928,439 ) 26,891,512
Schedule of Debt Conversions [Table Text Block]	Debt Instrument Number of Shares into Which 6% convertible notes due 2021 9,493,672 2015 Rule 144A convertible notes 2,338,560 August 2013 financing convertible notes 1,003,554 2014 Rule 144A convertible notes 867,376 13,703,162

Note 8 - Net Loss Per Share A_2

Note 8 - Net Loss Per Share Attributable to Common Stockholders (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Years Ended December 31, (In thousands, except shares and per share amounts) 2018 2017 (As Restated, Note 2) Net loss attributable to Amyris, Inc. (230,235 ) (155,982 ) Less deemed dividend related to beneficial conversion feature on Series A preferred stock — (562 ) Less deemed dividend related to beneficial conversion feature on Series B preferred stock — (634 ) Less deemed dividend related to beneficial conversion feature on Series D preferred stock — (5,757 ) Less deemed dividend upon settlement of make-whole provision on Series A preferred stock — (10,505 ) Less deemed dividend upon settlement of make-whole provision on Series B preferred stock — (22,632 ) Less deemed dividend related to the recognition of discounts on Series A preferred stock upon conversion — (21,578 ) Less deemed dividend related to the recognition of discounts on Series B preferred stock upon conversion — (24,366 ) Less deemed dividend related to proceeds discount upon conversion of Series D preferred stock (6,852 ) — Add: losses allocated to participating securities 13,991 40,159 Net loss attributable to Amyris, Inc. common stockholders $ (223,096 ) $ (201,857 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted 60,405,910 32,253,570 Basic and diluted loss per share $ (3.69 ) $ (6.26 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Years Ended December 31, 2018 2017 (As Restated, Note 2) Period-end common stock warrants 25,986,370 29,921,844 Convertible promissory notes (1) 13,703,162 8,203,821 Period-end stock options to purchase common stock 5,392,269 1,338,367 Period-end restricted stock units 5,294,848 685,007 Period-end preferred shares on an as-converted basis 2,955,732 4,504,212 Total potentially dilutive securities excluded from computation of diluted net loss per share 53,332,381 44,653,251

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule Of Future Minimum Payments For Lease Obligations [Table Text Block]	Years Ending December 31 (In thousands) Capital Operating Total Lease 2019 $ 513 $ 10,416 $ 10,929 2020 198 7,932 8,130 2021 1 7,226 7,227 2022 – 7,399 7,399 2023 – 3,034 3,034 Thereafter – – – Total future minimum payments 712 $ 36,007 $ 36,719 Less: amount representing interest (33 ) Present value of minimum lease payments 679 Less: current portion (484 ) Long-term portion $ 195

Note 10 - Revenue Recognition (

Note 10 - Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Years Ended December 31, 2018 2017 (As Restated, Note 2) Europe $ 29,405 $ 23,823 United States 26,241 78,286 Asia 6,331 23,290 Brazil 942 2,159 Other 685 113 $ 63,604 $ 127,671
Revenue in Connection with Significant Revenue Agreement [Table Text Block]	Years Ended December 31, (In thousands) 2018 2017 (As Restated, Note 2) Renewable Products Licenses and Royalties Grants and Collaborations TOTAL Renewable Products Licenses and Royalties Grants and Collaborations TOTAL Revenue from significant revenue agreements with: DSM (related party) $ 18 $ 5,958 $ 4,735 $ 10,711 $ – $ 57,972 $ 1,679 $ 59,651 Firmenich 3,727 1,700 5,717 11,144 9,621 1,199 5,803 16,623 DARPA – – 8,436 8,436 – – 12,333 12,333 Givaudan 4,078 – 4,358 8,436 1,950 – 6,000 7,950 Nenter – – – – 12,057 2,633 – 14,690 Ginkgo – – – – – (13,113 ) – (13,113 ) Subtotal revenue from significant revenue agreements 7,823 7,658 23,246 38,727 23,628 48,691 25,815 98,134 Revenue from all other customers 25,775 – (898 ) 24,877 18,742 12 10,783 29,537 Total revenue from all customers $ 33,598 $ 7,658 $ 22,348 $ 63,604 $ 42,370 $ 48,703 $ 36,598 $ 127,671
Contract with Customer, Asset and Liability [Table Text Block]	December 31, (In thousands) 2018 2017 Accounts receivable, net $ 16,003 $ 18,953 Accounts receivable - related party, net $ 1,349 $ 4,767 Accounts receivable, unbilled - related party $ 8,021 $ 9,901 Accounts receivable, unbilled, noncurrent - related party $ 1,203 $ 7,940 Contract liabilities (1) $ 8,236 $ 4,308 Contract liabilities, noncurrent (2) $ 1,587 $ –
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	(In thousands) As of December 31, 2018 2019 $ 14,131 2020 7,925 2021 — 2022 and thereafter — Total from all customers $ 22,056

Note 11 - Related Party Trans_2

Note 11 - Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Related Party Debt [Table Text Block]	December 31, (in thousands) 2018 2017 Principal Unamortized Net Principal Unamortized Net Total 2014 Rule 144A convertible notes $ 9,705 $ (422 ) $ 9,283 $ 9,705 $ (1,538 ) $ 8,167 August 2013 financing convertible notes – – – 21,711 897 22,608 R&D note – – – 3,700 (18 ) 3,682 9,705 (422 ) 9,283 35,116 (659 ) 34,457 DSM DSM note 25,000 (6,311 ) 18,689 25,000 (8,039 ) 16,961 Other DSM loan – – – 393 – 393 25,000 (6,311 ) 18,689 25,393 (8,039 ) 17,354 Biolding February 2016 private placement – – – 2,000 – 2,000 Foris 2014 Rule 144A convertible notes 5,000 (181 ) 4,819 5,000 (660 ) 4,340 Temasek 2014 Rule 144A convertible notes 10,000 (435 ) 9,565 10,000 (1,591 ) 8,409 $ 49,705 $ (7,349 ) $ 42,356 $ 77,509 $ (10,949 ) $ 66,560
Schedule of Related Party Revenues [Table Text Block]	Years Ended December 31, (In thousands) 2018 2017 (As restated, Note 2) Renewable Products Licenses and Royalties Grants and Collaborations TOTAL Renewable Products Licenses and Royalties Grants and Collaborations TOTAL Revenue from related parties: DSM $ 18 $ 5,958 $ 4,735 $ 10,711 $ — $ 57,972 $ 1,679 $ 59,651 Total 342 — — 342 (200 ) — — (200 ) Novvi — — — — 1,491 — — 1,491 Subtotal revenue from related parties 360 5,958 4,735 11,053 1,291 57,972 1,679 60,942 Revenue from all other customers (1) 33,238 1,700 17,613 52,551 41,079 (9,269 ) 34,919 66,729 Total revenue from all customers $ 33,598 $ 7,658 $ 22,348 $ 63,604 $ 42,370 $ 48,703 $ 36,598 $ 127,671
Schedule of Related Party Accounts Receivables [Table Text Block]	December 31, (In thousands) 2018 2017 DSM $ 1,071 $ 12,823 Novvi 188 1,607 Total 90 238 Related party accounts receivable, net $ 1,349 $ 14,668
Schedule of Related Party Assets and Liabilities [Table Text Block]	December 31, (In thousands) 2018 2017 Assets $ 12,904 $ 7,635 Liabilities $ 2,364 $ 3,187

Note 12 - Stock-based Compens_2

Note 12 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Years Ended December 31, (In thousands) 2018 2017 Research and development $ 1,797 $ 2,204 Sales, general and administrative 7,393 4,061 Total stock-based compensation expense $ 9,190 $ 6,265
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Years Ended December 31, 2018 2017 Expected dividend yield —% —% Risk-free interest rate 2.8 % 2.1 % Expected term (in years) 6.90 6.12 Expected volatility 80 % 84 %
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Year ended December 31, 2018 2017 Options granted 4,337,119 661,094 Weighted-average grant-date fair value per share $ 5.18 $ 3.26 Compensation expense related to stock options (in millions) $ 2.6 $ 3.3 Unrecognized compensation costs as of December 31 (in millions) $ 8.5 $ 2.7
Share-based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]	Number of Weighted- Weighted-average Aggregate Outstanding - December 31, 2017 1,338,367 $ 33.40 7.7 $ 97 Options granted 4,337,119 $ 5.18 Options exercised (70,807 ) $ 3.68 Options forfeited or expired (214,409 ) $ 19.61 Outstanding - December 31, 2018 5,390,270 $ 11.55 8.5 $ 29 Vested or expected to vest after December 31, 2018 4,833,615 $ 12.28 8.4 $ 28 Exercisable at December 31, 2018 972,229 $ 39.73 5.8 $ 12
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Number of Weighted- Weighted- Outstanding - December 31, 2017 683,554 $ 8.66 1.4 Awarded 5,452,664 $ 5.36 Vested (445,828 ) $ 8.43 Forfeited (395,587 ) $ 5.64 Outstanding - December 31, 2018 5,294,803 $ 5.50 1.7 Vested or expected to vest after December 31, 2018 4,953,264 $ 5.50 1.6
Performance-based Stock Options [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Stock Option Award with Performance and Market Vesting Conditions: Fair value of the Company’s common stock on grant date $ 5.08 Expected volatility 70 % Risk-free interest rate 2.75 % Dividend yield 0.0 %

Note 14 - Income Taxes (Tables)

Note 14 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Years Ended December 31, (In thousands) 2018 2017 (As Restated, Note 2) United States $ (218,109 ) $ (156,020 ) Foreign (12,125 ) 6,915 Loss before income taxes $ (230,234 ) $ (149,105 )
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Years Ended December 31, (In thousands) 2018 2017 (As Restated, Note 2) Current: Federal $ — $ 6,564 State — 18 Foreign — 964 Total current provision — 7,546 Deferred: Federal — (669 ) State — — Foreign — — Total deferred benefit — (669 ) Total provision for income taxes$ $ — $ 6,877
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Years Ended December 31, 2018 2017 (As Restated, Note 2) Statutory tax rate (21.0 )% (34.0 )% State taxes, net of federal tax benefit — % — % Stock-based compensation — % — % Federal R&D credit (0.6 )% (0.2 )% Derivative liability 4.3 % 13.9 % Nondeductible interest 1.0 % 3.0 % Other (0.1 )% (0.2 )% Foreign losses 0.9 % 8.5 % Change in U.S. federal tax rate — % 25.1 % IRC Section 382 limitation — % 7.2 % Change in valuation allowance 15.5 % (18.6 )% Effective income tax rate — % 4.7 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, (In thousands) 2018 2017 (As Restated, Note 2) Net operating loss carryforwards $ 57,921 $ 20,066 Property, plant and equipment 9,269 9,653 Research and development credits 12,046 9,480 Foreign tax credit – – Accruals and reserves 8,526 7,286 Stock-based compensation 6,496 5,471 Disallowed interest carryforward 2,359 – Capitalized start-up costs – – Capitalized research and development costs 27,888 32,085 Intangible and others 3,114 3,584 Equity investments 156 – Total deferred tax assets 127,775 87,625 Debt discount and derivatives (3,750 ) (6,539 ) Total deferred tax liabilities (3,750 ) (6,539 ) Net deferred tax assets prior to valuation allowance 124,025 81,086 Less: valuation allowance (124,025 ) (81,086 ) Net deferred tax assets $ – $ –
Summary of Valuation Allowance [Table Text Block]	(In thousands) Balance at Beginning Additions Reductions / Balance at Deferred tax assets valuation allowance: Year Ended December 31, 2018 $ 81,086 $ 42,939 $ – $ 124,025 Year Ended December 31, 2017 (As Restated, Note 2) $ 386,867 $ – $ (305,781 ) $ 81,086
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	(In thousands) Balance at December 31, 2016 $ 9,101 Increases in tax positions for prior period 50 Increases in tax positions during current period 19,682 Balance at December 31, 2017 28,833 Increases in tax positions for prior period 55 Increases in tax positions during current period 1,239 Balance at December 31, 2018 $ 30,127

Note 15 - Geographical Inform_2

Note 15 - Geographical Information (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]	December 31, 2018 2017 (As Restated, Note 2) United States $ 13,111 $ 10,357 Brazil 6,447 3,357 Europe 198 178 $ 19,756 $ 13,892

Note 1 - Basis of Presentatio_3

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	Jan. 01, 2019	Dec. 28, 2017	Dec. 31, 2018	Dec. 31, 2017		Sep. 16, 2019	Jul. 24, 2019	Dec. 10, 2018	Dec. 06, 2018	Jan. 01, 2018
Working Capital			$ 119,500,000
Retained Earnings (Accumulated Deficit), Ending Balance			(1,521,417,000)	$ (1,290,420,000)	[1]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total			17,100,000
Debt, Changes in Fair Value, Gain (Loss)			2,082,000
Long-term Debt, Total			209,697,000	163,704,000
Long-term Debt, Current Maturities, Including Due to Related Parties			147,677,000	56,943,000
Cash, Cash Equivalents, and Short-term Investments, Total			45,400,000
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal		$ 5,700,000	(1,778,000)	5,732,000
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax, Ending Balance			43,300,000	42,200,000
Foreign Currency Transaction Gain (Loss), before Tax, Total			2,223,000	1,230,000
Assets, Total			127,925,000	140,796,000
Liabilities, Total			339,744,000	352,884,000
Accounting Standards Update 2014-09 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance										$ (800,000)
Accounting Standards Update 2016-02 [Member]
Assets, Total	$ 25,700,000
Operating Lease, Liability, Total	33,600,000
Operating Lease, Right-of-Use Asset	29,700,000
Liabilities, Total	24,900,000
Accounting Standards Update 2017-11 [Member]
Increase (Decrease) in Derivative Liabilities	(41,000,000)
Stockholders' Equity, Period Increase (Decrease), Total	$ 41,000,000
Other Expense, Net [Member]
Foreign Currency Transaction Gain (Loss), before Tax, Total			$ 1,600,000	$ 400,000
Machinery, Equipment, and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life			3 years
Machinery, Equipment, and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life			15 years
Building [Member]
Property, Plant and Equipment, Useful Life			15 years
DSM [Member]
Charge Related to Final Working Capital Adjustments Between the Company and a Counterparty			$ 1,800,000
Convertible Senior Notes, 6.0%, Due in 2021, Second Exchange [Member] | Subsequent Event [Member]
Debt Instrument, Debt Default, Amount						$ 63,600,000
Debt Instrument, Interest Rate, Stated Percentage							18.00%
Convertible Senior Notes, 6.0% Due in 2021 [Member]
Debt, Changes in Fair Value, Gain (Loss)			$ 2,100,000
Debt Instrument, Interest Rate, Stated Percentage			6.00%					6.00%	6.00%
[1]	Sum of adjustments to net loss for the year ended December 31, 2017 as result of corrections.

Note 1 - Basis of Presentatio_4

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) - Customer Concentration Risk [Member]		12 Months Ended
		Dec. 31, 2018		Dec. 31, 2017
Accounts Receivable [Member] | Customer B [Member]
Concentration risk percentage		24.00%		10.00%
Accounts Receivable [Member] | Customer A [Member]
Concentration risk percentage			[1]	38.00%
Accounts Receivable [Member] | Customer C [Member]
Concentration risk percentage		19.00%		15.00%
Accounts Receivable [Member] | Customer G [Member]
Concentration risk percentage		11.00%			[1]
Revenues [Member] | Customer B [Member]
Concentration risk percentage		18.00%		13.00%
Revenues [Member] | Customer A [Member]
Concentration risk percentage		17.00%		46.00%
Revenues [Member] | Customer C [Member]
Concentration risk percentage		13.00%			[2]
Revenues [Member] | Customer D [Member]
Concentration risk percentage		13.00%			[2]
Revenues [Member] | Customer E [Member]
Concentration risk percentage			[2]	11.00%
Revenues [Member] | Customer F [Member]
Concentration risk percentage	[2]
[1]	Less than 10%
[2]	Less than 10%

Note 1 - Basis of Presentatio_5

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies - Adoption of ASC 606 (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues	$ 63,604	$ 127,671
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenues	(692)
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenues	62,912
Product [Member]
Revenues	33,598	42,370
Product [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenues
Product [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenues	33,598
Licenses and Royalties [Member]
Revenues	7,658	48,703	[1]
Licenses and Royalties [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenues	5,094
Licenses and Royalties [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenues	12,752
Grants and Collaborations [Member]
Revenues	22,348	$ 36,598
Grants and Collaborations [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenues	(5,786)
Grants and Collaborations [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenues	$ 16,562
[1]	Ginkgo partnership obligation and promissory note issuance recorded as reduction to revenue and correction of errors in recording revenue from non-cash consideration.

Note 2 - Restatement of Conso_3

Note 2 - Restatement of Consolidated Financial Statements - Consolidated Financial Statements (Details) - USD ($) $ / shares in Units, $ in Thousands		Dec. 28, 2017	May 31, 2017	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016
Cash and cash equivalents				$ 45,353	$ 57,059		$ 45,353	$ 57,059
Restricted cash				741	2,994		741	2,994
Accounts receivable, net							16,003	18,953	[1]
Accounts receivable - related party, net							1,349	4,767	[1]
Accounts receivable, unbilled - related party							8,021	9,901
Inventories							9,693	5,408
Prepaid expenses and other current assets							10,566	4,919	[2]
Total current assets							92,215	104,001
Property, plant and equipment, net							19,756	13,892
Accounts receivable, unbilled, noncurrent – related party							1,203	7,940
Restricted cash, noncurrent				960	959		960	959
Recoverable taxes from Brazilian government entities							3,005	1,445
Other assets							7,958	12,559	[3]
Total assets							127,925	140,796
Accounts payable							26,844	15,515	[4]
Accrued and other current liabilities							28,979	29,202	[5]
Contract liabilities	[6],[7]						8,236	4,308	[8]
Debt, current portion							124,010	36,924
Related party debt, current portion							23,667	20,019
Total current liabilities							211,736	105,968
Long-term debt, net of current portion							43,331	60,220	[9]
Related party debt, net of current portion							18,689	46,541
Derivative liabilities							42,796	116,497	[10]
Other noncurrent liabilities							23,192	23,658	[11]
Total liabilities							339,744	352,884
Mezzanine Equity							5,000	5,000
Preferred stock
Common stock - $0.0001 par value							8	5
Additional paid-in capital							1,346,996	1,114,546	[12]
Accumulated other comprehensive loss							(43,343)	(42,156)
Accumulated deficit							(1,521,417)	(1,290,420)	[13]
Total Amyris, Inc. stockholders’ deficit							(217,756)	(218,025)
Noncontrolling interest							937	937
Total stockholders' deficit							(216,819)	(217,088)		$ (183,508)
Total liabilities, mezzanine equity and stockholders' deficit							$ 127,925	140,796
Revenue from Contract with Customer, Including Assessed Tax				63,604	127,671
Cost of products sold				36,698	62,307	[14]
Research and development				68,722	57,562	[15]
Sales, general and administrative				90,902	63,853	[16]
Total cost and operating expenses				200,187	183,722	[16]
Loss from operations				(136,583)	(56,051)
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal		$ 5,700		(1,778)	5,732
Interest expense				(42,703)	(37,081)	[17]
Gain (Loss) on Derivative Instruments, Net, Pretax, Total				(30,880)	(48,852)	[18]
Gain (Loss) on Extinguishment of Debt, Total			$ (1,900)	(17,424)	(11,897)	[19]
Other income (expense), net				(2,949)	(956)
Total other expense, net				(93,652)	(93,054)
Loss before income taxes				(230,235)	(149,105)
Provision for income taxes					(6,877)	[20]
Net loss				(230,235)	(155,982)
Less deemed dividend on capital distribution to related parties	[19]
Less deemed dividend related to beneficial conversion feature on Series A preferred stock					(562)
Less deemed dividend related to beneficial conversion feature on Series B preferred stock					(634)
Less deemed dividend related to beneficial conversion feature on Series D preferred stock					(5,757)
Less deemed dividend upon settlement of make-whole provision on Series A preferred stock					(10,505)	[21]
Label Less deemed dividend upon settlement of make-whole provision on Series B preferred stock					(22,632)	[21]
Less deemed dividend related to proceeds discount and issuance costs upon conversion of Series A preferred stock					(21,578)	[21]
Less deemed dividend related to proceeds discount and issuance costs upon conversion of Series B preferred stock					(24,366)	[21]
Add: losses allocated to participating securities				13,991	40,159	[22]
Net loss attributable to Amyris, Inc. common stockholders				$ (223,096)	$ (201,857)
Basic and diluted loss per share (in dollars per share)				$ (3.69)	$ (6.26)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (in shares)				60,405,910	32,253,570
Depreciation and amortization				$ 4,921	$ 11,358
(Gain) loss on disposal of property, plant and equipment				941	142
Stock-based compensation				9,190	6,265
Amortization of debt discount				16,602	15,239
(Gain) loss upon extinguishment of debt				17,424	11,897
Receipt of equity in connection with collaboration arrangements revenue
(Gain) loss from change in fair value of derivative liabilities				30,880	48,852
(Gain) loss on foreign currency exchange rates				(2,223)	(1,230)
Noncash revenue reduction related to issuance of debt obligations under Ginkgo Partnership Agreement					13,413
Non-cash gain on divestiture		$ (5,700)		1,778	(5,732)
Receipt of noncash consideration in connection with license revenue					(8,046)
Accounts receivable				7,448	(19,647)
Accounts receivable, unbilled – related party				8,056	(7,940)
Inventories				(4,416)	(3,126)
Prepaid expenses and other assets				(6,383)	(18,730)
Accounts payable				11,603	5,452
Accrued and other liabilities				8,461	13,877
Increase (Decrease) in Contract with Customer, Liability				3,158	(7,241)
Net cash used in operating activities				(109,366)	(101,179)
Proceeds from Divestiture of Businesses					54,827
Change in short-term investments					1,293
Change in restricted cash
Purchases of property, plant and equipment				(12,472)	(4,412)
Net cash (used in) provided by investing activities				(12,472)	51,708
Proceeds from issuance of convertible preferred stock					98,246
Proceeds from exercises of common stock options				288
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units				(260)	(385)
Proceeds from issuance of common stock in August 2017 offering					5,759
Issuance costs incurred					(2,159)
Change in restricted cash related to contingently redeemable common stock
Proceeds from issuance of debt, net of issuance costs				94,371	18,925
Principal payments on debt				(41,668)	(37,500)
Payment of swap termination					(3,113)
Payment on early redemption of debt					(1,909)
Net cash provided by financing activities				107,957	77,864
Effect of exchange rate changes on cash, cash equivalents and restricted cash				(77)	186
Net (decrease) increase in cash, cash equivalents and restricted cash				(13,958)	28,579
Cash, cash equivalents and restricted cash at beginning of year				61,012	32,433
Cash, cash equivalents and restricted cash at end of year				47,054	61,012
Cash and cash equivalents				45,353	57,059
Restricted cash, current				741	2,994
Restricted cash, noncurrent				960	959
Cash paid for interest				18,524	11,539
Issuance of common stock upon conversion of convertible notes				24,970	28,702
Accrued interest added to debt principal				3,664	2,816
Issuance of common stock for settlement of debt principal and interest payments				1,800	3,436
Financing of insurance premium under note payable				495	467
Issuance of convertible preferred stock upon conversion of debt					40,204
Settlement of debt principal by a related party					25,000
Issuance of note payable in exchange for debt extinguishment with third party					16,954
Issuance of common stock for settlement of debt					10,708
Issuance of preferred stock attributed to derivative liabilities					72,725
Preferred Stock Series A and Series B [Member]
Less cumulative dividends on Series A and Series B preferred stock	[23]
Renewable Products [Member]
Revenue from Contract with Customer, Including Assessed Tax				33,598	42,370
Licenses and Royalties [Member]
Revenue from Contract with Customer, Including Assessed Tax				7,658	48,703	[24]
Grants and Collaborations [Member]
Revenue from Contract with Customer, Including Assessed Tax				22,348	36,598
Previously Reported [Member]
Cash and cash equivalents					57,059			57,059
Restricted cash					2,994			2,994
Accounts receivable, net	[1]							24,281
Accounts receivable - related party, net	[1]							9,340
Accounts receivable, unbilled - related party
Inventories								5,408
Prepaid expenses and other current assets	[2]							5,525
Total current assets								104,607
Property, plant and equipment, net								13,892
Accounts receivable, unbilled, noncurrent – related party								7,940
Restricted cash, noncurrent					959			959
Recoverable taxes from Brazilian government entities								1,445
Other assets	[3]							22,640
Total assets								151,483
Accounts payable	[4]							15,921
Accrued and other current liabilities	[5]							29,402
Contract liabilities	[8]							4,880
Debt, current portion								36,924
Related party debt, current portion								20,019
Total current liabilities								107,146
Long-term debt, net of current portion	[9]							61,893
Related party debt, net of current portion								46,541
Derivative liabilities	[10]							119,978
Other noncurrent liabilities	[11]							10,632
Total liabilities								346,190
Mezzanine Equity								5,000
Preferred stock
Common stock - $0.0001 par value								5
Additional paid-in capital	[12]							1,048,274
Accumulated other comprehensive loss								(42,156)
Accumulated deficit	[13]							(1,206,767)
Total Amyris, Inc. stockholders’ deficit								(200,644)
Noncontrolling interest								937
Total stockholders' deficit								(199,707)
Total liabilities, mezzanine equity and stockholders' deficit								151,483
Revenue from Contract with Customer, Including Assessed Tax					143,444
Cost of products sold	[14]				62,713
Research and development	[15]				57,027
Sales, general and administrative	[16]				63,219
Total cost and operating expenses	[16]				182,959
Loss from operations					(39,515)
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal					5,732
Interest expense	[17]				(34,033)
Gain (Loss) on Derivative Instruments, Net, Pretax, Total	[18]				(1,742)
Gain (Loss) on Extinguishment of Debt, Total	[19]				(1,521)
Other income (expense), net					(955)
Total other expense, net					(32,519)
Loss before income taxes					(72,034)
Provision for income taxes	[20]				(295)
Net loss					(72,329)
Less deemed dividend on capital distribution to related parties	[19]				(8,648)
Less deemed dividend related to beneficial conversion feature on Series A preferred stock					(562)
Less deemed dividend related to beneficial conversion feature on Series B preferred stock					(634)
Less deemed dividend related to beneficial conversion feature on Series D preferred stock					(5,757)
Less deemed dividend upon settlement of make-whole provision on Series A preferred stock	[21]
Label Less deemed dividend upon settlement of make-whole provision on Series B preferred stock	[21]
Less deemed dividend related to proceeds discount and issuance costs upon conversion of Series A preferred stock	[21]
Less deemed dividend related to proceeds discount and issuance costs upon conversion of Series B preferred stock	[21]
Add: losses allocated to participating securities	[22]
Net loss attributable to Amyris, Inc. common stockholders					$ (93,369)
Basic and diluted loss per share (in dollars per share)					$ (2.89)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (in shares)					32,253,570
Depreciation and amortization					$ 11,358
(Gain) loss on disposal of property, plant and equipment					142
Stock-based compensation					6,265
Amortization of debt discount					12,490
(Gain) loss upon extinguishment of debt					1,521
Receipt of equity in connection with collaboration arrangements revenue					(2,661)
(Gain) loss from change in fair value of derivative liabilities					1,742
(Gain) loss on foreign currency exchange rates					(1,230)
Noncash revenue reduction related to issuance of debt obligations under Ginkgo Partnership Agreement
Non-cash gain on divestiture					(5,732)
Receipt of noncash consideration in connection with license revenue					(8,046)
Accounts receivable					(19,647)
Accounts receivable, unbilled – related party					(7,940)
Inventories					(3,126)
Prepaid expenses and other assets					(19,336)
Accounts payable					5,858
Accrued and other liabilities					7,295
Increase (Decrease) in Contract with Customer, Liability					(7,241)
Net cash used in operating activities					(100,617)
Proceeds from Divestiture of Businesses					54,827
Change in short-term investments					712
Change in restricted cash					865
Purchases of property, plant and equipment					(4,412)
Net cash (used in) provided by investing activities					51,992
Proceeds from issuance of convertible preferred stock					101,124
Proceeds from exercises of common stock options					160
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units					(385)
Proceeds from issuance of common stock in August 2017 offering
Issuance costs incurred
Change in restricted cash related to contingently redeemable common stock					1,046
Proceeds from issuance of debt, net of issuance costs					18,925
Principal payments on debt					(37,500)
Payment of swap termination					(3,113)
Payment on early redemption of debt					(1,909)
Net cash provided by financing activities					78,348
Effect of exchange rate changes on cash, cash equivalents and restricted cash					186
Net (decrease) increase in cash, cash equivalents and restricted cash					29,909
Cash, cash equivalents and restricted cash at beginning of year				57,059	27,150
Cash, cash equivalents and restricted cash at end of year					57,059
Cash and cash equivalents					57,059
Restricted cash, current					2,994
Restricted cash, noncurrent					959
Cash paid for interest					11,539
Issuance of common stock upon conversion of convertible notes					28,702
Accrued interest added to debt principal					2,816
Issuance of common stock for settlement of debt principal and interest payments					3,436
Financing of insurance premium under note payable					467
Issuance of convertible preferred stock upon conversion of debt					40,204
Settlement of debt principal by a related party					25,000
Issuance of note payable in exchange for debt extinguishment with third party					16,954
Issuance of common stock for settlement of debt					10,708
Issuance of preferred stock attributed to derivative liabilities
Previously Reported [Member] | Preferred Stock Series A and Series B [Member]
Less cumulative dividends on Series A and Series B preferred stock	[23]				(5,439)
Previously Reported [Member] | Renewable Products [Member]
Revenue from Contract with Customer, Including Assessed Tax					45,781
Previously Reported [Member] | Licenses and Royalties [Member]
Revenue from Contract with Customer, Including Assessed Tax	[24]				57,703
Previously Reported [Member] | Grants and Collaborations [Member]
Revenue from Contract with Customer, Including Assessed Tax					39,960
Restatement Adjustment [Member]
Cash and cash equivalents	[25]
Restricted cash	[25]
Accounts receivable, net	[1]							(5,328)
Accounts receivable - related party, net	[1]							(4,573)
Accounts receivable, unbilled - related party								9,901
Inventories
Prepaid expenses and other current assets	[2]							(606)
Total current assets								(606)
Property, plant and equipment, net
Accounts receivable, unbilled, noncurrent – related party
Restricted cash, noncurrent	[25]
Recoverable taxes from Brazilian government entities
Other assets	[3]							(10,081)
Total assets								(10,687)
Accounts payable	[4]							(406)
Accrued and other current liabilities	[5]							(200)
Contract liabilities	[8]							(572)
Debt, current portion
Related party debt, current portion
Total current liabilities								(1,178)
Long-term debt, net of current portion	[9]							(1,673)
Related party debt, net of current portion
Derivative liabilities	[10]							(3,481)
Other noncurrent liabilities	[11]							13,026
Total liabilities								6,694
Mezzanine Equity
Preferred stock
Common stock - $0.0001 par value
Additional paid-in capital	[12]							66,272
Accumulated other comprehensive loss
Accumulated deficit	[13]							(83,653)
Total Amyris, Inc. stockholders’ deficit								(17,381)
Noncontrolling interest
Total stockholders' deficit								(17,381)
Total liabilities, mezzanine equity and stockholders' deficit								$ (10,687)
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	[25]
Net loss	[25]				(83,653)
Depreciation and amortization	[25]
(Gain) loss on disposal of property, plant and equipment	[25]
Stock-based compensation	[25]
Amortization of debt discount	[25]				2,749
(Gain) loss upon extinguishment of debt	[25]				10,376
Receipt of equity in connection with collaboration arrangements revenue	[25]				2,661
(Gain) loss from change in fair value of derivative liabilities	[25]				47,110
(Gain) loss on foreign currency exchange rates	[25]
Noncash revenue reduction related to issuance of debt obligations under Ginkgo Partnership Agreement	[25]				13,413
Non-cash gain on divestiture	[25]
Receipt of noncash consideration in connection with license revenue	[25]
Accounts receivable	[25]
Accounts receivable, unbilled – related party	[25]
Inventories	[25]
Prepaid expenses and other assets	[25]				606
Accounts payable	[25]				(406)
Accrued and other liabilities	[25]				6,582
Increase (Decrease) in Contract with Customer, Liability	[25]
Net cash used in operating activities	[25]				(562)
Proceeds from Divestiture of Businesses	[25]
Change in short-term investments	[25]				581
Change in restricted cash	[25]				(865)
Purchases of property, plant and equipment	[25]
Net cash (used in) provided by investing activities	[25]				(284)
Proceeds from issuance of convertible preferred stock	[25]				(2,878)
Proceeds from exercises of common stock options	[25]				(160)
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units	[25]
Proceeds from issuance of common stock in August 2017 offering	[25]				5,759
Issuance costs incurred	[25]				(2,159)
Change in restricted cash related to contingently redeemable common stock	[25]				(1,046)
Proceeds from issuance of debt, net of issuance costs	[25]
Principal payments on debt	[25]
Payment of swap termination	[25]
Payment on early redemption of debt	[25]
Net cash provided by financing activities	[25]				(484)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	[25]
Net (decrease) increase in cash, cash equivalents and restricted cash	[25]				(1,330)
Cash, cash equivalents and restricted cash at beginning of year	[25]			$ 3,953	5,283
Cash, cash equivalents and restricted cash at end of year	[25]				3,953
Cash and cash equivalents	[25]
Restricted cash, current	[25]
Restricted cash, noncurrent	[25]
Cash paid for interest	[25]
Issuance of common stock upon conversion of convertible notes	[25]
Accrued interest added to debt principal	[25]
Issuance of common stock for settlement of debt principal and interest payments	[25]
Financing of insurance premium under note payable	[25]
Issuance of convertible preferred stock upon conversion of debt	[25]
Settlement of debt principal by a related party	[25]
Issuance of note payable in exchange for debt extinguishment with third party	[25]
Issuance of common stock for settlement of debt	[25]
Issuance of preferred stock attributed to derivative liabilities	[25]				72,725
Restatement Adjustment [Member] | Reclassifications [Member]
Revenue from Contract with Customer, Including Assessed Tax	[25]
Cost of products sold	[14],[25]
Research and development	[15],[25]				(72)
Sales, general and administrative	[16],[25]				72
Total cost and operating expenses	[16],[25]
Loss from operations	[25]
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	[25]
Interest expense	[17],[25]
Gain (Loss) on Derivative Instruments, Net, Pretax, Total	[18],[25]
Gain (Loss) on Extinguishment of Debt, Total	[19],[25]
Other income (expense), net	[25]
Total other expense, net	[25]
Loss before income taxes	[25]
Provision for income taxes	[20],[25]
Net loss	[25]
Less deemed dividend on capital distribution to related parties	[19],[25]
Less deemed dividend related to beneficial conversion feature on Series A preferred stock	[25]
Less deemed dividend related to beneficial conversion feature on Series B preferred stock	[25]
Less deemed dividend related to beneficial conversion feature on Series D preferred stock	[25]
Less deemed dividend upon settlement of make-whole provision on Series A preferred stock	[21],[25]
Label Less deemed dividend upon settlement of make-whole provision on Series B preferred stock	[21],[25]
Less deemed dividend related to proceeds discount and issuance costs upon conversion of Series A preferred stock	[21],[25]
Less deemed dividend related to proceeds discount and issuance costs upon conversion of Series B preferred stock	[21],[25]
Add: losses allocated to participating securities	[22],[25]
Net loss attributable to Amyris, Inc. common stockholders	[25]
Basic and diluted loss per share (in dollars per share)	[25]
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (in shares)	[25]
Non-cash gain on divestiture	[25]
Restatement Adjustment [Member] | Reclassifications [Member] | Preferred Stock Series A and Series B [Member]
Less cumulative dividends on Series A and Series B preferred stock	[23],[25]
Restatement Adjustment [Member] | Corrections [Member]
Revenue from Contract with Customer, Including Assessed Tax					(15,773)
Cost of products sold	[14]				(406)
Research and development	[15]				607
Sales, general and administrative	[16]				562
Total cost and operating expenses	[16]				763
Loss from operations					(16,536)
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal
Interest expense	[17]				(3,048)
Gain (Loss) on Derivative Instruments, Net, Pretax, Total	[18]				(47,110)
Gain (Loss) on Extinguishment of Debt, Total	[19]				(10,376)
Other income (expense), net					(1)
Total other expense, net					(60,535)
Loss before income taxes					(77,071)
Provision for income taxes	[20]				(6,582)
Net loss					(83,653)
Less deemed dividend on capital distribution to related parties	[19]				8,648
Less deemed dividend related to beneficial conversion feature on Series A preferred stock
Less deemed dividend related to beneficial conversion feature on Series B preferred stock
Less deemed dividend related to beneficial conversion feature on Series D preferred stock
Less deemed dividend upon settlement of make-whole provision on Series A preferred stock	[21]				(10,505)
Label Less deemed dividend upon settlement of make-whole provision on Series B preferred stock	[21]				(22,632)
Less deemed dividend related to proceeds discount and issuance costs upon conversion of Series A preferred stock	[21]				(21,578)
Less deemed dividend related to proceeds discount and issuance costs upon conversion of Series B preferred stock	[21]				(24,366)
Add: losses allocated to participating securities	[22]				40,159
Net loss attributable to Amyris, Inc. common stockholders					$ (108,488)
Basic and diluted loss per share (in dollars per share)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (in shares)
Non-cash gain on divestiture
Restatement Adjustment [Member] | Corrections [Member] | Preferred Stock Series A and Series B [Member]
Less cumulative dividends on Series A and Series B preferred stock	[23]				5,439
Restatement Adjustment [Member] | Renewable Products [Member] | Reclassifications [Member]
Revenue from Contract with Customer, Including Assessed Tax	[25]				(3,411)
Restatement Adjustment [Member] | Renewable Products [Member] | Corrections [Member]
Revenue from Contract with Customer, Including Assessed Tax
Restatement Adjustment [Member] | Licenses and Royalties [Member] | Reclassifications [Member]
Revenue from Contract with Customer, Including Assessed Tax	[24],[25]				6,774
Restatement Adjustment [Member] | Licenses and Royalties [Member] | Corrections [Member]
Revenue from Contract with Customer, Including Assessed Tax	[24]				(15,774)
Restatement Adjustment [Member] | Grants and Collaborations [Member] | Reclassifications [Member]
Revenue from Contract with Customer, Including Assessed Tax	[25]				(3,363)
Restatement Adjustment [Member] | Grants and Collaborations [Member] | Corrections [Member]
Revenue from Contract with Customer, Including Assessed Tax					$ 1
[1]	Reclassification of related party accounts receivable to a separate line on the balance sheet.
[2]	Write-off of unrecoverable receivable in connection with facilities subleased to a related party.
[3]	Correction of error in recording amounts payable under Ginkgo Partnership Agreement as prepaid royalties instead of reduction in revenue.
[4]	Adjustment to uninvoiced receipts liability.
[5]	Adjustment to accrued liability.
[6]	The balance in contract liabilities at December 31, 2017 represents deferred revenue, current prior to the Company's adoption of ASC 606, "Revenue".
[7]	The balance in contract liabilities, current at December 31, 2017 represents deferred revenue, current prior to the Company's adoption of ASC 606, "Revenue".
[8]	Revision to accounting for equity received in satisfaction of a customer receivable.
[9]	Adjustment to issuance-date fair value of a debt instrument.
[10]	Make-whole derivative liabilities adjustment.
[11]	Accrual of the Ginkgo Partnership Payments obligation, net of reduction to deferred revenue liability.
[12]	Correction to the accounting for a make-whole equity instrument in connection with May 2017 equity offering.
[13]	Sum of adjustments to net loss for the year ended December 31, 2017 as result of corrections.
[14]	Correction in connection with a sales return, and adjustment to uninvoiced receipts liability.
[15]	Write-off of unrecoverable receivable in connection with facilities subleased to a related party, and reclassification of operating expense by classification to conform to the Company's current presentation.
[16]	Expense incurred in connection with May 2017 equity offering.
[17]	Correction to amortization of debt discounts, and interest expense in connection with partnership payments obligation.
[18]	Correction to accounting for make-whole liability in connection with May 2017 Offering.
[19]	Loss on extinguishment of related and unrelated party debt.
[20]	Tax provision to accrue liability for unrecognized tax benefit.
[21]	Correction to record deemed dividend in connection with discounts and freestanding instruments related to preferred stock offerings.
[22]	Correction in the computation of loss per share to reflect participating securities.
[23]	Correction in the computation of net loss per share related to make-whole deemed dividends.
[24]	Ginkgo partnership obligation and promissory note issuance recorded as reduction to revenue and correction of errors in recording revenue from non-cash consideration.
[25]	Reclassification of revenue and operating expense by type to conform to the Company's current presentation.

Note 2 - Restatement of Conso_4

Note 2 - Restatement of Consolidated Financial Statements - Consolidated Financial Statements (Details) (Parentheticals) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001

Note 3 - Balance Sheet Detail_2

Note 3 - Balance Sheet Details (Details Textual) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
		Nov. 30, 2017	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment, Net, Ending Balance			$ 19,756	$ 13,892
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance			78,631	88,269
Contract with Customer, Liability, Current	[1],[2]		8,236	4,308	[3]
Long-term Debt, Total			209,697	163,704
Realization of Certain NOL Tax Benefits [Member]
Contingent Consideration Receivable			0	3,900
Promissory Note for Partnership Agreement With Ginkgo Bioworks [Member]
Debt Instrument, Face Amount		$ 12,000
Long-term Debt, Total		8,000
Partnership Agreement with Ginkgo Bioworks Inc. [Member]
Partnership Agreement, Quarterly Payment Amount		$ 800
Contractual Obligation, Total			12,700
Contractual Obligation, Present Value			6,100
Contractual Obligation, Interest Payable			6,600
Contractual Obligation, Term		5 years
DSM International B.V. [Member]
Contract with Customer, Liability, Current			1,204	383
Other Expense, Net [Member]
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property			900	100
Property, Plant and Equipment, Including Capital Leases [Member]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance			4,900	11,400
Capital Lease Obligations [Member]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance			2,300	1,600
Capital Lease Obligations [Member] | Machinery and Equipment, Furniture and Office Equipment Under Capital Lease [Member]
Property, Plant and Equipment, Net, Ending Balance			$ 5,000	$ 4,200
[1]	The balance in contract liabilities at December 31, 2017 represents deferred revenue, current prior to the Company's adoption of ASC 606, "Revenue".
[2]	The balance in contract liabilities, current at December 31, 2017 represents deferred revenue, current prior to the Company's adoption of ASC 606, "Revenue".
[3]	Revision to accounting for equity received in satisfaction of a customer receivable.

Note 3 - Balance Sheet Detail_3

Note 3 - Balance Sheet Details - Allowance for Doubtful Accounts Activity and Balances (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Balance at Beginning of Year	$ 642	$ 501
Provisions		141
Balance at End of Year	$ 642	$ 642

Note 3 - Balance Sheet Detail_4

Note 3 - Balance Sheet Details - Inventory, Current (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Raw materials	$ 3,901	$ 819
Work in process	539	364
Finished goods	5,253	4,225
Total inventories	$ 9,693	$ 5,408

Note 3 - Balance Sheet Detail_5

Note 3 - Balance Sheet Details - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Prepayments, advances and deposits	$ 5,644	$ 3,599
Recoverable taxes from Brazilian government entities	631	87
Other	4,291	1,233
Total prepaid expenses and other current assets	$ 10,566	$ 4,919	[1]
[1]	Write-off of unrecoverable receivable in connection with facilities subleased to a related party.

Note 3 - Balance Sheet Detail_6

Note 3 - Balance Sheet Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property, plant and equipment	$ 98,387	$ 102,161
Less: accumulated depreciation and amortization	(78,631)	(88,269)
Total property, plant and equipment, net	19,756	13,892
Machinery and Equipment [Member]
Property, plant and equipment	43,713	46,317
Leasehold Improvements [Member]
Property, plant and equipment	39,922	40,036
Computer Equipment and Software [Member]
Property, plant and equipment	9,987	9,555
Furniture and Office Equipment, Vehicles and Land [Member]
Property, plant and equipment	3,016	3,415
Construction in Progress [Member]
Property, plant and equipment	$ 1,749	$ 2,838

Note 3 - Balance Sheet Detail_7

Note 3 - Balance Sheet Details - Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Contingent consideration	$ 4,286	$ 8,150
Deposits	2,465	2,462
Other	1,207	1,947
Total other assets	$ 7,958	$ 12,559	[1]
[1]	Correction of error in recording amounts payable under Ginkgo Partnership Agreement as prepaid royalties instead of reduction in revenue.

Note 3 - Balance Sheet Detail_8

Note 3 - Balance Sheet Details - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands		Dec. 31, 2018	Dec. 31, 2017
Payroll and related expenses		$ 9,220	$ 7,238
Contract termination fees		4,092
Accrued interest		3,853	8,213
Asset retirement obligation(1)	[1]	3,063	3,587
Ginkgo partnership payments obligation		2,155
Tax-related liabilities		2,139	5,837
Professional services		1,173	1,694
Other		3,284	2,633
Total accrued and other current liabilities		$ 28,979	$ 29,202	[2]
[1]	The asset retirement obligation represents liabilities incurred but not yet discharged in connection with our 2013 abandonment of a partially constructed facility in Pradópolis, Brazil.
[2]	Adjustment to accrued liability.

Note 3 - Balance Sheet Detail_9

Note 3 - Balance Sheet Details - Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands		Dec. 31, 2018	Dec. 31, 2017
Liability for unrecognized tax benefit		$ 6,582	$ 6,582
Deferred rent, net of current portion		6,440	7,818
Ginkgo partnership payments obligation, net of current portion		6,185	6,444
Contract liabilities, net of current portion		1,587	383
Contract termination fees, net of current portion(1)	[1]	1,530
Capital leases, net of current portion		195	217
Other		673	2,214
Total other noncurrent liabilities		$ 23,192	$ 23,658	[2]
[1]	Contract liabilities, net of current portion at December 31, 2018 and 2017 includes $1,204 and $383 in connection with DSM, which is a related party.
[2]	Accrual of the Ginkgo Partnership Payments obligation, net of reduction to deferred revenue liability.

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurement (Details Textual) shares in Millions, R$ in Millions	Mar. 29, 2019USD ($)	Nov. 19, 2018USD ($)shares	Dec. 31, 2018USD ($)	Dec. 10, 2018USD ($)	Dec. 06, 2018USD ($)	Dec. 31, 2017USD ($)	Aug. 31, 2017USD ($)	Jun. 30, 2012USD ($)	Jun. 30, 2012BRL (R$)
Long-term Debt, Gross			$ 228,921,000			$ 195,819,000
Long-term Debt, Fair Value			57,918,000			0
Derivative Liability, Total			42,796,000			116,497,000
Debt, Long-term and Short-term, Combined Amount, Total			151,700,000			165,400,000
Debt Instrument, Fair Value Disclosure, Total			149,300,000			$ 156,900,000
Stock Issued During Period, Value, New Issues			$ 1,415,000
Supply Agreement, Fair Value Consideration		$ 33,304,000
DSM Supply Agreement [Member]
Contract with Customer, Asset, after Allowance for Credit Loss, Total		$ 22,700,000
Stock Issued During Period, Shares, New Issues | shares		1,643,991
Stock Issued During Period, Value, New Issues		$ 6,100,000
Supply Agreement, Warrant Modification Amount		2,900,000
Supply Agreement, Payments for Obligation Settlements		1,800,000
Supply Agreement, Fair Value Consideration		$ 33,300,000
DSM Supply Agreement [Member] | Subsequent Event [Member]
Stock Issued During Period, Value, New Issues	$ 7,300,000
May 2017 warrants , May 2017 Offering Make Whole Provision [Member]
Derivative Liability, Total							$ 113,100,000
Interest Rate Swap [Member] | Banco Pine [Member]
Derivative, Notional Amount								$ 6,600,000	R$ 22
Derivative, Fixed Interest Rate								3.94%	3.94%
Measurement Input, Discount Rate [Member] | DSM Supply Agreement [Member]
Supply Agreement, Measurement Input		0.225
Discount to Gross Cash Flows [Member] | DSM Supply Agreement [Member]
Supply Agreement, Measurement Input		0
Convertible Senior Notes, 6.0% Due in 2021 [Member]
Debt Instrument, Face Amount				$ 60,000,000	$ 60,000,000
Debt Instrument, Interest Rate, Stated Percentage			6.00%	6.00%	6.00%
Long-term Debt, Gross			$ 60,000,000
Long-term Debt, Fair Value			$ 57,900,000
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Measurement Input, Discount Rate [Member]
Long-term Debt, Measurement Input			0.252
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Measurement Input, Price Volatility [Member]
Long-term Debt, Measurement Input			0.45
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Probability of Principal Repayment in Cash [Member]
Long-term Debt, Measurement Input			0.5
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Probability of Principal Repayment in Stock [Member]
Long-term Debt, Measurement Input			0.5
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Measurement Input, Probability of Change in Control [Member]
Fair Value Adjustment of Debt			$ 2,100,000

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Debt, current portion, fair value	$ 57,918	$ 0
Fair Value, Recurring [Member]
Total assets measured and recorded at fair value		57,352
Debt, current portion, fair value	57,918
Embedded derivatives in connection with the issuance of debt and equity instruments		723
Freestanding derivative instruments in connection with the issuance of equity instruments	42,796	115,774
Total liabilities measured and recorded at fair value	100,714	116,497
Fair Value, Recurring [Member] | Money Market Funds [Member]
Cash equivalents		53,199
Fair Value, Recurring [Member] | Certificates of Deposit [Member]
Cash equivalents		4,153
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Total assets measured and recorded at fair value		53,199
Debt, current portion, fair value
Embedded derivatives in connection with the issuance of debt and equity instruments
Freestanding derivative instruments in connection with the issuance of equity instruments
Total liabilities measured and recorded at fair value
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]
Cash equivalents		53,199
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Certificates of Deposit [Member]
Cash equivalents
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Total assets measured and recorded at fair value		4,153
Debt, current portion, fair value
Embedded derivatives in connection with the issuance of debt and equity instruments
Freestanding derivative instruments in connection with the issuance of equity instruments
Total liabilities measured and recorded at fair value
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]
Cash equivalents
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Certificates of Deposit [Member]
Cash equivalents		4,153
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Total assets measured and recorded at fair value
Debt, current portion, fair value	57,918
Embedded derivatives in connection with the issuance of debt and equity instruments		723
Freestanding derivative instruments in connection with the issuance of equity instruments	42,796	115,774
Total liabilities measured and recorded at fair value	100,714	116,497
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]
Cash equivalents
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Certificates of Deposit [Member]
Cash equivalents

Note 4 - Fair Value Measureme_5

Note 4 - Fair Value Measurement - Convertible Debt (Details) - Long-term Debt [Member] $ in Thousands	1 Months Ended
	Dec. 31, 2018USD ($)
Fair value at issuance on December 10, 2018	$ 60,000
Change in fair value	(2,082)
Fair value at December 31, 2018	$ 57,918

Note 4 - Fair Value Measureme_6

Note 4 - Fair Value Measurement - Derivative Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Derivative liabilities	$ 42,796	$ 116,497
Derivative Liability, Equity-related [Member]
Derivative liabilities	41,272	108,887
Derivative Liability, Debt-related [Member]
Derivative liabilities	$ 1,524	$ 7,610

Note 4 - Fair Value Measureme_7

Note 4 - Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair value at issuance on December 10, 2018	$ 116,497	$ 4,135
Additions	4,089	133,517
Change in fair value	30,880	48,852
Derecognition to additional paid-in capital upon conversion or extinguishment	(108,670)	(70,007)
Fair value at December 31, 2018	$ 42,796	$ 116,497

Note 4 - Fair Value Measureme_8

Note 4 - Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details)	12 Months Ended
	Dec. 31, 2018$ / shares	Dec. 31, 2017$ / shares
Share Price	$ 3.34	$ 3.75
Measurement Input, Probability of Change in Control [Member]
Derivative liabilities, measurement input	0	0.05
Minimum [Member]
Estimated conversion dates	2019	2018
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Derivative liabilities, measurement input	0.025	0.017
Minimum [Member] | Measurement Input, Risk-adjusted Yields [Member]
Derivative liabilities, measurement input	0.172	0.184
Minimum [Member] | Measurement Input, Price Volatility [Member]
Derivative liabilities, measurement input	0.45	0.45
Minimum [Member] | Measurement Input, Credit Spread [Member]
Derivative liabilities, measurement input	0.146	0.166
Maximum [Member]
Estimated conversion dates	2025	2025
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Derivative liabilities, measurement input	0.03	0.024
Maximum [Member] | Measurement Input, Risk-adjusted Yields [Member]
Derivative liabilities, measurement input	0.273	0.285
Maximum [Member] | Measurement Input, Price Volatility [Member]
Derivative liabilities, measurement input	0.85	0.8
Maximum [Member] | Measurement Input, Credit Spread [Member]
Derivative liabilities, measurement input	0.249	0.267

Note 4 - Fair Value Measureme_9

Note 4 - Fair Value Measurement - Allocation of Consideration Fair Value (Details) $ in Thousands	Nov. 19, 2018USD ($)
Manufacturing capacity reservation fee	$ 24,395
Legal settlement and consent waiver	6,764
Working capital adjustment	2,145
Total fair value of consideration transferred	$ 33,304

Note 5 - Debt (Details Textual)

Note 5 - Debt (Details Textual) - USD ($)	Jul. 26, 2019	Jul. 24, 2019	Jul. 02, 2019	Jun. 24, 2019	May 15, 2019	Dec. 10, 2018	Dec. 06, 2018	Nov. 08, 2018	Oct. 16, 2018	Jun. 29, 2018	Dec. 28, 2017	Feb. 15, 2016	May 31, 2019	Dec. 31, 2018	Nov. 30, 2018	Jul. 02, 2018	Mar. 31, 2018	Dec. 31, 2017	May 31, 2017	Feb. 28, 2017	Jan. 31, 2017	Dec. 31, 2016	Oct. 31, 2015	Jul. 31, 2015	May 31, 2014	Jan. 31, 2014	Oct. 31, 2013	Jul. 02, 2018	Dec. 31, 2018	Dec. 31, 2017		Nov. 30, 2015	Jan. 14, 2019	Aug. 31, 2018	Jul. 31, 2018	Nov. 30, 2017	Aug. 31, 2017	Oct. 31, 2016	Mar. 31, 2016	Feb. 29, 2016	Mar. 31, 2014	Aug. 31, 2013	Jun. 30, 2012
Debt Instrument, Unamortized Discount, Total														$ 17,100,000															$ 17,100,000
Debt, Changes in Fair Value, Gain (Loss)																													2,082,000
Gain (Loss) on Extinguishment of Debt, Total																			$ (1,900,000)										(17,424,000)	(11,897,000)	[1]
Repayments of Long-term Debt, Total																													41,668,000	37,500,000
Long-term Debt, Gross														228,921,000				$ 195,819,000											228,921,000	195,819,000
Long-term Debt, Total														209,697,000				163,704,000											209,697,000	163,704,000
Debt Instrument, Fair Value Disclosure, Total														149,300,000				156,900,000											149,300,000	156,900,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total														17,100,000															17,100,000
Interest Expense, Total																													42,703,000	37,081,000	[2]
Proceeds from Issuance of Private Placement																													1,415,000
Letters of Credit Outstanding, Amount																																											$ 1,000,000
Restricted Cash and Cash Equivalents, Noncurrent, Total														960,000				959,000											960,000	959,000
Private Placement February 2016 [Member]
Debt Instrument, Interest Rate, Stated Percentage												13.50%
DSM Credit Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage											10.00%
Line of Credit Facility, Maximum Borrowing Capacity											$ 25,000,000							25,000,000												25,000,000
Proceeds from Long-term Lines of Credit											25,000,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total											$ 8,000,000
Letter of Credit [Member]
Restricted Cash and Cash Equivalents, Noncurrent, Total														$ 1,000,000				1,000,000											$ 1,000,000	$ 1,000,000
Foris Ventures, LLC [Member] | Private Placement February 2016 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												152,381
Proceeds from Issuance of Private Placement												$ 16,000,000
Naxyris S.A. [Member] | Private Placement February 2016 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												19,048
Proceeds from Issuance of Private Placement												$ 2,000,000
Biolding Investment SA [Member] | Private Placement February 2016 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												19,048
Proceeds from Issuance of Private Placement												$ 2,000,000
The February 2016 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														171,429															171,429
Class of Warrant or Right, Term																														5 years
Class of Warrant or Right, Exercises During the Period																													0
Related Party Convertible Notes [Member]
Debt, Changes in Fair Value, Gain (Loss)
Debt Instrument Covenant Terms Minimum Amount Of Transactions Requiring Consent Of Noteholders														$ 20,000,000															20,000,000
Long-term Debt, Gross														24,705,000				50,116,000											24,705,000	$ 50,116,000
Long-term Debt, Total														$ 23,667,000				47,211,000											$ 23,667,000	47,211,000
Unsecured Promissory Notes, 2016 [Member] | Private Placement February 2016 [Member]
Debt Instrument, Face Amount																																								$ 20,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														190,477															190,477
Class of Warrant or Right, Exercise Price of Warrants or Rights														$ 0.15															$ 0.15
Proceeds from Issuance of Private Placement												$ 20,000,000
Subsequent Event [Member] | Warrants in Connection of Extinguishment of Tranche II Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,080,000
Subsequent Event [Member] | Common Stock Issued upon Extinguishment of Tranche II Note [Member]
Debt Conversion, Converted Instrument, Shares Issued			1,767,632
Series A Preferred Stock [Member]
Preferred Stock, Dividend Rate, Percentage																			17.38%
Total and Temasek [Member] | Common Stock Issued Upon Conversion of Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price																								$ 34.50
Total [Member]
Debt Instrument, Repurchase Amount																																							$ 3,700,000
Convertible Senior Notes, 6.0% Due in 2021 [Member]
Debt Instrument, Face Amount						$ 60,000,000	$ 60,000,000
Debt Instrument, Interest Rate, Stated Percentage						6.00%	6.00%							6.00%															6.00%
Proceeds from Convertible Debt						$ 56,200,000
Debt Instrument, Convertible, Conversion Price							$ 6.32
Debt Instrument, Periodic Payment, Cash Percentage of Each Installment Amount							108.00%
Debt Instrument, Covenant Terms, Minimum Cash Amount Redeemed Percentage Upon Default							125.00%
Debt Instrument, Covenant Terms, Minimum Cash Amount Redeemed Percentage Upon Fundamental Transaction							125.00%
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Except Under Specified Conditions							4.99%
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Under Specified Conditions							9.99%
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage, Conditions, Number of Days After Written Notice							61 days
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum							15,271,047
Debt Instrument, Covenant Terms, Percent of Principal Compensation to be Paid							2.00%
Debt, Changes in Fair Value, Gain (Loss)																													$ 2,100,000
Long-term Debt, Gross														$ 60,000,000															$ 60,000,000
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Subsequent Event [Member]
Debt Conversion, Original Debt, Amount	$ 4,700,000	$ 53,300,000		$ 4,700,000	$ 53,300,000
Rule 144A Convertible Note Offering [Member]
Debt Instrument, Face Amount																							$ 57,600,000
Debt Instrument, Interest Rate, Stated Percentage																							9.50%
Proceeds from Convertible Debt																							$ 54,400,000		$ 72,000,000
Debt Instrument, Convertible, Conversion Price														$ 56.16															$ 56.16
Convertible Note Offering																									$ 75,000,000
Debt Instrument, Interest Rate, Effective Percentage																									6.50%
Rule 144A Convertible Note Offering [Member] | Subsequent Event [Member]
Debt Conversion, Original Debt, Amount													$ 38,200,000
Rule 144A Convertible Note Offering [Member] | Denominator [Member]
Debt Instrument, Convertible, Conversion Rate, Principle Amount																													$ 1,000
Rule 144A Convertible Note Offering [Member] | Reverse Stock Split [Member]
Debt Instrument, Convertible, Conversion Ratio																													17.8073
Rule 144A Convertible Note Offering [Member] | Affiliated Entity [Member]
Debt Instrument, Repurchase Amount																							18,300,000
Debt Instrument, Repurchased Face Amount																							$ 22,900,000
Convertible Senior Notes, 9.5% [Member]
Debt Instrument, Interest Rate, Stated Percentage																							9.50%
Debt Instrument, Convertible, Conversion Price														$ 16.20															$ 16.20
Debt Instrument, Interest, Payable in Common Stock, Percentage of Market-based Price																							92.50%
Debt Instrument, Convertible, Conversion Rate, Shares																													61.7246
Debt Instrument, Convertible, Conversion Rate, Principle Amount																													$ 1,000
Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments														0.75%															0.75%
Debt Instrument, Convertible Percentage of Average Price Per Share the Stock will be Valued upon Early Conversion																													92.50%
Convertible Promissory Note, Additional Principal Amount Issued During Period																					$ 19,100,000
Debt Instrument, Decrease, Forgiveness																					$ 15,300,000
Shares Issuable with Respect to Debt Instrument, Maximum Number of Shares of Common Stock Without Prior Approval																					3,652,935
Gain (Loss) on Extinguishment of Debt, Total																														100,000
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member]
Gain (Loss) on Extinguishment of Debt, Total																														2,000,000
Debt Conversion, Original Debt, Amount																			$ 3,700,000
March 2014 Letter Agreement [Member]
Gain (Loss) on Extinguishment of Debt, Total																														(1,800,000)
Debt Conversion, Original Debt, Amount																			$ 3,400,000
August 2013 Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price																																		$ 4.40	$ 5.2977
August 2013 Convertible Notes [Member] | Related Party Convertible Notes [Member]
Debt, Changes in Fair Value, Gain (Loss)
Convertible Promissory Notes, Period After Which Notes Will Be Due																											5 years
Long-term Debt, Gross																		21,711,000												21,711,000
Long-term Debt, Total																		$ 22,608,000												$ 22,608,000
August 2013 Convertible Notes [Member] | Total and Temasek [Member]
Debt Instrument, Face Amount																																										$ 73,000,000
First Tranche [Member] | Related Party Convertible Notes [Member]
Gain (Loss) on Extinguishment of Debt, Total									$ (10,900,000)
Plant Manufacturing Production, Product Sales, Percentage																											5.00%
Repayments of Long-term Debt, Total									15,200,000
Second Tranche [Member] | Related Party Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price														$ 4.40															$ 4.40
Convertible Promissory Notes, Period After Which Notes Will Be Due																										60 years
Debt Instrument, Convertible, Conversion Price, Interest Accrued																										10.00%
Debt Instrument, Covenant Terms, Maximum Debt														$ 200,000,000															$ 200,000,000
Debt Instrument, Covenant Terms, Maximum Debt, Percentage of Consolidated Assets														50.00%															50.00%
Debt Instrument, Covenant Terms, Maximum Secured Debt														$ 125,000,000															$ 125,000,000
Debt Instrument, Covenant Terms, Maximum Secured Debt, Percentage of Consolidated Assets														30.00%															30.00%
Second Tranche [Member] | Subsequent Event [Member] | Related Party Convertible Notes [Member]
Debt Instrument, Cash Waiver Fee Amount Payable																																	$ 600,000
Tranche Notes [Member] | Related Party Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price																		$ 5.2977												$ 5.2977				$ 4.40
Gain (Loss) on Extinguishment of Debt, Total								$ (6,500,000)
Repayments of Long-term Debt, Total								9,800,000
Related Party Convertible Notes [Member] | Temasek [Member]
Debt Conversion, Original Debt, Amount																								$ 71,000,000
Related Party Convertible Notes [Member] | Total [Member]
Debt Conversion, Original Debt, Amount																								70,000,000
Long-term Debt, Gross																								21,800,000
Related Party 2014 144A Convertible Notes [Member] | Temasek [Member]
Long-term Debt, Gross																								10,000,000
Related Party 2014 144A Convertible Notes [Member] | Total [Member]
Long-term Debt, Gross																								9,700,000
The 2015 Exchange Agreement [Member]
Debt Instrument, Covenant, Maximum Amount of Debt																								$ 200,000,000
Debt Instrument, Covenant, Maximum Amount of Debt Percentage of Total Assets																								50.00%
Debt Instrument, Covenant, Maximum Amount of Secured Debt																								$ 125,000,000
Debt Instrument, Covenenant, Maximum Amount of Secured Debt to Total Assets																								30.00%
The $5 Million Note [Member]
Debt Instrument, Face Amount																		$ 5,000,000												$ 5,000,000
Proceeds from Convertible Debt																		5,000,000
Convertible Debt, Fair Value Disclosures																		$ 0												0
Tranche I Notes [Member]
Gain (Loss) on Extinguishment of Debt, Total									$ 10,900,000
Debt Conversion, Converted Instrument, Shares Issued									3,448,821
Long-term Debt, Total									$ 15,200,000
Tranche II Notes [Member]
Gain (Loss) on Extinguishment of Debt, Total								$ 6,500,000
Debt Conversion, Converted Instrument, Shares Issued								2,226,105
Long-term Debt, Total								$ 9,800,000
Total Purchase Agreement [Member] | Total [Member]
Debt Instrument, Face Amount																																							$ 105,000,000
Loan and Security Agreement [Member] | Great American Capital Partners, LLC [Member]
Debt Instrument, Face Amount										$ 36,000,000
Line of Credit Facility, Maximum Borrowing Capacity										$ 35,000,000
Loan Annual Amortization Percentage of Loan Accounts Outstanding										2.50%
Debt Instrument, Facility Charge, Percentage														4.00%															4.00%
Debt Instrument, Origination Fee Amount														$ 1,400,000															$ 1,400,000
Debt Instrument, Funded Amount and Other Closing Costs														200,000															200,000
Debt Instrument, Agency Fee Amount Per Quarter														25,000															25,000
Unamortized Debt Issuance Expense														$ 1,600,000															$ 1,600,000
Loan and Security Agreement [Member] | Great American Capital Partners, LLC [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage														8.25%	6.25%														8.25%
Loan and Security Agreement [Member] | Great American Capital Partners, LLC [Member] | Minimum [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate										4.00%				4.00%	4.00%
Loan and Security Agreement [Member] | Great American Capital Partners, LLC [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage														9.00%	8.25%														9.00%
Loan and Security Agreement [Member] | Great American Capital Partners, LLC [Member] | Maximum [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate										6.25%				4.75%	4.00%
Loan and Security Agreement [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member]
Debt Instrument, Face Amount																																									$ 25,000,000
Line of Credit Facility, Maximum Borrowing Capacity																																$ 31,000,000
Proceeds from Long-term Lines of Credit																																$ 16,000,000
Loan and Security Agreement [Member] | Stegodon [Member]
Repayments of Lines of Credit																	$ 5,500,000
Proceeds from (Repayments of) Lines of Credit, Total																												$ 5,500,000
Debt Instrument, Interest Rate, Increase (Decrease)																5.00%
Secured Promissory Note In Connection With Termination of Ginkgo Collaboration Agreement [Member]
Debt Instrument, Face Amount																																				$ 12,000,000
Debt Instrument, Interest Rate, Stated Percentage																																				10.50%
Debt Instrument, Fair Value Disclosure, Total																																				$ 7,000,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total																																				$ 5,000,000
Secured Promissory Note In Connection With Termination of Ginkgo Collaboration Agreement [Member] | License [Member]
Interest Expense, Total																														$ 7,000,000
Nikko Note [Member] | Nikko [Member]
Debt Instrument, Face Amount																						$ 3,900,000
Debt Instrument, Interest Rate, Stated Percentage																						5.00%
Debt Instrument, Proceeds Used to Repay Liabilities																						$ 3,500,000
Debt Instrument, Term																						13 years
Debt Instrument, Percentage of Joint Venture Interests Owned By the Company Securing the Debt Instrument																						10.00%
Debt Instrument, Additional Payments Required in Four Monthly Installments																						$ 400,000
Debt Instrument, Additional Equal Monthly Installments, Amount																						100,000
Aprinnova Notes [Member] | Unsecured Debt [Member] | Aprinnova JV [Member]
Debt Instrument, Face Amount																				$ 1,500,000
Debt Instrument, Periodic Payment, Total																				$ 375,000
Second Aprinnova Loan [Member] | Nikko [Member]
Debt Instrument, Face Amount																						$ 1,500,000
Second Aprinnova Loan [Member] | Unsecured Debt [Member] | Aprinnova JV [Member] | Nikko [Member]
Debt Instrument, Face Amount																																					$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage																				2.75%
Guanfu Credit Agreement [Member] | Unsecured Debt [Member] | Guanfu Holding Co., Ltd [Member]
Line of Credit Facility, Maximum Borrowing Capacity																																						$ 25,000,000
[1]	Loss on extinguishment of related and unrelated party debt.
[2]	Correction to amortization of debt discounts, and interest expense in connection with partnership payments obligation.

Note 5 - Debt - Debt Components

Note 5 - Debt - Debt Components (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Nov. 30, 2017
Principal	$ 228,921,000	$ 195,819,000
Unamortized Debt Premium	(17,142,000)	(32,115,000)
Gain from change in fair value of debt	(2,082,000)
Net	209,697,000	163,704,000
Net	(147,677,000)	(56,943,000)
Net	62,020,000	106,761,000
Convertible Senior Notes, 6.0% Due in 2021 [Member]
Principal	60,000,000
Gain from change in fair value of debt	(2,100,000)
Convertible Debt [Member]
Principal	126,306,000	70,900,000
Unamortized Debt Premium	(3,350,000)	(14,779,000)
Gain from change in fair value of debt	(2,082,000)
Net	120,874,000	56,121,000
Convertible Debt [Member] | Convertible Senior Notes, 6.0% Due in 2021 [Member]
Principal	60,000,000
Unamortized Debt Premium
Gain from change in fair value of debt	(2,082,000)
Net	57,918,000
Convertible Debt [Member] | The 2015 144A Notes [Member]
Principal	37,887,000	37,887,000
Unamortized Debt Premium	(2,413,000)	(9,458,000)
Gain from change in fair value of debt
Net	35,474,000	28,429,000
Convertible Debt [Member] | The 2014 144A Notes [Member]
Principal	24,004,000	24,004,000
Unamortized Debt Premium	(867,000)	(3,170,000)
Gain from change in fair value of debt
Net	23,137,000	20,834,000
Convertible Debt [Member] | August 2013 Convertible Notes [Member]
Principal	4,415,000	4,009,000
Unamortized Debt Premium	(70,000)	(2,126,000)
Gain from change in fair value of debt
Net	4,345,000	1,883,000
Convertible Debt [Member] | December 2017 Convertible Note [Member]
Principal		5,000,000
Unamortized Debt Premium		(25,000)
Gain from change in fair value of debt
Net		4,975,000
Related Party Convertible Notes [Member]
Principal	24,705,000	50,116,000
Unamortized Debt Premium	(1,038,000)	(2,905,000)
Gain from change in fair value of debt
Net	23,667,000	47,211,000
Related Party Convertible Notes [Member] | The 2014 144A Notes [Member]
Principal	24,705,000	24,705,000
Unamortized Debt Premium	(1,038,000)	(3,784,000)
Gain from change in fair value of debt
Net	23,667,000	20,921,000
Related Party Convertible Notes [Member] | August 2013 Convertible Notes [Member]
Principal		21,711,000
Unamortized Debt Premium		897,000
Gain from change in fair value of debt
Net		22,608,000
Related Party Convertible Notes [Member] | Secured R&D Notes [Member]
Principal		3,700,000
Unamortized Debt Premium		(18,000)
Gain from change in fair value of debt
Net		3,682,000
Nonrelated Party Debt [Member]
Principal	36,000,000
Unamortized Debt Premium	(1,349,000)
Gain from change in fair value of debt
Net	34,651,000
Loans Payable [Member]
Principal	52,910,000	47,410,000
Unamortized Debt Premium	(6,443,000)	(6,392,000)
Gain from change in fair value of debt
Net	46,467,000	41,018,000
Loans Payable [Member] | Ginkgo Collaboration Note [Member]
Principal	12,000,000	12,000,000	$ 12,000,000
Unamortized Debt Premium	(4,047,000)	(4,862,000)
Gain from change in fair value of debt
Net	7,953,000	7,138,000
Loans Payable [Member] | Other Loans Payable [Member]
Principal	4,910,000	6,463,000
Unamortized Debt Premium	(1,047,000)	(1,277,000)
Gain from change in fair value of debt
Net	3,863,000	5,186,000
Loans Payable [Member] | Senior Secured Convertible Note [Member]
Principal		28,566,000
Unamortized Debt Premium		(253,000)
Gain from change in fair value of debt
Net		28,313,000
Loans Payable [Member] | Other Credit Facilities [Member]
Principal		381,000
Unamortized Debt Premium
Gain from change in fair value of debt
Net		381,000
Related Party Loan Payable [Member]
Principal	25,000,000	27,393,000
Unamortized Debt Premium	(6,311,000)	(8,039,000)
Gain from change in fair value of debt
Net	18,689,000	19,354,000
Related Party Loan Payable [Member] | Other Loans Payable [Member]
Principal		393,000
Unamortized Debt Premium
Gain from change in fair value of debt
Net		393,000
Related Party Loan Payable [Member] | DSM Note [Member]
Principal	25,000,000	25,000,000
Unamortized Debt Premium	(6,311,000)	(8,039,000)
Gain from change in fair value of debt
Net	18,689,000	16,961,000
Related Party Loan Payable [Member] | Private Placement February 2016 [Member]
Principal		2,000,000
Unamortized Debt Premium
Gain from change in fair value of debt
Net		$ 2,000,000

Note 5 - Debt - Long-term Debt

Note 5 - Debt - Long-term Debt Instruments (Details) $ in Thousands	Dec. 31, 2018USD ($)
2019	$ 172,595
2020	12,481
2021	62,261
2022	13,417
2023	367
Thereafter	2,200
Total future minimum payments	263,321
Less: amount representing interest(1)	(33,706)	[1]
Less: future conversion of accrued interest to principal	(694)
Present value of minimum debt payments	228,921
Less: current portion of debt principal	(154,840)
Noncurrent portion of debt principal	74,081
Convertible Debt [Member]
2019	134,368
2020
2021
2022
2023
Thereafter
Total future minimum payments	134,368
Less: amount representing interest(1)	(7,368)	[1]
Less: future conversion of accrued interest to principal	(694)
Present value of minimum debt payments	126,306
Less: current portion of debt principal	(126,306)
Noncurrent portion of debt principal
Loans Payable and Credit Facilities [Member]
2019	10,219
2020	9,981
2021	34,740
2022	13,417
2023	367
Thereafter	2,200
Total future minimum payments	70,924
Less: amount representing interest(1)	(18,014)	[1]
Less: future conversion of accrued interest to principal
Present value of minimum debt payments	52,910
Less: current portion of debt principal	(3,829)
Noncurrent portion of debt principal	49,081
Related Party Convertible Notes [Member]
2019	25,508
2020
2021
2022
2023
Thereafter
Total future minimum payments	25,508
Less: amount representing interest(1)	(803)	[1]
Less: future conversion of accrued interest to principal
Present value of minimum debt payments	24,705
Less: current portion of debt principal	(24,705)
Noncurrent portion of debt principal
Related Party Loans Payable and Credit Facilities [Member]
2019	2,500
2020	2,500
2021	27,521
2022
2023
Thereafter
Total future minimum payments	32,521
Less: amount representing interest(1)	(7,521)	[1]
Less: future conversion of accrued interest to principal
Present value of minimum debt payments	25,000
Less: current portion of debt principal
Noncurrent portion of debt principal	$ 25,000
[1]	Excluding net debt discount of $17.1 million that will be amortized to interest expense over the term of the debt.

Note 6 - Mezzanine Equity (Deta

Note 6 - Mezzanine Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Apr. 08, 2016	Dec. 31, 2018	Dec. 31, 2017
Share Price		$ 3.34	$ 3.75
Proceeds from Issuance of Private Placement		$ 1,415
Gates Foundation Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues	292,398
Share Price	$ 17.10
Proceeds from Issuance of Private Placement	$ 5,000
Compound Annual Return	10.00%
Research and Development Obligation, Remaining Amount		$ 700

Note 7 - Stockholders' Defici_2

Note 7 - Stockholders' Deficit (Details Textual)	May 03, 2019USD ($)	Apr. 29, 2019USD ($)$ / sharesshares	Apr. 26, 2019USD ($)	Apr. 16, 2019USD ($)	Mar. 29, 2019USD ($)	Nov. 20, 2018USD ($)$ / sharesshares	Nov. 19, 2018USD ($)$ / sharesshares	Oct. 19, 2018shares	Apr. 12, 2018USD ($)$ / sharesshares	Oct. 28, 2017USD ($)	Aug. 07, 2017USD ($)$ / sharesshares	Aug. 03, 2017USD ($)$ / sharesshares	Aug. 03, 2017USD ($)$ / sharesshares	Mar. 08, 2016USD ($)	Nov. 30, 2018USD ($)	Aug. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Aug. 31, 2017USD ($)	May 31, 2017USD ($)$ / sharesshares	Jul. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares		Mar. 28, 2019USD ($)$ / shares	Jul. 31, 2018$ / shares
Class of Warrants or Right, Issued in Period | shares																							17,898,107
Stock Issued During Period, Shares, Warrants Exercised | shares																							20,928,439
Proceeds from Warrant Exercises																							$ 57,767,000
Derivative Liability, Total																	$ 116,497,000				$ 42,796,000	$ 116,497,000	$ 42,796,000	$ 116,497,000
Share Price | $ / shares																	$ 3.75				$ 3.34	$ 3.75	$ 3.34	$ 3.75
Proceeds from Issuance of Common Stock																								$ 5,759,000
Extinguishment of Debt, Amount																			$ 40,200,000
Preferred Stock, Shares Outstanding, Ending Balance | shares																	22,171				14,656	22,171	14,656	22,171
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings																			8,600,000
Gain (Loss) on Extinguishment of Debt, Total																			$ (1,900,000)				$ (17,424,000)	$ (11,897,000)	[1]
Payments of Stock Issuance Costs																								2,159,000
Deemed Dividend Related to Proceeds Discount and Issuance Costs Upon Conversion of Series B Preferred Stock																								24,366,000	[2]
Adjustments to Additional Paid in Capital, Other																					$ 6,800,000
Proceeds from Issuance of Private Placement																							1,415,000
Revenue from Contract with Customer, Including Assessed Tax																							63,604,000	127,671,000
Preferred Stock, Value, Issued, Ending Balance
Gain (Loss) on Derivative Instruments, Net, Pretax, Total																							(30,880,000)	(48,852,000)	[3]
Revenues, Total																							63,604,000	127,671,000
Deemed Dividend, Beneficial Conversion Feature on Series A Preferred Stock																								$ 562,000
Preferred Stock, Par or Stated Value Per Share | $ / shares																	$ 0.0001				$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Stock Issued During Period, Value, New Issues																							$ 1,415,000
Common Stock, Shares, Outstanding, Ending Balance | shares																	45,637,433				76,564,829	45,637,433	76,564,829	45,637,433
Foris and Naxyris [Member]
Conversion of Stock, Shares Converted | shares																			1,394,706
Affiliated Entity [Member]
Stock Issued During Period, Shares, New Issues | shares																				1,068,379
Common Stock [Member]
Stock Issued During Period, Shares, Warrants Exercised | shares																							20,891,038	3,148,097
Stock Issued During Period, Shares, New Issues | shares																							205,168	2,826,711
Stock Issued During Period, Value, New Issues
Embedded Derivative Financial Instruments [Member]
Class of Warrant or Right, Securities Called by Warrants As Percentage of Shares Purchased By Investor																					100.00%		100.00%
Series A Preferred Stock Converted Into Common Stock [Member]
Conversion of Stock, Shares Converted | shares																							22,140
Series B Preferred Stock Converted Into Common Stock [Member]
Conversion of Stock, Shares Converted | shares																							89,528
Due to Related Parties [Member]
Extinguishment of Debt, Amount																			$ 33,100,000
Due to Related Parties [Member] | Foris Ventures, LLC [Member]
Extinguishment of Debt, Amount																			27,000,000
Due to Related Parties [Member] | Naxyris S.A. [Member]
Extinguishment of Debt, Amount																			$ 2,000,000
Series A Preferred Stock [Member]
Preferred Stock, Capital Shares Reserved for Future Issuance | shares																			22,140
Preferred Stock, Dividend Rate, Percentage																			17.38%
Preferred Stock, Stated Value | $ / shares																			$ 1,000
Preferred Stock, Conversion Price Per Share to Common Stock | $ / shares																			17.25
Preferred Stock, Anniversary Payment | $ / shares																			$ 1,738
Preferred Stock, Shares Outstanding, Ending Balance | shares																					0		0
Adjustments to Additional Paid in Capital, Deemed Dividends on Preferred Stock Discounts Upon Conversion of Preferred Stock																								$ 21,578,000
Stockholders' Equity, Deemed Dividend Upon Settlement of Make-whole Provision on Series A Preferred Stock																		$ 10,500,000						10,505,000
Stock Issued During Period, Value, New Issues																								562,000
Series A Preferred Stock [Member] | Common Stock [Member]
Adjustments to Additional Paid in Capital, Deemed Dividends on Preferred Stock Discounts Upon Conversion of Preferred Stock
Stockholders' Equity, Deemed Dividend Upon Settlement of Make-whole Provision on Series A Preferred Stock
Stock Issued During Period, Value, New Issues
Series A Preferred Stock [Member] | Minimum [Member]
Beneficiary Ownership, Conversion Percentage, Maximum																			4.99%
Series A Preferred Stock [Member] | Maximum [Member]
Beneficiary Ownership, Conversion Percentage, Maximum																			9.99%
Series B Preferred Stock [Member]
Preferred Stock, Capital Shares Reserved for Future Issuance | shares																			70,904
Preferred Stock, Dividend Rate, Percentage																			17.38%
Preferred Stock, Shares Outstanding, Ending Balance | shares																	9,213				6,376	9,213	6,376	9,213
Adjustments to Additional Paid in Capital, Deemed Dividends on Preferred Stock Discounts Upon Conversion of Preferred Stock																								$ 24,366,000
Stockholders' Equity, Deemed Dividend Upon Settlement of Make-whole Provision on Series A Preferred Stock																								22,632,000
Stock Issuance Costs Recognized																							1,200,000
Stock Issued During Period, Value, New Issues																								16,675,000
Series B Preferred Stock [Member] | Common Stock [Member]
Adjustments to Additional Paid in Capital, Deemed Dividends on Preferred Stock Discounts Upon Conversion of Preferred Stock
Stockholders' Equity, Deemed Dividend Upon Settlement of Make-whole Provision on Series A Preferred Stock
Stock Issued During Period, Value, New Issues
Series B Preferred Stock [Member] | Foris Ventures, LLC [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares																			30,729
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares																			4,877,386
Series B Preferred Stock [Member] | Naxyris S.A. [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares																			2,333
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares																			370,404
Series A and Series B Preferred Stock [Member]
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum | shares																			3,792,778
Embedded Derivative, Fair Value of Embedded Derivative Liability																			$ 11,000,000		$ 10,600,000		$ 10,600,000
Convertible Preferred Stock, Beneficial Conversion Feature, Proceeds Allocated to Preferred Stock																			600,000
Convertible Preferred Stock, Proceeds Allocated to Preferred Stock																			$ 600,000
Series D Preferred Stock [Member]
Preferred Stock, Stated Value | $ / shares												$ 1,000	$ 1,000
Preferred Stock, Conversion Price Per Share to Common Stock | $ / shares												$ 4.26	$ 4.26
Preferred Stock, Shares Outstanding, Ending Balance | shares																	12,958				8,280	12,958	8,280	12,958
Adjustments to Additional Paid in Capital, Deemed Dividends on Preferred Stock Discounts Upon Conversion of Preferred Stock																							$ 6,852,000
Payments of Stock Issuance Costs												$ 200,000
Common Stock, Dividends, Per Share, Declared | $ / shares												$ 0.0001
Dividends, Preferred Stock, Total																							$ 0
Preferred Stock, Beneficial Conversion Feature												$ 5,800,000
Deemed Dividend, Beneficial Conversion Feature on Series A Preferred Stock																						$ 5,800,000
Preferred Stock, Beneficial Ownership Limitation																					9.99%		9.99%
Stock Issued During Period, Value, New Issues																								6,197,000
Series D Preferred Stock [Member] | Common Stock [Member]
Adjustments to Additional Paid in Capital, Deemed Dividends on Preferred Stock Discounts Upon Conversion of Preferred Stock
Stock Issued During Period, Value, New Issues
Series C Preferred Stock [Member]
Preferred Stock, Stated Value | $ / shares																			$ 1,000
Preferred Stock, Conversion Price Per Share to Common Stock | $ / shares																			$ 15
Series C Preferred Stock [Member] | Conversion of Common Stock Into Series C Preferred Stock [Member] | Foris and Naxyris [Member]
Conversion of Stock, Shares Issued | shares																			20,921
DSM Supply Agreement [Member]
Stock Issued During Period, Shares, New Issues | shares							1,643,991,000,000
Stock Issued During Period, Value, New Issues							$ 6,100,000
Subsequent Event [Member]
Share Price | $ / shares																										$ 2.10
Subsequent Event [Member] | DSM Supply Agreement [Member]
Shares Issued, Price Per Share | $ / shares																										$ 4.41
Stock Issued During Period, Value, New Issues					$ 7,300,000
DSM International B.V. [Member]
Adjustments to Additional Paid in Capital, Other																			$ 600,000
Warrants and Rights Outstanding																		$ 10,600,000
Payments for Legal Settlements																							6,800,000
Designated Holder Maximum Common Stock Ownership																		33.00%
Second Tranche Closing, Anniversary Payment																		$ 5,000,000
Reserved Second Tranche Securities																		25,000,000
Proceeds from Issuance of Private Placement																		25,900,000
Credit Letter																		7,100,000
Consideration Transferred													$ 34,000,000					34,000,000
Equity Conversion Feature Embedded Derivative Liability Fair Value Disclosures																		$ 0
Gain (Loss) on Derivative Instruments, Net, Pretax, Total																								(4,000,000)
Reversal of Remaining Unrecognized Deferred Revenue Liability																	$ 4,500,000
DSM International B.V. [Member] | Measurement Input, Discount Rate [Member]
Debt Instrument, Measurement Input																		0.086
DSM International B.V. [Member] | License [Member]
Revenue from Contract with Customer, Including Assessed Tax																	27,500,000							54,600,000
DSM International B.V. [Member] | Designated Director One [Member]
Designated Director, Minimum Beneficial Ownership Level																		4.50%
DSM International B.V. [Member] | Designated Director Two [Member]
Designated Director, Minimum Beneficial Ownership Level																		10.00%
DSM International B.V. [Member] | Minimum [Member]
Credit Utilization Likelihood Percentage																		50.00%
DSM International B.V. [Member] | Maximum [Member]
Credit Utilization Likelihood Percentage																		90.00%
DSM International B.V. [Member] | Series B Preferred Stock [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability																			$ 12,400,000		$ 11,900,000		11,900,000
Stockholders' Equity, Deemed Dividend Upon Settlement of Make-whole Provision on Series A Preferred Stock															$ 22,600,000
Payments of Stock Issuance Costs																		$ 200,000					200,000
Deemed Dividend Related to Proceeds Discount and Issuance Costs Upon Conversion of Series B Preferred Stock																							$ 24,400,000
Preferred Stock, Value, Issued, Ending Balance																		$ 15,600,000
DSM International B.V. [Member] | Series B Convertible Preferred Stock [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																					$ 4.40		$ 4.40
Stock Issued During Period, Shares, New Issues | shares											25,000
Share Price | $ / shares											$ 1,000
Proceeds from Issuance of Convertible Preferred Stock											$ 25,900,000
DSM International B.V. [Member] | Intellectual Property License [Member]
Revenues, Total																							$ 7,800,000
Liability Reversal For The Consideration Recorded Related to Deferred Revenue Now Being Terminated																								3,300,000
DSM International B.V. [Member] | Intellectual Property License [Member] | License [Member]
Revenue from Contract with Customer, Including Assessed Tax										$ 9,000,000
DSM International B.V. [Member] | Subsequent Event [Member]
Extinguishment of Debt, Amount				$ 27,900,000
Consideration Transferred				$ 57,000,000
Foris and Naxyris [Member] | Series C Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share | $ / shares																			$ 0.0001
Private Placement [Member] | Subsequent Event [Member]
Proceeds from Issuance of Common Stock	$ 5,000,000	$ 5,800,000	$ 23,200,000
Private Placement [Member] | DSM [Member]
Stock Issued During Period, Shares, New Issues | shares						1,643,991
Shares Issued, Price Per Share | $ / shares						$ 3.68
Derivative Liability, Total						$ 1,200,000															$ 1,800,000		1,800,000
Gain (Loss) From Fair Value Adjustment in Collaboration Agreement																							$ 600,000
Private Placement [Member] | DSM [Member] | Subsequent Event [Member]
Derivative Liability, Total																										$ 3,800,000
Private Placement [Member] | Vivo Capital LLC [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues | shares		913,529
Shares Issued, Price Per Share | $ / shares		$ 4.76
At the Market Offering [Member]
Stock Issued During Period, Shares, New Issues | shares																							205,168
Common Stock, Value, Subscriptions														$ 50,000,000			$ 0				$ 0	$ 0	$ 0	0
Commission Rate														3.00%
Proceeds from Issuance of Common Stock																							$ 1,400,000
At The Market Offering, Six Months Ended [Member]
Shares Issued, Price Per Share | $ / shares																					$ 6.90		$ 6.90
May 2017 Offering Closing [Member]
Proceeds from Issuance or Sale of Equity, Total																			$ 50,700,000
May 2017 Offering Closing [Member] | Series A Preferred Stock and Warrants [Member]
Proceeds from Issuance or Sale of Equity, Total																			22,100,000
May 2017 Offering Closing [Member] | Series B Preferred Stock and Warrants [Member]
Proceeds from Issuance or Sale of Equity, Total																			30,700,000
Securities Purchase Agreement [Member] | Vivo Capital LLC [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares												$ 6.39	$ 6.39
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares												5,575,118	5,575,118
Stock Issued During Period, Shares, New Issues | shares												2,826,711
Shares Issued, Price Per Share | $ / shares												$ 4.26	$ 4.26
Proceeds from Issuance of Common Stock												$ 24,800,000
Class of Warrant or Right, Term												5 years
Securities Purchase Agreement [Member] | Vivo Capital LLC [Member] | Series D Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues | shares												12,958
Share Price | $ / shares												$ 1,000	$ 1,000
August 2013 Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares																$ 4.40											$ 5.2977
March 2014 Letter Agreement [Member]
Debt Conversion, Original Debt, Amount																			3,400,000
Gain (Loss) on Extinguishment of Debt, Total																								(1,800,000)
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member]
Debt Conversion, Original Debt, Amount																			3,700,000
Gain (Loss) on Extinguishment of Debt, Total																								$ 2,000,000
The DSM Credit Letter [Member] | DSM International B.V. [Member] | Minimum [Member]
Debt Instrument, Term																		1 year 180 days
The DSM Credit Letter [Member] | DSM International B.V. [Member] | Maximum [Member]
Debt Instrument, Term																		4 years
May 2017 Warrants [Member]
Class of Warrants or Right, Issued in Period | shares									3,616,174														8,523,560	0
Proceeds from Issuance of Warrants									$ 14,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 7								$ 4.40				$ 4.40	$ 4.40	$ 4.40	$ 4.40
Derivative Liability, Total																			$ 39,500,000
Fair Value Adjustment of Warrants																							$ 13,500,000	$ 40,400,000
Class of Warrant or Right, Term																							5 years
Warrants and Rights Outstanding																					$ 24,100,000		$ 24,100,000
Cash Warrants and Dilution Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																$ 4.40											$ 6.39
Stock Issued During Period, Shares, Warrants Exercised | shares																12,600,000
Proceeds from Warrant Exercises																$ 43,000,000
August 2018 New Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																$ 7.52
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																12.1
Temasek Funding Warrant [Member]
Stock Issued During Period, Shares, Warrants Exercised | shares								1,852,585
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																					471,204		471,204
Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights | shares																471,204
Class Of Warrant Or Right, Cashless Exercise Provision, Number Exercised | shares								1,889,986
Increase (Decrease) in Derivative Liabilities																							$ 14,000,000
May 2017 Warrants, Warrant 1 [Member]
Class of Warrants or Right, Issued in Period | shares																							14,768,380
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																			$ 7.80
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																			7,384,190
Class of Warrant or Right, Dilution Period																							3 years
May 2017 Warrants, Warrant 2 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																			$ 9.30
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																			7,384,190
May 2017 Dilution Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																					$ 0.0015		$ 0.0015
Dilution Warrants [Member]
Class of Warrants or Right, Issued in Period | shares																							6,377,466
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																					4.40		$ 4.40
Stock Issued During Period, Shares, Warrants Exercised | shares																							6,329,488
Preferred Stock Effective Conversion Price | $ / shares																					$ 6.30		$ 6.30
Fair Value Adjustment of Warrants																							$ 64,100,000
DSM Warrants [Member] | DSM International B.V. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 4.40				$ 6.30
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares											3,968,116
Class of Warrant or Right, Term											5 years
DSM Dilution Warrant [Member] | DSM International B.V. [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																					1,713,565		1,713,565
Preferred Stock Effective Conversion Price | $ / shares											$ 6.30
Class of Warrant or Right, Term											5 years
Common Stock, Dividends, Per Share, Declared | $ / shares											$ 0.10
Cash Warrants [Member] | DSM International B.V. [Member]
Stock Issued During Period, Shares, Warrants Exercised | shares																							0
Warrants and Rights Outstanding																		$ 10,600,000
Revenues, Total																		$ 7,800,000
Vivo Cash Warrants [Member]
Fair Value Adjustment of Warrants																							$ 7,700,000	3,000,000
Warrants and Rights Outstanding												$ 13,000,000	$ 13,000,000				$ 12,000,000					$ 12,000,000		12,000,000
Vivo Cash Warrants [Member] | Common Stock [Member]
Warrants and Rights Outstanding												$ 5,600,000	$ 5,600,000				$ 25,000,000					$ 25,000,000		$ 25,000,000
August 2017 Vito Dilution Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																$ 4.40
Stock Issued During Period, Shares, Warrants Exercised | shares																					4,678			0
Class Of Warrant Or Right, Cashless Exercise Provision, Number Exercised | shares																							5,575,118
Preferred Stock Effective Conversion Price | $ / shares												$ 4.26	$ 4.26
Class of Warrant or Right, Term												5 years
Designated Holder Maximum Common Stock Ownership												33.00%
Minimum Beneficial Ownership Level to Designate a Director												4.50%
July 2015 PIPE Warrants [Member] | Affiliated Entity [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																	$ 0.15					$ 0.15		$ 0.15
Stock Issued During Period, Shares, Warrants Exercised | shares																								25,643
Share Price | $ / shares																				$ 23.40
Class of Warrant or Right, Securities Called by Warrants As Percentage of Shares Purchased By Investor																	10.00%					10.00%		10.00%
Stock Issued During Period, Value, New Issues																				$ 25,000,000
Common Stock, Shares, Outstanding, Ending Balance | shares																	81,197					81,197		81,197
[1]	Loss on extinguishment of related and unrelated party debt.
[2]	Correction to record deemed dividend in connection with discounts and freestanding instruments related to preferred stock offerings.
[3]	Correction to accounting for make-whole liability in connection with May 2017 Offering.

Note 7 - Stockholders' Defici_3

Note 7 - Stockholders' Deficit - Warrant Activity (Details)	12 Months Ended
	Dec. 31, 2018shares
Number outstanding, beginning balance (in shares)	29,921,844
Additional Warrants Issued (in shares)	17,898,107
Exercises (in shares)	(20,928,439)
Number outstanding, ending balance (in shares)	26,891,512
Warrant 6 [Member]
Number outstanding, beginning balance (in shares)
Additional Warrants Issued (in shares)	12,097,164
Exercises (in shares)
Number outstanding, ending balance (in shares)	12,097,164
Warrant 4 [Member]
Number outstanding, beginning balance (in shares)	18,042,568
Additional Warrants Issued (in shares)
Exercises (in shares)	(11,749,770)
Number outstanding, ending balance (in shares)	6,292,798
Warrant 5 [Member]
Number outstanding, beginning balance (in shares)	9,543,234
Additional Warrants Issued (in shares)	1,713,565
Exercises (in shares)	(7,288,683)
Number outstanding, ending balance (in shares)	3,968,116
Warrant 7 [Member]
Number outstanding, beginning balance (in shares)
Additional Warrants Issued (in shares)	3,616,174
Exercises (in shares)
Number outstanding, ending balance (in shares)	3,616,174
Warrant 2 [Member]
Number outstanding, beginning balance (in shares)	2,082,010
Additional Warrants Issued (in shares)	471,204
Exercises (in shares)	(1,889,986)
Number outstanding, ending balance (in shares)	663,228
Warrant 3 [Member]
Number outstanding, beginning balance (in shares)	171,429
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	171,429
Warrant 1 [Member]
Number outstanding, beginning balance (in shares)	81,197
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	81,197
Warrant 8 [Member]
Number outstanding, beginning balance (in shares)	1,406
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	1,406

Note 7 - Stockholders' Defici_4

Note 7 - Stockholders' Deficit - Number of Callable Shares (Details)	12 Months Ended
	Dec. 31, 2018
Convertible Senior Notes, 6.0% Due in 2021 [Member]
Number of shares into which debt instrument is convertible	9,493,672
The 2015 144A Notes [Member]
Number of shares into which debt instrument is convertible	2,338,560
August 2013 Convertible Notes [Member]
Number of shares into which debt instrument is convertible	1,003,554
The 2014 144A Notes [Member]
Number of shares into which debt instrument is convertible	867,376
Convertible Notes [Member]
Number of shares into which debt instrument is convertible	13,703,162

Note 8 - Net Loss Per Share A_3

Note 8 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Aug. 31, 2017	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Less deemed dividend related to beneficial conversion feature on Series A preferred stock				$ (562)
Less deemed dividend related to beneficial conversion feature on Series B preferred stock				(634)
Less deemed dividend related to beneficial conversion feature on Series D preferred stock				(5,757)
Add: losses allocated to participating securities			13,991	40,159	[1]
Net loss attributable to Amyris, Inc. common stockholders			$ (223,096)	$ (201,857)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (in shares)			60,405,910	32,253,570
Basic and diluted loss per share (in dollars per share)			$ (3.69)	$ (6.26)
Series A Preferred Stock [Member]
Less deemed dividend upon settlement of make-whole provision on preferred stock	$ (10,500)			$ (10,505)
Less deemed dividend related to the recognition of discounts on Series A preferred stock upon conversion				(21,578)
Series B Preferred Stock [Member]
Less deemed dividend upon settlement of make-whole provision on preferred stock				(22,632)
Less deemed dividend related to the recognition of discounts on Series A preferred stock upon conversion				(24,366)
Series D Preferred Stock [Member]
Less deemed dividend related to beneficial conversion feature on Series A preferred stock		$ (5,800)
Less deemed dividend related to the recognition of discounts on Series A preferred stock upon conversion			$ (6,852)
[1]	Correction in the computation of loss per share to reflect participating securities.

Note 8 - Net Loss Per Share A_4

Note 8 - Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Antidilutive securities (in shares)		53,332,381	44,653,251
Period-end Common Stock Warrants [Member]
Antidilutive securities (in shares)		25,986,370	29,921,844
Convertible Promissory Notes [Member]
Antidilutive securities (in shares)	[1]	13,703,162	8,203,821
Stock Options to Purchase Common Stock [Member]
Antidilutive securities (in shares)		5,392,269	1,338,367
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)		5,294,848	685,007
Period-end Preferred Shares [Member]
Antidilutive securities (in shares)		2,955,732	4,504,212
[1]	The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect at the respective year-end. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Note 9 - Commitments and Cont_3

Note 9 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Leases, Rent Expense, Total	$ 5,800	$ 5,100
Liabilities for Guarantees on Long-Duration Contracts, Guaranteed Benefit Liability, Net, Ending Balance	$ 0	$ 0

Note 9 - Commitments and Cont_4

Note 9 - Commitments and Contingencies - Future Minimum Payments for Lease Obligations (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Capital leases 2019	$ 513
Operating leases 2019	10,416
Total lease obligations 2019	10,929
Capital leases 2020	198
Operating leases 2020	7,932
Total lease obligations 2020	8,130
Capital leases 2021	1
Operating leases 2021	7,226
Total lease obligations 2021	7,227
Capital leases 2022
Operating leases 2022	7,399
Total lease obligations 2022	7,399
Capital leases 2023
Operating leases 2023	3,034
Total lease obligations 2023	3,034
Capital leases thereafter
Operating leases thereafter
Total lease obligations thereafter
Total future minimum capital lease payments	712
Total future minimum operating lease payments	36,007
Total future minimum lease payments	36,719
Less: amount representing interest	(33)
Present value of minimum lease payments	679
Less: current portion	(484)
Long-term portion	$ 195	$ 217

Note 10 - Revenue Recognition 1

Note 10 - Revenue Recognition 1 (Details Textual) - USD ($)		Nov. 19, 2018	Aug. 03, 2017	Dec. 31, 2017		Nov. 30, 2017	Aug. 31, 2017	Jul. 31, 2017	Jun. 30, 2016	Apr. 30, 2016	Jun. 30, 2017	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016	Sep. 30, 2017	Sep. 30, 2015
Revenues, Total												$ 63,604,000	$ 127,671,000
Revenue from Contract with Customer, Including Assessed Tax												63,604,000	127,671,000
Long-term Debt, Gross				$ 195,819,000								228,921,000	195,819,000
Due to Related Parties, Current, Total				20,019,000								23,667,000	20,019,000
Debt Instrument, Unamortized Discount, Total												17,100,000
Interest Expense, Total												42,703,000	37,081,000	[1]
Increase (Decrease) in Contract with Customer, Liability												3,158,000	(7,241,000)
Contract with Customer, Liability, Current	[3],[4]			4,308,000	[2]							8,236,000	4,308,000	[2]
Revenue, Remaining Performance Obligation, Constrained Variable Consideration, Amount												21,400,000
Accounting Standards Update 2014-09 [Member]
Increase (Decrease) in Contract with Customer, Liability												3,900,000
Contract with Customer, Liability, Current												800,000
Loans Payable [Member]
Long-term Debt, Gross				47,410,000								52,910,000	47,410,000
Ginkgo Collaboration Note [Member] | Loans Payable [Member]
Long-term Debt, Gross				12,000,000		$ 12,000,000						12,000,000	12,000,000
Debt Instrument, Unamortized Discount, Total												6,600,000
Licenses and Royalties [Member]
Revenues, Total												7,658,000	48,703,000
Revenue from Contract with Customer, Including Assessed Tax												7,658,000	48,703,000	[5]
Royalty [Member]
Contract with Customer, Liability, Revenue Recognized												3,300,000
Technology Investment Agreement with DARPA [Member]
Maximum DARPA Funding to be Received if all Milestones are Achieved																	$ 35,000,000
Collective Obligation Due																	$ 15,500,000
Firmenich [Member] | Master Collaboration Agreement [Member] | Flavors and Fragrances Compounds [Member]
Sales Margin Company Percentage Split								30.00%
Sales Margin Collaborator Percentage Split								70.00%
Return Required for Collaboration Partner Before Adjusting Split on Sales Margin								$ 15,000,000
Sales Margin Company Percentage Split Following Return Requirements								50.00%
Success Bonus								$ 2,500,000
Contingent Consideration Liability												500,000
Nenter & Co., Inc. [Member] | Supply Agreements [Member]
Supply Agreement, Renewable Terms										5 years
DSM International B.V. [Member]
Consideration Transferred			$ 34,000,000				$ 34,000,000
Warrants and Rights Outstanding							10,600,000
Performance Agreement, Contingent Obligation				1,800,000									1,800,000
DSM International B.V. [Member] | Cash Warrants [Member]
Warrants and Rights Outstanding							10,600,000
Revenues, Total							$ 7,800,000
DSM International B.V. [Member] | License [Member]
Revenue from Contract with Customer, Including Assessed Tax				$ 27,500,000									54,600,000
DSM International B.V. [Member] | Collaborative Arrangement [Member]
Receivable from Collaborators																$ 9,000,000
Credit to Collaboration Agreements																12,000,000
DSM International B.V. [Member] | Collaborative Arrangement [Member] | Maximum [Member]
Credit to Collaboration Agreements																6,000,000
DSM International B.V. [Member] | DSM Licneses [Member]
Contract with Customer, Liability, Revenue Recognized													3,300,000
Contract with Customer, Liability, Total																$ 4,500,000
DSM International B.V. [Member] | DSM Value Sharing Agreement [Member]
Agreement, Accelerated Payment Fee												750,000
Revenue from Contract with Customer, Including Assessed Tax												7,900,000
DSM International B.V. [Member] | DSM November 2018 Supply Agreement Amendment [Member]
Cash Reservation Fee, Payable		$ 15,500,000
Stock Issued During Period, Shares, New Issues		1,643,991
Cash Fee		$ 7,300,000
Contingent Fee, Share Price Trigger		$ 4.41
DSM International B.V. [Member] | DSM November 2018 Letter Agreement [Member]
Common Stock, Value Reserved for Future Issuance		$ 5,000,000
Ginkgo Bioworks [Member]
Expected Proceeds from Collaborators									$ 20,000,000
Royalty Percentage									10.00%
Proceeds from Collaborators											$ 5,000,000				$ 15,000,000
Ginkgo Bioworks, Inc. [Member] | Partnership Agreement [Member]
Sales Margin Company Percentage Split						50.00%
Partnership Payments, Quarterly Fees						$ 800,000
Partnership Payments Expected to Be Made						12,700,000
Payments for Other Fees						$ 500,000
Collaboration Agreement Period						2 years
Collaboration Agreement, Automatic Renewal Term						1 year
Increase (Decrease) in Notes Payable, Current, Total													13,100,000
Ginkgo Bioworks, Inc. [Member] | Partnership Agreement [Member] | Other Liabilities [Member]
Due to Related Parties, Current, Total												$ 6,100,000
Ginkgo Bioworks, Inc. [Member] | Partnership Agreement [Member] | License [Member]
Related Party Costs													6,100,000
Interest Expense, Total													7,000,000
Ginkgo Bioworks, Inc. [Member] | Partnership Agreement [Member] | Licenses and Royalties [Member]
Increase (Decrease) in Revenue													$ 13,100,000
[1]	Correction to amortization of debt discounts, and interest expense in connection with partnership payments obligation.
[2]	Revision to accounting for equity received in satisfaction of a customer receivable.
[3]	The balance in contract liabilities at December 31, 2017 represents deferred revenue, current prior to the Company's adoption of ASC 606, "Revenue".
[4]	The balance in contract liabilities, current at December 31, 2017 represents deferred revenue, current prior to the Company's adoption of ASC 606, "Revenue".
[5]	Ginkgo partnership obligation and promissory note issuance recorded as reduction to revenue and correction of errors in recording revenue from non-cash consideration.

Note 10 - Revenue Recognition 2

Note 10 - Revenue Recognition 2 (Details Textual)	Dec. 31, 2018
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year

Note 10 - Revenue Recognition -

Note 10 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues	$ 63,604	$ 127,671
Product [Member]
Revenues	33,598	42,370
Europe [Member]
Revenues		23,823
Europe [Member] | Product [Member]
Revenues	29,405
UNITED STATES
Revenues	26,241	78,286
Asia [Member]
Revenues	6,331	23,290
BRAZIL
Revenues	942	2,159
Other Area [Member]
Revenues	$ 685	$ 113

Note 10 - Revenue Recognition_2

Note 10 - Revenue Recognition - Revenue in Connection With Significant Revenue Agreement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues	$ 63,604	$ 127,671
Renewable Products [Member]
Revenues	33,598	42,370
Licenses and Royalties [Member]
Revenues	7,658	48,703	[1]
Grants and Collaborations [Member]
Revenues	22,348	36,598
All Other Customers [Member]
Revenues	24,877	29,537
All Other Customers [Member] | Renewable Products [Member]
Revenues	25,775	18,742
All Other Customers [Member] | Licenses and Royalties [Member]
Revenues		12
All Other Customers [Member] | Grants and Collaborations [Member]
Revenues	(898)	10,783
Significant Revenue Agreement [Member]
Revenues	38,727	98,134
Significant Revenue Agreement [Member] | Renewable Products [Member]
Revenues	7,823	23,628
Significant Revenue Agreement [Member] | Licenses and Royalties [Member]
Revenues	7,658	48,691
Significant Revenue Agreement [Member] | Grants and Collaborations [Member]
Revenues	23,246	25,815
Significant Revenue Agreement [Member] | DSM International B.V. [Member]
Revenues	10,711	59,651
Significant Revenue Agreement [Member] | DSM International B.V. [Member] | Renewable Products [Member]
Revenues	18
Significant Revenue Agreement [Member] | DSM International B.V. [Member] | Licenses and Royalties [Member]
Revenues	5,958	57,972
Significant Revenue Agreement [Member] | DSM International B.V. [Member] | Grants and Collaborations [Member]
Revenues	4,735	1,679
Significant Revenue Agreement [Member] | Firmenich [Member]
Revenues	11,144	16,623
Significant Revenue Agreement [Member] | Firmenich [Member] | Renewable Products [Member]
Revenues	3,727	9,621
Significant Revenue Agreement [Member] | Firmenich [Member] | Licenses and Royalties [Member]
Revenues	1,700	1,199
Significant Revenue Agreement [Member] | Firmenich [Member] | Grants and Collaborations [Member]
Revenues	5,717	5,803
Significant Revenue Agreement [Member] | DARPA [Member]
Revenues	8,436	12,333
Significant Revenue Agreement [Member] | DARPA [Member] | Renewable Products [Member]
Revenues
Significant Revenue Agreement [Member] | DARPA [Member] | Licenses and Royalties [Member]
Revenues
Significant Revenue Agreement [Member] | DARPA [Member] | Grants and Collaborations [Member]
Revenues	8,436	12,333
Significant Revenue Agreement [Member] | Givaudan International, SA [Member]
Revenues	8,436	7,950
Significant Revenue Agreement [Member] | Givaudan International, SA [Member] | Renewable Products [Member]
Revenues	4,078	1,950
Significant Revenue Agreement [Member] | Givaudan International, SA [Member] | Licenses and Royalties [Member]
Revenues
Significant Revenue Agreement [Member] | Givaudan International, SA [Member] | Grants and Collaborations [Member]
Revenues	4,358	6,000
Significant Revenue Agreement [Member] | Nenter & Co., Inc. [Member]
Revenues		14,690
Significant Revenue Agreement [Member] | Nenter & Co., Inc. [Member] | Renewable Products [Member]
Revenues		12,057
Significant Revenue Agreement [Member] | Nenter & Co., Inc. [Member] | Licenses and Royalties [Member]
Revenues		2,633
Significant Revenue Agreement [Member] | Nenter & Co., Inc. [Member] | Grants and Collaborations [Member]
Revenues
Significant Revenue Agreement [Member] | Ginkgo Bioworks, Inc. [Member]
Revenues		(13,113)
Significant Revenue Agreement [Member] | Ginkgo Bioworks, Inc. [Member] | Renewable Products [Member]
Revenues
Significant Revenue Agreement [Member] | Ginkgo Bioworks, Inc. [Member] | Licenses and Royalties [Member]
Revenues		(13,113)
Significant Revenue Agreement [Member] | Ginkgo Bioworks, Inc. [Member] | Grants and Collaborations [Member]
Revenues
[1]	Ginkgo partnership obligation and promissory note issuance recorded as reduction to revenue and correction of errors in recording revenue from non-cash consideration.

Note 10 - Revenue Recognition_3

Note 10 - Revenue Recognition - Contract Balances (Details) - USD ($) $ in Thousands		Dec. 31, 2018	Dec. 31, 2017
Accounts receivable, net		$ 16,003	$ 18,953	[1]
Accounts receivable - related party, net		1,349	4,767	[1]
Accounts receivable, unbilled - related party		8,021	9,901
Accounts receivable, unbilled, noncurrent - related party		1,203	7,940
Contract liabilities(1)	[2],[3]	8,236	4,308	[4]
Contract liabilities, noncurrent(2)	[5]	$ 1,587
[1]	Reclassification of related party accounts receivable to a separate line on the balance sheet.
[2]	The balance in contract liabilities at December 31, 2017 represents deferred revenue, current prior to the Company's adoption of ASC 606, "Revenue".
[3]	The balance in contract liabilities, current at December 31, 2017 represents deferred revenue, current prior to the Company's adoption of ASC 606, "Revenue".
[4]	Revision to accounting for equity received in satisfaction of a customer receivable.
[5]	The balances in contract liabilities, noncurrent are included in other noncurrent liabilities on the consolidated balance sheets.

Note 10 - Revenue Recognition_4

Note 10 - Revenue Recognition - Remaining Performance Obligations (Details) $ in Thousands	Dec. 31, 2018USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 22,056

Note 10 - Revenue Recognition_5

Note 10 - Revenue Recognition - Remaining Performance Obligations 2 (Details) $ in Thousands	Dec. 31, 2018USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 22,056
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Amount	$ 14,131
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Amount	$ 7,925
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Amount
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Amount

Note 11 - Related Party Trans_3

Note 11 - Related Party Transactions (Details Textual) - USD ($)		Dec. 28, 2017	Jun. 30, 2018	Dec. 31, 2016	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2019
Derivative Liability, Total					$ 42,796,000		$ 42,796,000	$ 116,497,000
Accounts Receivable, Related Parties					1,349,000		1,349,000	14,668,000
Due to Related Parties, Current, Total					23,667,000		23,667,000	20,019,000
Revenue from Contract with Customer, Including Assessed Tax							63,604,000	127,671,000
Working Capital					119,500,000		119,500,000
Contract with Customer, Liability, Current	[1],[2]				8,236,000		8,236,000	4,308,000	[3]
Contract with Customer, Liability, Noncurrent	[4]				$ 1,587,000		1,587,000
Operating Leases, Rent Expense, Sublease Rentals							$ 600,000	500,000
Nikko [Member] | First Aprinnova Loan [Member]
Debt Instrument, Face Amount				$ 500,000
Nikko [Member] | Second Aprinnova Loan [Member]
Debt Instrument, Face Amount				1,500,000
Aprinnova JV [Member] | Nikko [Member]
Equity Method Investment, Ownership Percentage					50.00%		50.00%
Payments to Acquire Businesses, Gross				10,000,000
Notes Receivable, Related Parties				$ 3,900,000
Forecast [Member] | Aprinnova JV [Member] | Nikko [Member] | Maximum [Member]
Proceeds from Equity Method Investment, Distribution, Return of Capital										$ 10,000,000
Licenses and Royalties [Member]
Revenue from Contract with Customer, Including Assessed Tax							$ 7,658,000	48,703,000	[5]
Related Party Convertible Notes [Member]
Derivative Liability, Total					$ 200,000		200,000	0
Derivative, Gain (Loss) on Derivative, Net, Total							(8,500,000)	600,000
Ginkgo Collaboration Agreement [Member] | Licenses and Royalties [Member]
Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract								13,100,000
DSM International B.V. [Member]
Accounts Receivable, Related Parties					1,071,000		1,071,000	12,823,000
Revenue from Contract with Customer, Including Assessed Tax			$ 9,300,000
Disposal Group, Including Discontinued Operation, Consideration		$ 17,800,000
Contract with Customer, Liability, Total					34,700,000		34,700,000
Legal Fees							6,800,000
Working Capital					2,100,000		2,100,000
Contract with Customer, Liability, Current					1,204,000		1,204,000	383,000
Post-closing Working Capital Adjustment Payment Recorded as Loss on Divestiture							2,100,000
Contract with Customer, Liability, Fair Value Adjustment					1,400,000
DSM International B.V. [Member] | Contract Assets - Related Party and Contract Assets, Noncurrent - Related Party [Member]
Accounts Receivable, Related Parties					8,000,000		8,000,000
DSM International B.V. [Member] | Other Assets [Member]
Accounts Receivable, Related Parties					4,300,000		4,300,000
DSM International B.V. [Member] | Accounts Payable [Member]
Due to Related Parties, Current, Total					2,100,000		2,100,000
DSM International B.V. [Member] | Accrued and Other Current Liabilities [Member]
Due to Related Parties, Current, Total					600,000		600,000
DSM International B.V. [Member] | License [Member]
Revenue from Contract with Customer, Including Assessed Tax		27,500,000					54,700,000
DSM International B.V. [Member] | Royalty [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 15,000,000
Line of Credit Facility, Maximum Borrowing Capacity								$ 25,000,000
Early Payment Discount			$ 700,000
DSM International B.V. [Member] | Royalty [Member] | Forecast [Member]
Revenue from Contract with Customer, Including Assessed Tax						$ 8,100,000
DSM International B.V. [Member] | Manufactured Product, Other [Member]
Contract with Customer, Liability, Total					24,400,000		24,400,000
Contract with Customer, Liability, Current					3,300,000		3,300,000
Contract with Customer, Liability, Noncurrent					$ 21,000,000		$ 21,000,000
[1]	The balance in contract liabilities at December 31, 2017 represents deferred revenue, current prior to the Company's adoption of ASC 606, "Revenue".
[2]	The balance in contract liabilities, current at December 31, 2017 represents deferred revenue, current prior to the Company's adoption of ASC 606, "Revenue".
[3]	Revision to accounting for equity received in satisfaction of a customer receivable.
[4]	The balances in contract liabilities, noncurrent are included in other noncurrent liabilities on the consolidated balance sheets.
[5]	Ginkgo partnership obligation and promissory note issuance recorded as reduction to revenue and correction of errors in recording revenue from non-cash consideration.

Note 11 - Related Party Trans_4

Note 11 - Related Party Transactions - Related Party Debt (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2015
Related party debt, gross	$ 228,921,000	$ 195,819,000
Unamortized Debt Premium	(17,142,000)	(32,115,000)
Due to related parties, net	209,697,000	163,704,000
Total [Member] | Related Party 2014 144A Convertible Notes [Member]
Related party debt, gross			$ 9,700,000
Temasek [Member] | Related Party 2014 144A Convertible Notes [Member]
Related party debt, gross			$ 10,000,000
Related Party Debt [Member] | DSM Note [Member]
Due to related parties, net		16,961,000
Related Party Debt [Member] | Total [Member]
Related party debt, gross	9,705,000	35,116,000
Unamortized Debt Premium	(422,000)	(659,000)
Due to related parties, net	9,283,000	34,457,000
Related Party Debt [Member] | Total [Member] | The 2014 144A Notes [Member]
Related party debt, gross	9,705,000	9,705,000
Unamortized Debt Premium	(422,000)	(1,538,000)
Due to related parties, net	9,283,000	8,167,000
Related Party Debt [Member] | Total [Member] | August 2013 Convertible Notes [Member]
Related party debt, gross		21,711,000
Unamortized Debt Premium		897,000
Due to related parties, net		22,608,000
Related Party Debt [Member] | Total [Member] | R&D Note [Member]
Related party debt, gross		3,700,000
Unamortized Debt Premium		(18,000)
Due to related parties, net		3,682,000
Related Party Debt [Member] | DSM International B.V. [Member]
Related party debt, gross	25,000,000	25,393,000
Unamortized Debt Premium	(6,311,000)	(8,039,000)
Due to related parties, net	18,689,000	17,354,000
Related Party Debt [Member] | DSM International B.V. [Member] | DSM Note [Member]
Related party debt, gross	25,000,000	25,000,000
Unamortized Debt Premium	(6,311,000)	(8,039,000)
Due to related parties, net	18,689,000
Related Party Debt [Member] | DSM International B.V. [Member] | Other Loans Payable [Member]
Related party debt, gross		393,000
Unamortized Debt Premium
Due to related parties, net		393,000
Related Party Debt [Member] | Biolding Investment SA [Member] | Private Placement February 2016 [Member]
Related party debt, gross		2,000,000
Unamortized Debt Premium
Due to related parties, net		2,000,000
Related Party Debt [Member] | Foris Ventures, LLC [Member]
Related party debt, gross	49,705,000	77,509,000
Unamortized Debt Premium	(7,349,000)	(10,949,000)
Due to related parties, net	42,356,000	66,560,000
Related Party Debt [Member] | Foris Ventures, LLC [Member] | Related Party 2014 144A Convertible Notes [Member]
Related party debt, gross	5,000,000	5,000,000
Unamortized Debt Premium	(181,000)	(660,000)
Due to related parties, net	4,819,000	4,340,000
Related Party Debt [Member] | Temasek [Member] | Related Party 2014 144A Convertible Notes [Member]
Related party debt, gross	10,000,000	10,000,000
Unamortized Debt Premium	(435,000)	(1,591,000)
Due to related parties, net	$ 9,565,000	$ 8,409,000

Note 11 - Related Party Trans_5

Note 11 - Related Party Transactions - Related Party Revenues (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Revenues		$ 63,604	$ 127,671
Customers Other Than Related Parties [Member]
Revenues	[1]	52,551	66,729
DSM International B.V. [Member]
Revenues		10,711	59,651
Total [Member]
Revenues		342	(200)
Novvi LLC [Member]
Revenues			1,491
Related Parties [Member]
Revenues		11,053	60,942
Renewable Products [Member]
Revenues		33,598	42,370
Renewable Products [Member] | Customers Other Than Related Parties [Member]
Revenues	[1]	33,238	41,079
Renewable Products [Member] | DSM International B.V. [Member]
Revenues		18
Renewable Products [Member] | Total [Member]
Revenues		342	(200)
Renewable Products [Member] | Novvi LLC [Member]
Revenues			1,491
Renewable Products [Member] | Related Parties [Member]
Revenues		360	1,291
Licenses and Royalties [Member]
Revenues		7,658	48,703
Licenses and Royalties [Member] | Customers Other Than Related Parties [Member]
Revenues	[1]	1,700	(9,269)
Licenses and Royalties [Member] | DSM International B.V. [Member]
Revenues		5,958	57,972
Licenses and Royalties [Member] | Total [Member]
Revenues
Licenses and Royalties [Member] | Novvi LLC [Member]
Revenues
Licenses and Royalties [Member] | Related Parties [Member]
Revenues		5,958	57,972
Grants and Collaborations [Member]
Revenues		22,348	36,598
Grants and Collaborations [Member] | Customers Other Than Related Parties [Member]
Revenues	[1]	17,613	34,919
Grants and Collaborations [Member] | DSM International B.V. [Member]
Revenues		4,735	1,679
Grants and Collaborations [Member] | Total [Member]
Revenues
Grants and Collaborations [Member] | Novvi LLC [Member]
Revenues
Grants and Collaborations [Member] | Related Parties [Member]
Revenues		$ 4,735	$ 1,679
[1]	Licenses and royalties revenues is negative for 2017 due to the $13.1 million reversal of cumulative inception to date revenue as a result of entering into the 2017 Ginkgo Partnership Agreement. See Note 10. Revenue Recognition.

Note 11 - Related Party Trans_6

Note 11 - Related Party Transactions - Related Party Accounts Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accounts receivable, net	$ 1,349	$ 14,668
DSM International B.V. [Member]
Accounts receivable, net	1,071	12,823
Novvi LLC [Member]
Accounts receivable, net	188	1,607
Total [Member]
Accounts receivable, net	$ 90	$ 238

Note 11 - Related Party Trans_7

Note 11 - Related Party Transactions - Aprinnova JV's Assets and Liabilities (Details) - Aprinnova JV [Member] - Nikko [Member] - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Assets	$ 12,904	$ 7,635
Liabilities	$ 2,364	$ 3,187

Note 12 - Stock-based Compens_3

Note 12 - Stock-based Compensation (Details Textual) - USD ($)	Sep. 28, 2010	May 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2005
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance			5,390,270	1,338,367
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance			$ 11.55	$ 33.40
Performance-based Stock Options, Grant Date Fair Value			$ 5,100,000
Share-based Payment Arrangement, Expense			9,190,000	$ 6,265,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value			$ 200,000	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			70,807
Chief Executive Officer [Member]
Purchasable Shares Under Performance Based Options		3,250,000
Performance-Based Stock Options, Exercise Price			$ 5.08
Performance-based Stock Options [Member]
Performance-Based Stock Options, Exercise Price			$ 5.08
Share-based Payment Arrangement, Expense			$ 700,000
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense			$ 2,600,000	3,300,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			3 years 292 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			5,452,664
Share-based Payment Arrangement, Expense			$ 6,400,000	2,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value			$ 5,452,664	$ 523,167
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 5.36	$ 5.51
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 23,800,000	$ 5,000,000
Minimum [Member] | Chief Executive Officer [Member]
Performance-Based Stock Options Contingently Available for Issuance			0
Maximum [Member] | Chief Executive Officer [Member]
Performance-Based Stock Options Contingently Available for Issuance			3,250,000
Equity Incentive Plan, 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Period Available to Grant	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date	100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Shareholder Triggering Higher Exercise Price	10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date of Ten Percent or Greater Shareholder of Company	110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance			5,339,214	1,255,045
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance			$ 33.40	$ 26.29
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		9,280,000	2,359,750	252,107
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		9,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee		4,000,000
Equity Incentive Plan, 2010 [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			5,294,803	683,554
Equity Incentive Plan, 2010 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Equity Incentive Plan, 2010 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Stock Options and Stock Issuance Plans, 2005 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Period Available to Grant					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date					100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Shareholder Triggering Higher Exercise Price					10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Minimum Percent of Execrise Price to Fair Market Value on Grant Date of Ten Percent or Greater Shareholder of Company					110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance			52,389	79,322
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance			$ 185.93	$ 144.58
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			0
Employee Stock Purchase Plan, 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		1,666,666
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			382,824	80,594
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	85.00%
Shares Available for Issuance, Percentage of Total Outstanding Shares	1.00%
Share-based Payment Arrangement, Expense			$ 200,000	$ 100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			246,230	47,058

Note 12 - Stock-based Compens_4

Note 12 - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Allocated share-based compensation expense	$ 9,190	$ 6,265
Research and Development Expense [Member]
Allocated share-based compensation expense	1,797	2,204
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	$ 7,393	$ 4,061

Note 12 - Stock-based Compens_5

Note 12 - Stock-based Compensation - Share-based Payment Award, Stock Options with Performance, Valuation Assumptions (Details) - Performance-based Stock Options [Member]	12 Months Ended
	Dec. 31, 2018$ / shares
Fair value of the Company’s common stock on grant date (in dollars per share)	$ 5.08
Expected volatility	70.00%
Risk-free interest rate	2.75%
Dividend yield	0.00%

Note 12 - Stock-based Compens_6

Note 12 - Stock-based Compensation - Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Options granted (in shares)	4,337,119	661,094
Weighted-average grant-date fair value per share (in dollars per share)	$ 5.18	$ 3.26
Allocated share-based compensation expense	$ 9,190	$ 6,265
Unrecognized compensation costs as of December 31 (in millions)	8,500	2,700
Share-based Payment Arrangement, Option [Member]
Allocated share-based compensation expense	$ 2,600	$ 3,300

Note 12 - Stock-based Compens_7

Note 12 - Stock-based Compensation - Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Share-based Payment Arrangement, Option [Member]	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Expected dividend yield
Risk-free interest rate	2.80%	2.10%
Expected term (in years) (Year)	6 years 328 days	6 years 43 days
Expected volatility	80.00%	84.00%

Note 12 - Stock-based Compens_8

Note 12 - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Outstanding (in shares)	1,338,367
Outstanding, weighted average exercise price (in dollars per share)	$ 33.40
Outstanding, weighted average remaining contractual life (Year)	8 years 182 days	7 years 255 days
Outstanding, aggregate intrinsic value	$ 29	$ 97
Options granted (in shares)	4,337,119	661,094
Granted, weighted average exercise price (in dollars per share)	$ 5.18
Exercised (in shares)	(70,807)
Exercised, weighted average exercise price (in dollars per share)	$ 3.68
Forfeited or expired (in shares)	(214,409)
Forfeited or expired, weighted average exercise price (in dollars per share)	$ 19.61
Outstanding (in shares)	5,390,270	1,338,367
Outstanding, weighted average exercise price (in dollars per share)	$ 11.55	$ 33.40
Vested or expected to vest (in shares)	4,833,615
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 12.28
Vested and expected to vest, weighted average remaining contractual life (Year)	8 years 146 days
Vested and expected to vest, aggregate intrinsic value	$ 28
Exercisable (in shares)	972,229
Exercisable, weighted average exercise price (in dollars per share)	$ 39.73
Exercisable, weighted average remaining contractual life (Year)	5 years 292 days
Exercisable, aggregate intrinsic value	$ 12

Note 12 - Stock-based Compens_9

Note 12 - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Outstanding, RSUs (in shares)	683,554
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 8.66
Outstanding, weighted average remaining contractual life (Year)	1 year 255 days	1 year 146 days
Awarded (in shares)	5,452,664
Awarded, weighted average grant-date fair value (in dollars per share)	$ 5.36	$ 5.51
Vested (in shares)	(445,828)
Vested, weighted average grant-date fair value (in dollars per share)	$ 8.43
Forfeited (in shares)	(395,587)
Forfeited, weighted average grant-date fair value (in dollars per share)	$ 5.64
Outstanding, RSUs (in shares)	5,294,803	683,554
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 5.50	$ 8.66
Vested or expected to vest (in shares)	4,953,264
Vested or expected to vest, weighted average grant-date fair value (in dollars per share)	$ 5.50
Vested or expected to vest, weighted average remaining contractual life (Year)	1 year 219 days

Note 13 - Divestiture (Details

Note 13 - Divestiture (Details Textual) - USD ($)	Dec. 28, 2017	Nov. 30, 2018	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	$ 5,700,000			$ (1,778,000)	$ 5,732,000
Revenue from Contract with Customer, Including Assessed Tax				63,604,000	127,671,000
Proceeds from Divestiture of Businesses					54,827,000
DSM International B.V. [Member]
Disposal Group, Including Discontinued Operation, Consideration	17,800,000
Post-closing Working Capital Adjustment Payment Recorded as Loss on Divestiture				2,100,000
Revenue from Contract with Customer, Including Assessed Tax			$ 9,300,000
Contract with Customer, Liability, Total				34,700,000
DSM Credit Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity	25,000,000				25,000,000
Royalty [Member] | DSM International B.V. [Member]
Revenue from Contract with Customer, Including Assessed Tax	15,000,000
Line of Credit Facility, Maximum Borrowing Capacity					$ 25,000,000
License [Member] | DSM International B.V. [Member]
Revenue from Contract with Customer, Including Assessed Tax	27,500,000			54,700,000
Performance Option and Transition Services Agreements [Member] | DSM International B.V. [Member]
Contract with Customer, Liability, Total				2,100,000
DSM [Member]
Disposal Group, Including Discontinued Operation, Consideration	17,800,000
DSM [Member] | License and Service [Member]
Revenue from Contract with Customer, Including Assessed Tax	27,500,000
DSM [Member] | Royalty [Member]
Revenue from Contract with Customer, Including Assessed Tax	15,000,000
Amyris Brasil [Member]
Divestiture of Business, Consideration Transferred	56,900,000
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	5,700,000
Proceeds from Divestiture of Businesses				$ 54,800,000
Amyris Brasil [Member] | DSM [Member]
Post-closing Working Capital Adjustment Payment Recorded as Loss on Divestiture		$ 1,800,000
Amyris Brasil [Member] | Disposal Group, Not Discontinued Operations [Member]
Disposal Group, Including Discontinued Operation, Consideration	33,000,000
Repayments of Debt	$ 12,600,000

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 42,900	$ 305,800
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	34.00%
Provisional Amount Due to Remeasurement of Deferred Tax Assets and Liabilities, Before Valuation Allowance		$ 37,700
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	$ 0	0
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	$ 290,700
Operating Loss Carryforwards, Write-off		456,200
Open Tax Year	2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Write-offs		14,700
Tax Credit Carryforward, Amount	$ 1,600
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	154,300
Operating Loss Carryforwards, Write-off		$ 115,500
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	13,500
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Total	$ 7,300
Foreign Tax Authority [Member] | Secretariat of the Federal Revenue Bureau of Brazil [Member]
Open Tax Year	2010 2011 2012 2013 2014 2015 2016 2017 2018

Note 14 - Income Taxes - Compon

Note 14 - Income Taxes - Components of Income Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
United States	$ (218,109)	$ (156,020)
Foreign	(12,125)	6,915
Loss before income taxes	$ (230,234)	$ (149,105)

Note 14 - Income Taxes - Comp_2

Note 14 - Income Taxes - Components of Benefit (Provision) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Current:
Federal		$ 6,564
State		18
Foreign		964
Total current provision		7,546
Deferred:
Federal		(669)
State
Foreign
Total deferred benefit		(669)
Total provision for income taxes$		$ 6,877	[1]
[1]	Tax provision to accrue liability for unrecognized tax benefit.

Note 14 - Income Taxes - Effect

Note 14 - Income Taxes - Effective Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statutory tax rate	(21.00%)	(34.00%)
State taxes, net of federal tax benefit
Stock-based compensation
Federal R&D credit	(0.60%)	(0.20%)
Derivative liability	4.30%	13.90%
Nondeductible interest	1.00%	3.00%
Other	(0.10%)	(0.20%)
Foreign losses	0.90%	8.50%
Change in U.S. federal tax rate		25.10%
IRC Section 382 limitation		7.20%
Change in valuation allowance	15.50%	(18.60%)
Effective income tax rate		4.70%

Note 14 - Income Taxes - Deferr

Note 14 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Net operating loss carryforwards	$ 57,921	$ 20,066
Property, plant and equipment	9,269	9,653
Research and development credits	12,046	9,480
Foreign tax credit
Accruals and reserves	8,526	7,286
Stock-based compensation	6,496	5,471
Disallowed interest carryforward	2,359
Capitalized start-up costs
Capitalized research and development costs	27,888	32,085
Intangible and others	3,114	3,584
Equity investments	156
Total deferred tax assets	127,775	87,625
Debt discount and derivatives	(3,750)	(6,539)
Total deferred tax liabilities	(3,750)	(6,539)
Net deferred tax assets prior to valuation allowance	124,025	81,086
Less: valuation allowance	(124,025)	(81,086)	$ (386,867)
Net deferred tax assets

Note 14 - Income Taxes - Activi

Note 14 - Income Taxes - Activity in the Deferred Tax Assets Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Balance at Beginning of Year	$ 81,086	$ 386,867
Additions	42,939
Reductions/Charges		(305,781)
Balance at End of Year	$ 124,025	$ 81,086

Note 14 - Income Taxes - Uncert

Note 14 - Income Taxes - Uncertain Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Balance	$ 28,833	$ 9,101
Increases in tax positions for prior period	55	50
Increases in tax positions during current period	1,239	19,682
Balance	$ 30,127	$ 28,833

Note 15 - Geographical Inform_3

Note 15 - Geographical Information - Long-lived Assets by Geography (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Long-Lived Assets	$ 19,756	$ 13,892
UNITED STATES
Long-Lived Assets	13,111	10,357
BRAZIL
Long-Lived Assets	6,447	3,357
Europe [Member]
Long-Lived Assets	$ 198	$ 178

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual)

Sep. 23, 2019USD ($)

Sep. 19, 2019USD ($)

Sep. 17, 2019USD ($)

Sep. 10, 2019USD ($)$ / sharesshares

Aug. 19, 2019

Aug. 14, 2019USD ($)$ / sharesshares

Aug. 08, 2019USD ($)

Jul. 30, 2019USD ($)

Jul. 26, 2019USD ($)

Jul. 24, 2019USD ($)$ / sharesshares

Jul. 08, 2019shares

Jun. 24, 2019USD ($)$ / sharesshares

May 15, 2019USD ($)$ / sharesshares

May 14, 2019USD ($)$ / sharesshares

May 10, 2019USD ($)$ / sharesshares

May 10, 2019BRL (R$)shares

May 03, 2019USD ($)$ / sharesshares

Apr. 29, 2019USD ($)$ / sharesshares

Apr. 26, 2019USD ($)$ / sharesshares

Apr. 16, 2019USD ($)$ / sharesshares

Apr. 15, 2019USD ($)

Apr. 04, 2019USD ($)

Mar. 18, 2019USD ($)

Aug. 03, 2017USD ($)

Aug. 31, 2017USD ($)

May 31, 2017USD ($)

Jun. 30, 2020USD ($)

Dec. 31, 2018USD ($)shares

Dec. 31, 2017USD ($)

Sep. 30, 2019

Sep. 16, 2019USD ($)

Aug. 29, 2019USD ($)$ / shares

Aug. 28, 2019$ / shares

Jul. 29, 2019USD ($)

Jul. 18, 2019

Jul. 16, 2019

Jul. 10, 2019USD ($)$ / shares

Jun. 11, 2019USD ($)

Apr. 08, 2019USD ($)

Jan. 14, 2019USD ($)

Jan. 01, 2019shares

Dec. 10, 2018USD ($)

Dec. 06, 2018USD ($)

Nov. 30, 2018

Aug. 17, 2018$ / shares

Jun. 29, 2018USD ($)

Shares, Outstanding, Ending Balance | shares

76,564,829

Long-term Debt, Gross

$ 228,921,000

$ 195,819,000

Proceeds from Issuance of Common Stock

5,759,000

Extinguishment of Debt, Amount

$ 40,200,000

Long-term Debt, Total

$ 209,697,000

163,704,000

July Foris Credit Agreement [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 7.52

Convertible Senior Notes, 6.0% Due in 2021 [Member]

Debt Instrument, Interest Rate, Stated Percentage

6.00%

6.00%

6.00%

Debt Instrument, Face Amount

$ 60,000,000

$ 60,000,000

Long-term Debt, Gross

$ 60,000,000

Great American Capital Partners, LLC [Member] | Loan and Security Agreement [Member]

Debt Instrument, Face Amount

$ 36,000,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 35,000,000

Great American Capital Partners, LLC [Member] | Loan and Security Agreement [Member] | Minimum [Member]

Debt Instrument, Interest Rate, Stated Percentage

8.25%

6.25%

Great American Capital Partners, LLC [Member] | Loan and Security Agreement [Member] | Maximum [Member]

Debt Instrument, Interest Rate, Stated Percentage

9.00%

8.25%

DSM International B.V. [Member]

Consideration Transferred

$ 34,000,000

$ 34,000,000

Convertible Debt [Member]

Long-term Debt, Gross

$ 126,306,000

70,900,000

Long-term Debt, Total

120,874,000

56,121,000

Convertible Debt [Member] | Convertible Senior Notes, 6.0% Due in 2021 [Member]

Long-term Debt, Gross

60,000,000

Long-term Debt, Total

57,918,000

Convertible Debt [Member] | August 2013 Convertible Notes [Member]

Long-term Debt, Gross

4,415,000

4,009,000

Long-term Debt, Total

$ 4,345,000

$ 1,883,000

Subsequent Event [Member] | Private Placement [Member]

Warrant Exercise, Beneficial Common Stock Ownership Maximum Percentage

19.99%

Proceeds from Issuance of Common Stock

$ 5,000,000

$ 5,800,000

$ 23,200,000

Subsequent Event [Member] | LSA Amendment Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

1,438,829

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 2.87

Warrants and Rights Outstanding, Term

2 years

Warrant Exercise, Beneficial Common Stock Ownership Maximum Percentage

19.99%

Subsequent Event [Member] | July Foris Credit Agreement [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 2.87

Subsequent Event [Member] | August Foris Credit Agreement [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

4,871,795

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 3.90

Class of Warrant or Right, Term

2 years

Class of Warrant or Right, Stock Ownership Percentage, Restriction on Ability to Exercise

19.99%

Subsequent Event [Member] | Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member]

Class of Warrant or Right, Stock Ownership Percentage, Restriction on Ability to Exercise

4.99%

Subsequent Event [Member] | Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

2,000,000

181,818

2,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 5.12

$ 5.12

Debt Instrument, Repayment Price, Percent of Face Amount

4.99%

4.99%

Class of Warrant or Right, Term

2 years

2 years

Subsequent Event [Member] | Warrants Issued in Exchange for Convertible Senior Notes, 6.0% Due 2021, Second Exchange [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

2,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 2.87

Class of Warrant or Right, Term

2 years

Subsequent Event [Member] | Warrants Issued in Exchange for August 2013 Financing Convertible Note [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

1,080,000

Class of Warrant or Right, Stock Ownership Percentage, Restriction on Ability to Exercise

4.99%

Subsequent Event [Member] | Investor Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

3,205,128

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 3.90

Warrants and Rights Outstanding, Term

2 years

Warrants or Rights Outstanding, Maximum Percent of Common Stock Outstanding

9.99%

Warrants or Rights Outstanding, Reduction in Exercise Price

10.00%

Warrants or Rights Outstanding, Additional Reduction in Exercise Price

5.00%

Subsequent Event [Member] | Minimum [Member] | Investor Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 3.31

Subsequent Event [Member] | Foris Ventures, LLC [Member]

Related Party Transaction, Purchases from Related Party

$ 2,500,000

Subsequent Event [Member] | Raizen Energia S.A. [Member]

Capital Contribution to the Joint Venture | R$

R$ 2500000

Equity Method Investment, Ownership Percentage

50.00%

Equity Method Investment, Ownership Percentage by Counterparty

50.00%

Subsequent Event [Member] | Raizen Energia S.A. [Member] | Fixed Assets Owned by the Company [Member]

Payments to Acquire Property, Plant, and Equipment, Total

$ 9,000,000

Subsequent Event [Member] | Raizen Energia S.A. [Member] | Fixed Assets From Sao Martinho S.A. [Member]

Payments to Acquire Property, Plant, and Equipment, Total

$ 3,000,000

Subsequent Event [Member] | Loan and Security Agreement Amendment and Waiver [Member]

Debt Instrument, Interest Rate, Stated Percentage

4.75%

Long-term Debt, Gross

$ 71,000,000

Subsequent Event [Member] | Loan and Security Agreement Amendment and Waiver [Member] | Base Rate [Member] | Minimum [Member]

Debt Instrument, Basis Spread on Variable Rate

9.00%

Subsequent Event [Member] | Loan and Security Agreement Amendment and Waiver [Member] | Base Rate [Member] | Maximum [Member]

Debt Instrument, Basis Spread on Variable Rate

12.00%

Subsequent Event [Member] | Convertible Senior Notes, 6.0% Due in 2021 [Member]

Debt Instrument, Repayment Price, Percent of Face Amount

125.00%

125.00%

125.00%

Debt Conversion, Original Debt, Amount

$ 4,700,000

$ 53,300,000

$ 4,700,000

$ 53,300,000

Debt Instrument, Penalty for Failure to Make Payment, Premium Increase Percentage

25.00%

Debt Instrument, Periodic Payment, Principal

$ 6,400,000

Subsequent Event [Member] | Convertible Senior Notes, 6.0%, Due in 2021, Second Exchange [Member]

Debt Instrument, Interest Rate, Stated Percentage

18.00%

Debt Instrument, Face Amount

$ 68,300,000

Debt Instrument, Periodic Payment, Principal

$ 3,200,000

Debt Instrument, Debt Default, Amount

$ 63,600,000

Subsequent Event [Member] | Nikko Loan Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Long-term Debt, Total

$ 5,000,000

Subsequent Event [Member] | Nikko Loan Agreement, First Installment [Member]

Debt Instrument, Face Amount

$ 3,000,000

Proceeds from Issuance of Long-term Debt, Total

2,800,000

Subsequent Event [Member] | Nikko Loan Agreement, Second Installment [Member]

Debt Instrument, Face Amount

$ 2,000,000

Proceeds from Issuance of Long-term Debt, Total

1,900,000

Subsequent Event [Member] | The Naxyris Loan Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, Face Amount

$ 10,435,000

Debt Instrument, Failure to Pay Fee

6.00%

Subsequent Event [Member] | The Naxyris Loan Agreement [Member] | Interest Wtih Respect to Indebtedness [Member]

Debt Instrument, Basis Spread on Variable Rate

0.25%

Subsequent Event [Member] | The Investor Notes [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, Face Amount

$ 12,500,000

Debt Instrument, Early Repayment Amount, Percentage

100.00%

Subsequent Event [Member] | Great American Capital Partners, LLC [Member] | Loan and Security Agreement [Member]

Debt Instrument, Requirement, Unrestricted, Unencumbered Cash

$ 15,000,000

Payments for debt agreement amendment

$ 800,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | April Foris Credit Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

0.00%

Debt Instrument, Face Amount

$ 8,000,000

Line of Credit Facility, Maximum Borrowing Capacity

8,000,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | April Foris Credit Agreement [Member] | Minimum [Member]

Debt Instrument, Fee Amount

1,000,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | April Foris Credit Agreement [Member] | Maximum [Member]

Debt Instrument, Fee Amount

$ 500,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | June Foris Credit Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.50%

Debt Instrument, Face Amount

$ 8,500,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 8,500,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | July Foris Credit Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.50%

12.50%

Debt Instrument, Face Amount

$ 8,000,000

$ 8,000,000

Line of Credit Facility, Maximum Borrowing Capacity

16,000,000

Long-term Line of Credit, Total

$ 8,000,000

$ 8,000,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | Foris Credit Agreements [Member]

Debt Instrument, Repayment Price, Percent of Face Amount

100.00%

Subsequent Event [Member] | Foris Ventures, LLC [Member] | August Foris Credit Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, Face Amount

$ 19,000,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 19,000,000

Debt Instrument, Repayment Price, Percent of Face Amount

100.00%

Subsequent Event [Member] | DSM International B.V. [Member] | The 2019 DSM Credit Agreement [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 8,000,000

Debt Instrument, Repayment Price, Percent of Face Amount

100.00%

Proceeds from Sale of Equity Securities, Gross, Trigger Repayment of Amounts Outstanding Under Line of Credit

$ 50,000,000

Subsequent Event [Member] | DSM International B.V. [Member] | The 2019 DSM Credit Agreement, First Installment [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.50%

Debt Instrument, Face Amount

$ 3,000,000

Extinguishment of Debt, Amount

3,000,000

Line of Credit Facility, Incremental Draw Down Amount

$ 3,000,000

Subsequent Event [Member] | DSM International B.V. [Member] | The 2019 DSM Credit Agreement, Second Installment [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.50%

Debt Instrument, Face Amount

$ 3,000,000

Extinguishment of Debt, Amount

3,000,000

Line of Credit Facility, Incremental Draw Down Amount

$ 3,000,000

Subsequent Event [Member] | DSM International B.V. [Member] | The 2019 DSM Credit Agreement, Third Installment [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.50%

Debt Instrument, Face Amount

$ 2,000,000

Extinguishment of Debt, Amount

1,500,000

Line of Credit Facility, Incremental Draw Down Amount

$ 2,000,000

Subsequent Event [Member] | The Investors [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 12,500,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | Private Placement [Member]

Stock Issued During Period, Shares, New Issues | shares

2,832,440

6,732,369

Shares Issued, Price Per Share | $ / shares

$ 5.12

$ 2.87

Proceeds from Issuance of Common Stock

$ 20,000,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | Private Placement, April 16, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

5,424,804

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 2.87

Class of Warrant or Right, Term

2 years

Subsequent Event [Member] | Foris Ventures, LLC [Member] | Private Placement, April 26, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

3,983,230

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 5.12

$ 3.90

Class of Warrant or Right, Term

2 years

Subsequent Event [Member] | Foris Ventures, LLC [Member] | Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 4.56

$ 3.90

Class of Warrant or Right, Term

2 years

Debt Conversion, Converted Instrument, Warrants Issued | shares

352,638

Subsequent Event [Member] | Foris Ventures, LLC [Member] | Rule 144A Convertible Notes [Member]

Debt Conversion, Original Debt, Amount

$ 5,000,000

Debt Conversion, Converted Instrument, Shares Issued | shares

1,122,460

Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Private Placement [Member]

Stock Issued During Period, Shares, New Issues | shares

1,243,781

323,382

2,043,781

Shares Issued, Price Per Share | $ / shares

$ 4.02

$ 4.02

$ 4.02

Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Private Placement, April 26, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

1,635,025

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 5.02

Warrants and Rights Outstanding, Term

2 years

Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Private Placement April 29, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

258,704

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 5.02

Warrants and Rights Outstanding, Term

2 years

Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Private Placement May 3, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

995,024

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 5.02

Warrants and Rights Outstanding, Term

2 years

Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 5.02

Class of Warrant or Right, Term

2 years

2 years

Debt Conversion, Converted Instrument, Warrants Issued | shares

1,391,603

1,391,603

Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Rule 144A Convertible Notes [Member]

Debt Conversion, Original Debt, Amount

$ 13,500,000

Debt Conversion, Converted Instrument, Shares Issued | shares

3,479,008

3,479,008

Subsequent Event [Member] | Vivo Capital LLC [Member] | Private Placement [Member]

Stock Issued During Period, Shares, New Issues | shares

913,529

Shares Issued, Price Per Share | $ / shares

$ 4.76

Subsequent Event [Member] | Vivo Capital LLC [Member] | Private Placement April 29, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

1,212,787

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 4.76

Warrants and Rights Outstanding, Term

2 years

Subsequent Event [Member] | DSM International B.V. [Member]

Consideration Transferred

$ 57,000,000

Consideration Transferred, Cash Amount

29,100,000

Extinguishment of Debt, Amount

$ 27,900,000

Subsequent Event [Member] | Maxwell (Mauritius) Pte Ltd [Member] | Rule 144A Convertible Notes [Member]

Debt Conversion, Original Debt, Amount

$ 10,000,000

Debt Conversion, Converted Instrument, Shares Issued | shares

2,500,000

Subsequent Event [Member] | Total [Member] | Rule 144A Convertible Notes [Member]

Debt Conversion, Original Debt, Amount

$ 9,700,000

Subsequent Event [Member] | Total [Member] | Convertible Senior Notes, 10.5% [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

10.50%

Subsequent Event [Member] | Nikko [Member] | Nikko Loan Agreement [Member] | Aprinnova JV [Member]

First Priority Lien on Interests Owned by the Company

12.80%

Subsequent Event [Member] | Nikko [Member] | Nikko Loan Agreement, First Installment [Member]

Proceeds from Issuance of Long-term Debt, Withheld as Prepayment of Interest Payable

$ 200,000

Subsequent Event [Member] | Nikko [Member] | Nikko Loan Agreement, Second Installment [Member]

Proceeds from Issuance of Long-term Debt, Withheld as Prepayment of Interest Payable

$ 100,000

Subsequent Event [Member] | The Cannabinoid Agreement [Member] | Lavvan [Member]

Agreement Amount

$ 300,000,000

Agreement, Amount of Research and Development Funding that Could Be Received

$ 300,000,000

Agreement, Profit Sharing to Be Received from the Counterparty, Period

20 years

Subsequent Event [Member] | Equity Incentive Plan, 2010 [Member]

Automatic Annual Increase in the Number of Shares Available for Grant and Issuance | shares

3,828,241

Automatic Annual Increase in Shares Available for Grant and Issuance, Percentage of Outstanding Stock

5.00%

Automatic Annual Increase in the Number of Shares Reserved for Issuance | shares

382,824

Automatic Annual Increase in Shares Reserved for Issuance, Percentage of Outstanding Stock | shares

0.5

Subsequent Event [Member] | Tranche II Notes [Member]

Debt Instrument, Cash Waiver Fee Amount Payable

$ 600,000

Debt Instrument, Interest Rate, Stated Percentage

1.75%

Subsequent Event [Member] | Unsecured Promissory Note [Member] | Loan and Security Agreement Amendment and Waiver [Member]

Debt Instrument, Face Amount

$ 32,500,000

Subsequent Event [Member] | Convertible Debt [Member] | August 2013 Convertible Notes [Member]

Debt Conversion, Converted Instrument, Shares Issued | shares

1,767,632

Debt Conversion, Converted Instrument, Warrants or Options Issued | shares

1